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Challenges to adherence surrounding instructions for taking prescription medications have been 
around for centuries. Within chronic diseases, ‘medication adherence’ has unlimited 
complexities and contributes to poorer health outcomes of intended treatments. Unfortunately, 
medication nonadherence is very difficult to change due to a multitude of factors. Furthermore, 
interventions intended to help have been mostly unsuccessful over time. Significant research has 
been conducted with the aim of understanding medication adherence’s complexity and 
importance. Consistently, it is argued that ‘simple’ approaches for improvement are difficult to 
achieve. Researchers agree that potential solutions are more complicated than would be ideal.  
 
In recent decades, the advancement of various forms of interventions has opened up new 
opportunities to improve upon medication adherence. Progress has been slow and many gaps still 
exist. Utilizing frontline practitioners, retail pharmacists, who spend significant time engaged in 
providing specialty medications, this action research (AR) assessed opinions aligned with the 
accepted categorizations put forth by the World Health Organization (WHO). Additionally, the 
research sought to garner further knowledge within the use of technology and pharmaceutical 
industry-initiated financial assistance. The research desired to provide recommendations to help 
guide practical actions in an attempt to improve adherence rates which may optimally lead to 
better health outcomes. Further research and follow-up are recommended as the incremental 
upside of even the smallest improvements in medication adherence is significant. 
 
Guidance was provided to the participants in order to assess or convey gaps in the existing 
knowledge. A total of seven concentrated categories were pursued for the mixed methods 
research thesis. A survey component of the study meant to garner a small convenience sample 
had 115 respondents while focus groups sessions had a total of 12 participants. To support 
analysis of the data collected, an integrated design was used as an assessment tool for synthesis 
assimilation. In total, a subset of 40 themes were assessed between the mixed methodologies. 
Seven themes emerged as dominant and included the cost of medications, reimbursement, the 
use of technology (prescription refill monitoring), third party financial assistance, drug 
navigation seeking funding, and two ‘timing’ concepts. Interestingly, four of the seven dominant 
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themes relate directly to the cost of the medication or how to fund it. The dominant themes 
provided a foundation for a set of recommendations.  
 
The findings throughout this AR suggest that retail pharmacists in Atlantic Canada believe that 
medication adherence is a significant issue in the delivery of healthcare. However, improving 
adherence rates in diseases which require specialty medications will be challenging. It is agreed 
that taking a multifactorial approach will be fundamental. However, as this fact is already well 
known, to help improve upon the significant global issue and to potentially generate actionable 
knowledge that may avail change, this thesis puts forth two smart recommendations. It is hoped 
that these recommendations will be both accepted and pursued by both academics and 
practitioners in the field.  
 
Two recommendations align directly with the advances in the use of technology and 
pharmaceutical industry-initiated financial assistance. Firstly, increase the timeliness, emphasis, 
and support for a national standardized approach of medication reviews as it directly relates to 
content, funding, training, and implementation. And secondly, establish a centralized repository 
of information regarding access and availability of Patient Assistance Programs (PAP). 
Furthermore, the effort must not stop there as both these recommendations will have limitations 
on whom designs, supports, and funds such coordination. Attention, action, and evolvement of 
the recommendations must be at the forefront of scholarly and practical stakeholders moving 
forward.  
 
Future research leading to enhanced practical solutions is recommended and will need to be 
focused, consistent, and evolving in order to improve upon medication adherence rates and the 
lives of patients.  
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Terms and Definitions 
 
Biosimilars: a biologic medication that is ‘similar’ in chemical makeup to that of an original 
brand medication. Sometimes known as a subsequent entry biologic. 
 
Brand Name Medication: a medication that has legal patent protection in a given geographical 
jurisdiction. The medication would have been discovered, clinically developed, and provided to 
the marketplace as a single source without risk of competitors copying, manufacturing, and 
marketing the same chemical. Manufacturers who wish to copy brand name medications for 
commercial purpose are known as generics. In Canada, generics are not legally allowed to be 
manufactured and sold legally within a geographical jurisdiction if a medication is within the 
limits of their patent protection.  
 
Copay: “a fixed cost that a beneficiary may be required to pay per prescription (e.g., $3.00 per 
prescription), or a system in which a beneficiary pays a percentage of the cost required to fill a 
prescription (e.g., 20 percent per prescription)” (Sutherland, Greg, and Thy, 2017). Both take 
place after deductible limits assigned to an individual drug or a benefit plan have been reached. 
Many Canadian drug or benefit plans, either public or private, require a co-pay amount by the 
patient. Copay requirements vary widely depending on the plan itself.  
 
Chronic Diseases: “Diseases which have one or more of the following characteristics:  they are 
permanent, leave a residual disability, are caused by nonreversible pathological alteration, 
require special training of the patient for rehabilitation, or may be expected to require a long 
period of supervision, observation or care” (Dictionary of health services management, 2nd ed., 
1982). 
 
Drug Navigation:  A subset of health navigation, drug navigation provides methods of assisting 
the patient in accessing medication (drug) relating to the overall health care they require. In 
general, the approach utilizes services or individuals that understand and work with each patient 
uniquely given the patient’s own circumstances including factors such as the personal health 
coverage, income level, or geographical location. This service often includes the service provider 
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directly reaching out to external resources to ‘navigate’ through processes, exception guidelines, 
and perceived barriers to accessing medication. Overall, the objective of the navigation service is 
to assess the patient medication requirements provided by the healthcare provider, determine the 
resources that are already provided by the individual’s drug or benefit plans, and engage external 
offerings as to fill in the gaps of care. Drug navigation is meant to seek out optimal medication 
coverage relative to the individual’s personal circumstances regardless of one’s broader status 
within the healthcare system.  
 
Drug or Benefit Plan: Publicly (funded by the tax base) offered within Canada by the provincial 
or territorial Public Drug Benefit Programs. Each provincial and territorial government offers 
a drug benefit plan for eligible groups (Health Canada, 2017). Private plans are paid for by the 
individual either through their employer as part of an overall compensation package or by the 
person themselves. Individuals may have both a Public and Private plan. 
 
Electronic Payment Cards: In the context of this AR, a payment system provided by the 
pharmaceutical industry for financial assistance toward the purchase of medications by the 
patient. The payment system would issue a payment to the processor and dispenser of the 
medication, the retail pharmacy. The electronic payment card is processed or adjudicated using 
pharmacy software systems. In general, the financial assistance provided by this means is 
intended to assist in the partial or whole payment provision of a patient’s medical prescription, 
similar to an individual’s public or private drug plan card.  
 
Equivalence: Generic, multiple manufacturers of the same medication. Medication may be 
considered equivalent and not identical. 
 
Exception Request: Funding request as an exception within a drug or benefit plan for a 
medication which is not listed as a predetermined benefit on the plan. 
 
Generic Medication: a medication manufactured within a predetermined set of standards and 
assumed to be the same as a brand name medication as it relates to quality, dosage, safety, and 
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administration. In Canada, generic medications of the same chemical are approved under 
bioequivalence parameters and a considered interchangeable with the brand medication. 
 
Healthcare Professional (HCP):  known as one who is able to provide professional healthcare 
services or care for the patient, individually or as part of an integrated team. Within this action 
research, the healthcare professional was specific to the trained pharmacist working directly 
within the retail pharmacy setting. 
 
HIV: Acquired Immunodeficiency Syndrome (AIDS) caused by the Human Immunodeficiency 
Virus (HIV). 
 
IVR: Voice response technology 
 
Me Toos:  medications that are marketed and meant to emulate another medication of similar 
attributes which has already been deemed to have shown success.  
 
Medication Adherence: “refers to whether patients take their medications as prescribed” (Ho et 
al, 2009). This would include taking the medications as instructed, including, for example, the 
number of times required daily or continuation over time. 
 
Medication Compliance: “defined as the degree or extent to which a patient follows or completes 
a prescribed, diagnostic, treatment, or preventive procedure” (Capgemini Consulting, 2011).  
This perspective is from the health care provider as if the patient chooses to comply to the 
instructions. Generally, the terminology is used interchangeably with medication adherence. 
 
Medication Review: One-on-one consultation with patients that elicits essential information for a 
medication assessment. During this time, which is generally separately assigned outside of the 
initial prescription dispensation, pharmacists and patients are able to reflect on a systematic 
approach for identifying medication and therapy problems while determining components of an 
adequate care plan and follow-up steps. Pharmacists provide a comprehensive assessment of a 
patient’s medications and inform them on their appropriate use, safety and effectiveness. In 
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Canada, sessions generally last approximately 20 – 30 minutes whereby a patient goes through 
the two-way communication process and is provided a formal written document at the end, 
which they may use to provide to other healthcare professionals in their respective scope of care. 
Essentially, this acts as a personal medication summary and is intended to assist in providing 
better health outcomes due to the patient’s engagement and understanding of how to properly 
take their medications, both prescription and non-prescription. The review also helps prevent 
medication wastage and misuse. Most provinces in Canada reimburse pharmacies for the 
services provided during a medication review (Canadian Pharmacist Association, 2018). 
 
Pharmacists in different provinces across Canada are reimbursed for a medication review, 
medication assessment and care plan professional services. The Canadian Pharmacist 
Association (2018) notes that these services provide: 
Essential information to elicit for a Medication Assessment. 
Reflect on a systematic approach for identifying drug-therapy problems. 
Identify and describe components of an adequate care plan and follow up. 
Often, develop a written care plan for a patient scenario including solutions, suggestions, 
monitoring, and follow up. 
Use criteria to self-assess the completeness and effectiveness of a care plan. 
Reflect on how a patient care plan can be implemented in the community pharmacy practice 
setting. 
Reflect on elements of successful communication and collaboration with other health care 
professionals as it pertains to Medication Review/Medication Assessment. 
Utilize criteria to self-assess the effectiveness of a documentation note. 
 
Payer of Last Resort: Within the context of processing of a prescription claim, the payer of last 
resort is sequenced last while seeking funding or payment from drug or benefit plans. 
 
Payers: Public or private insurance plans which, on behalf of patients, pay for services such as 
medical treatments, prescriptions, etc. In the public context, within Canada, these are generally 
funded by the tax payer base at the federal level but administered at the provincial level. From a 
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private perspective, these are generally funded by employers as part of an employee’s overall 
compensation plan or paid for directly by the individual. 
 
Prescription: a written instruction provided by a medical professional, generally a prescribing 
physician, that authorizes the provider of medications, the dispensing pharmacist, to issue 
medications or treatment to an individual patient. In Canada, prescriptions are regulated by 
independent pharmacy regulatory bodies at both the national and provincial level.  
 
Primary and Secondary payer: Within the context of processing of a prescription claim, the payer 
whom is sequenced first during the funding or payment is considered primary. Thereafter, the 
payer sequenced second is considered secondary, and so on.  
 
Specialty Medications: a relatively new concept within the delivery of medications relating to 
high cost, frequent touch points, and complex disease management. Examples of diseases 
requiring specialty medications include cancer, rheumatoid arthritis, HIV, and multiple sclerosis. 
 
















This thesis engaged retail pharmacist to critically assess medication adherence as it directly 
relates to the interactions with patients on the front lines of healthcare. These interactions form 
the locus of action throughout this study. The aim was to develop a set of recommendations that 
may help improve medication adherence success rates and enhance the lives of patients.  
 
My personal background includes 30 years in the pharmaceutical industry known to invent and 
manufacture medications. This background has availed exposure to the retail pharmacy 
professionals who are responsible for dispensation of the medications as part of the supply chain. 
Approximately 18 years ago, I was a co-founder of a Canadian organization known by retail 
pharmacists to have invented innovative processes to assist patients in accessing brand name 
medications in circumstances where they may not otherwise have been able to afford it. 
Although sitting as an outsider and free of commitment to the participant group, within the 
research I was not seen as a stranger. As such, I was quickly able to garner trust, credibility, 
acceptance, and cooperation. I was seen as a facilitator in pursuit of the research goals and as a 
competent, objective observer.   
 
To commence with the research, it was important to establish a high-quality search methodology 
as to fully understand what medication adherence is by definition, prevalence, and how it is 
viewed or classified by those that have already spent so much time and effort attempting to 
understand it. In other words, what was the current state of knowledge in the field? The 
sensitivity to the answer of this question led to a critical view of the solutions currently provided. 
Not so much as lack of solutions, but rather the organization, formal coordination, and use of 
already existing knowledge. Furthermore, the search provided a view of the gaps and 
inadequacies thus setting the stage for potential actionable knowledge. The following 
introductory chapter attempts to shed light on how I approached these questions and ultimately, 








Consistencies throughout this research suggest the importance of taking a multifactorial 
approach to improving medication adherence. Evidently, this was a complicated subject. Thus, I 
theorized that the complexities may likely be the root cause of stagnant medication adherence 
rates over recent decades. The current knowledge and paradigms of the participants required a 
baseline assessment. Thereafter, inquiry through discussions surrounding the everyday practical 
setting articulated themes leading to actionable solutions. 
 
It is important to note that terminology used to describe medication adherence can vary 
depending on the communication. For example, the words ‘compliance’ or ‘adherence’, when 
referring to actions required to complete or act upon medication instructions, are generally 
known to be interchangeable. In the healthcare environment, when patients do not take their 
medications as required, it is an occurrence formally known as ‘medication nonadherence’ and 
the challenges are justified given the fact that the patient, being human, is solely responsible for 
the decision to adhere to the instructions given.  
 
The term ‘medication adherence’ may be an unfamiliar topic to the general public. Arguably, the 
terminology used to introduce this concept would confuse most. Hence, society’s lack of 
awareness of the enormous impact nonadherence has on the population as a whole. From a 
healthcare worker’s perspective, specifically that of a retail pharmacist working in the practical 
setting, a greater understanding exists regarding both the individual and societal implications of 
medication nonadherence. Retail pharmacists may be the first to agree that, even though 
advancements have been proposed, there has been little impact on how adherence rates affect 
patients. 
 
Nonadherence by patients to prescription medication regimens required as part of a treatment 
plan put forth by healthcare professionals is quite common, can be a complicated, and potentially 
an expensive societal issue (Dayer et al, 2013). Logically, it has a negative impact on treatment 
outcomes for the patient and consumes financial and non-financial resources, both directly and 
indirectly. Furthermore, accurate measurement of nonadherence and its impact is difficult. 
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Interventions and numerous ideas to improve upon troublesome medication adherence rates 
across chronic diseases have not been successful (Dayer et al, 2013). 
 
Could times be changing? Arguably, technological advances, especially in the last couple of 
decades, provide opportunities for improvements. From this perspective, one can ask, “Does the 
intervention of technology or financial assistance provided to patients by the pharmaceutical 
industry have an impact on medication adherence?” Furthermore, what affect do these 
interventions have on adherence rates within diseases requiring specialty medications? 
 
Fundamentally, what is medication adherence? Ho et al (2009) highlights that the term relates to 
how patients take their medications according to the instructions given by the healthcare 
provider. Or similarly, as Urquhart (1996) claims, how one’s drug administration corelates to the 
recommended regimen. Cramer et al (2008) refers to the International Society for 
Pharmacoeconomics and Outcome Research and defines medication adherence as the level of 
which the patient acts in accordance to what the healthcare professional has set as the 
prescription interval, dose level and regimen.  
 
The WHO emphasizes the importance of taking into consideration aspects not only related to 
medications, but also non-pharmaceutical variables such as health related actions (Sabate, 2003). 
Other contributing factors to an individual’s health such as lifestyle, age, and taking an active 
role in one’s health are important. Literature has demonstrated the importance of the relationship 
between the healthcare provider and the patient as being a critical factor of adherence (Sabate, 
2003). This includes the initiation of effective treatment regimens, discussion, and planned 
follow-up. Numerous researchers have eloquently provided layman’s wording on the meaning of 
medication adherence in an attempt to help all of society better understand and internalize its 
broader importance.  
 
This research attempted to garner the status of current opinions relating to the five WHO 
categorizations of contributing factors to nonadherence while expanding upon the concepts of 




1.2 Research Aims 
 
• Seek to engage, inquire, and navigate relations (Ramsey, 2014) of the perceived barriers to 
medication adherence given the advancements of various forms of modern technology and 
financial assistance provided by the pharmaceutical industry. 
 
• Pursue AR with retail pharmacists in order to determine the potential impact of each of these 
perspectives in the workplace. These may be considered nontraditional pathways to improve 
medication adherence in diseases requiring specialty medications. 
 
• Acquire new levels of deliberate attention (Ramsey, 2014) from key informants; namely the 
retail pharmacist, a frontline healthcare practitioner, to improve medication adherence rates 
by consideration and development of a set of smart recommendations. The approach focuses 
on the input and opinion of participants within a defined geographical area, Atlantic Canada 










1.3 Research Question 
 
Does the intervention of technology and financial assistance provided by the pharmaceutical 
industry to patients have an impact on medication adherence within diseases requiring specialty 
medications? If so, what are some smart recommendations that may be realistically implemented 




The WHO reports rates of medication nonadherence for chronic conditions in developed 
countries at approximately 50% (Sabate, 2003). This has not improved over decades. 
Furthermore, according to the WHO, chronic disease prevalence is expected to rise to 57% of the 
world’s population by 2020. For patients in Canada with chronic diseases, 90% will be utilizing 
one or more prescribed medicines (Mo et al, 2011 and Rotermann et al, 2014). These rates of 
nonadherence are deemed significant, given the pressures for advancements in research and the 
invention of new medications, considering that once those medications are available to the 
patient they are not taken properly about half the time.  
 
The severity of the problem is enormous. In Canada, 5% of hospital admissions and 5% of 
physician visits were shown to be directly related to medication nonadherence (Sun Life, 2014). 
In 2019, Express Scripts Canada, utilizing prescription drug trending data ending 2018, reported 
quantitative statistics of medication nonadherence rates to at least one treatment of 44%, 58%, 
and 77% for patients (claimants) prescribed one, two or three, and more than four combined 
medications respectively. This data was measured across all diseases and is consistent with 
overall 50% nonadherence rates on average globally.  
 
Critical judgement in a review of the five WHO categorized factors reveals that several gaps 
exist. The overall lack of improvements in medication adherence rates, along with the enormous 
modern-day societal reliance on electronic technology and pharmaceutical industry financial 
incentives to accept the use of newer medications, have opened up the possibility of finding 
solutions to improve upon previous shortcomings. Although the concepts of technology and 
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financial assistance provided by the pharmaceutical industry may be argued to fall into one of the 
formal WHO categories, these warrant further research and investigation given the rapid 
advancements of both in recent decades.  
 
Although extensively researched, the aspect of medication adherence improvements has been 
challenging. Lack of adherence at approximately 50% (Sabate, 2003) is staggering given the 
current reliance on, and general acceptance of, medications to treat diseases and the constant 
pressure on providers (including the manufacturers and payers) to lower prices globally. Even 
with significant medication advancements for many serious diseases, significant nonadherence 
exists. 
 
Understanding the concept of the ‘human actor’ is essential to evoking change, as not only is the 
patient human, so too are the providers of healthcare embedded in the Canadian system. This 
‘human' aspect brings potential variations of what can be deemed optimal care, as the 
interpretations of a single one-on-one engagement or communication regarding medications can 
be wide ranging. For example, patients are only able to recall about half of any given medical 
encounter (Schillinger et al, 2003). Given this single fact, one can easily understand the stagnant 
progress regarding medication adherence over time. Ultimately, a deeper understanding of the 
wide-ranging types of patients may uncover clues toward finding potential multifactorial 
approaches to tackling the problem of medication nonadherence.  
 
1.5 History of Nonadherence and Recognition 
 
The problem of medication nonadherence reaches a broad group of stakeholders including the 
patient, healthcare providers, and those that fund the medications. Arguably, it may be the largest 
healthcare problem in the world today, much of which is unavoidable. The WHO notes that 
improvements to medication adherence rates may have a larger effect on the overall health of 
patients than advancements of medications themselves (Brown & Bussell, 2011). Arguably, this 
holds validity as it highlights the reality that, at this point in time, although we have many great 
treatments available for the advancement of patient health, about half the time, patients simply 




For all the Canadian stakeholders that medication nonadherence affects, it is the ‘patient’ that is 
nestled within the core of any negative repercussions inclusive of increased morbidity and 
mortality. Common direct impact manifests itself in poorer health outcomes and lessened well-
being such as faster disease progression and temporary disability. Indirect impact includes work 
related absenteeism and increased individual and societal costs (Sun Life, 2014).  
 
The concept of medication adherence has been recognized for centuries. Sackett (1979) notes 
that even Hippocrates knew that patients often pretended to take their medicines. In more recent 
times, Dunbar-Jacob et al (1991) draw attention to medication adherence in the 1950s, 
highlighting a poor understanding and few improvements as recent as the 1970s and 80s. 
Certainly, advancements of new medications in the last century have brought huge attention to 
the importance of not only the invention, but also the necessity to use such inventions properly in 
order to achieve optimal outcomes. 
 
Capgemini Consulting (2011) note the ever-growing importance of medication adherence in 
citing the WHO, the US National Institutes of Health, and the National Council on Patient 
Information and Education; each taking the position that poor adherence is a major public health 
issue and becoming more severe at a huge cost to the healthcare system.   
 
From an epidemiological perspective, adherence rates remain consistent across chronic 
conditions irrespective of disease, complexity, or measurement (Iihara et al, 2004). Measurement 
continues to have its limitations in that most methods are proxy measures (Garfield et al, 2011) 
and include patient self-report, counting pills or refill rates, or biological or electronic 
monitoring. All of these measurement tactics have some form of flaw. Self-reporting relies 
heavily on memory and any of the possible inaccuracies that are associated with it, regardless of 
the disease or demographic (Weingart et al, 2008). The counting of pills by a patient’s healthcare 
professional is also reliant on the patient and is subject to potential inaccuracies due to the risk of 
unreported actions such as destruction and/or dumping of pills or pill containers before counting 
(Osterberg et al, 2005). Biological monitoring seems impractical and requires specific timing and 
dose administration verification if it is to be relied upon (Dayer et al, 2013). With the exception 
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of microchips embedded directly within the medication, which is a relatively new technology, 
the various forms of electronic monitoring associated with packaging still have an inability to 
accurately determine if a patient has taken a pill, as they too rely on self-report or simply 
knowing if the pill bottle was opened. 
 
The reasons for medication nonadherence are varied and extremely broad. In their basic form, 
researchers classify them as either intentional or unintentional (Dayer et al, 2013). In other 
words, did the patient consciously know that their actions led to nonadherence, or were they 
unaware of that as an outcome? Unfortunately, this broad or unspecific denotation of 
nonadherence may oversimplify the in-depth complexity of the concept (Garfield et al, 2011). 
Behavioral models of medication adherence largely focus on social cognition principles and rely 
upon individual beliefs and experiences influencing their behaviors (Dayer et al, 2013). 
 
Numerous solutions have been put forth over decades highlighting the concept of multifactorial 
approaches. These include how to remind, counsel, and educate the patient, as well as, reinforce 
positive and negative actions and simplify the issue (Dayer et al, 2013). Often, many of these 
methodological approaches are pursued in combination with one another. There are numerous 
forms of improvement methods that are considered to be traditional approaches, including 
medication reminder systems such as containers that demonstrate the weekday and time of the 
action required, unit dose packaging, or packaged calendars. All of these systems are intended to 
be used by those whom unintentionally forget to take their medications. More modern 
approaches include technology such as the traditional landline telephone, pager, cell phone, or 
audiovisual devices (Dayer et al, 2013). Behavioral interventions such as counselling exist and 
take the form of patient education aimed to stimulate a patient’s active participation. 
Unfortunately, many gaps remain in terms of successful, long-standing, positive results.  
 
1.6 Significance of the Problem 
 
Medication nonadherence rates are consistently at 50 percent regardless of numerous factors 
including the disease or patient (Iihara, et al, 2004). Even with these facts and retrospective 
views, rates remain constant. Globally, the problem is significant. The problem of medication 
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nonadherence has both direct and indirect implications which span across healthcare in relation 
to patients, healthcare providers (HCPs), and funders of medications such as private and public 
insurance payers (Brown & Bussell, 2011). The negative outcomes can be significant and 
impactful from both human and societal perspectives. It affects not only patients, but also those 
providers who may be either clinically or commercially focused. For patients, medication 
nonadherence leads to increased morbidity and mortality and manifests itself in higher rates of 
hospitalization and poorer health outcomes. Kleinsinger (2018) highlighted estimates of 
approximately 125,000 avoidable worldwide deaths annually directly linked to the problem.  
 
For HCPs, including retail pharmacists on whom this research was the focus, the patient’s 
misunderstanding of their medications and disease leads to increased burden on the system due 
to medication errors, additional hospital visits, and compromised patient health. For society as a 
whole, and those that pay for medications either through private employer plans or public 
funding, the financial burden is enormous. In the United States alone, medication nonadherence 
has been deemed the number one most avoidable cost (Clifton et al, 2018) at a direct impact of 
US$105 billion annually (QuintilesIMS, 2016). Furthermore, overall 
 
 1.7 Research Gaps and Opportunities for Improvement 
 
This action research was intended to encourage retail pharmacists to think critically about 
medication adherence and put forth practical recommendations to improve upon poor adherence 
rates. The large amount of previous scientific work noted throughout the literature search was 
not only largely empirical research, but revealed limited meaningful improvements in any of the 
five noted categories of medication adherence put forth by the WHO. Although numerous 
improvement methods have been studied and continue to be researched in an attempt to shed 
light on the patient journey, this research is distinct in that it takes an immersive approach to 
activities with practicing retail pharmacists in order to pursue engagement, inquiry, and 
navigation of relations (Ramsey, 2014). They are the point of direct contact with patients.  
 
The emphasis is on ‘action research’. Arguably, other than the patients themselves, retail 
pharmacists are at the closest ‘touch point’ in understanding the human concept related to the 
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consumption of medications. The research is seeking to find what are the important factors that 
drive medication adherence while encouraging discussions over and above the research 
participation to that of an everyday practical setting. It sought to elevate the cycling discussions 
to a generative level whereby the focus was meant to push the effort put forth by expert 
practitioners attempting to clearly explain what may not always be explicit or transferable given 
the human context. With this insight, and through the use of action cycling, it intended to 
articulate themes and put forth actionable recommendations given the continuous development 
over the last decade of various forms of technology to compliment disease treatments. 
 
The research shows that advancements in medication adherence on a global scale appear to have 
stalled. Data published by the WHO suggest that medication adherence is a complex problem 
with outcomes influenced by the patient, as well as, health systems. Understanding the issues 
from a retail pharmacist’s perspective during the AR cycles provided insight into opportunities to 
improve medication adherence through various technologies and pharmaceutical industry-
supported financial assistance.  
 
Research into the use of technology within medication adherence has been increasing in recent 
years as the problem evolves. Opportunities continue to arise and exist in furthering our abilities 
to understand the epidemiology of nonadherence, measure rates, categorization, denotation of 
any associated behavioral models, and identification of methods leading to improvement (Dayer 
et al, 2013). Past research suggests that the most favorable means to improving adherence may 
require a combination of technologies, albeit more complex for the patient, and multiple or 
multimodal strategies if adherence is going to be sustained (Haynes et al, 2008). Furthermore, it 
can be argued that a multifactorial approach tailoring communication to the individual, based on 
an analysis of their past adherence behaviors regardless of the technological combination, is the 
more likely pathway forward (Haynes et al, 2008). 
 
Although further AR is suggested, including a variety of healthcare professions addressing 
different vantage points and perspectives, acceptance and use of the recommendations put forth 
by retail pharmacist in Atlantic Canada may provide some insight into new opportunities and 
help improve upon health outcomes. Even the smallest steps forward may be beneficial, given 
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that researchers suggest positive improvements may have a large effect on healthcare (Brown 
and Bussell, 2011).  
 
1.8 Thesis Overview 
 
Medication nonadherence is prevalent, complicated, and costly. This action research was pursued 
in order to engage retail pharmacists to critically assess the problem with mindfulness and 
purpose in order to potentially arrive at practical solutions.  
 
Previous research over decades noted throughout the literature availed limited improvements, 
especially in terms of improvement rates. This included over 200 subset variables (Vermeire et 
al, 2001) within these categories that have been isolated as contributing factors. Still, and 
although medication adherence has been well researched, gaps exist. Given advancements in 
technology and industry’s financial assistance tactics, especially in the retail pharmacy setting, is 
it possible that, finally, these pathways may open up solutions to help improve upon 
nonadherence rates? This thesis attempts to partially fill that void. 
 
In order to assess this question, this research pursued a mixed methods methodological approach 
utilizing both an online survey and focus groups in a cycling sequence to combine constructionist 
and positivist epistemological perspectives. All four Atlantic pharmacy associations supported 
the issuance of the survey using their own databases which preceded the focus group sessions. 
Total survey participants came in at 115 and provided a convenience sample to commence the 
AR cycling with a total of 12 individuals within the focus groups. 
 
The purpose and objective of this thesis set out to identify themes of importance that might lead 
to potential organizational solutions. In total, forty themes emerged garnering narrowed 
discussions which led to the ability to isolate seven convergent themes of priority importance. 
Surprisingly, throughout the process, several other themes were given high importance during 
the first research cycle but faded out of importance thereafter. The research cycling availed the 
ability to provide those themes that were most significant and meaningful to retail pharmacists in 




The roadmap for this thesis commenced with outlining the current status of medication 
nonadherence including its history, known understanding, and significance to patients and 
healthcare providers (Chapter one). Modern day advances in any of the numerous previously 
researched variables put forth provided the ability to open up gaps in the current knowledge 
while at the same time opening up possible opportunities for improvement.  
 
The extensive literature search provided the background knowledge and baseline as to guide the 
first cycle (Chapter two). Not only did it provide the current baseline of knowledge and scientific 
work previously done, it provided the direction to set up the cycle 1 survey. For the research 
participants, this was fundamentally critical as to align on the definition, prevalence, factors, 
impact on society, and potential gaps given each individual came from varying backgrounds. 
 
Methodologically, a mixed methods approach fit well in terms of the AR cycling (Chapter three). 
The quantitative approach during cycle 1 was meant to set the stage appropriately by opening up 
the broad variety of pathways that that needed to be considered regarding the subject matter. 
Thereafter, cycling through the focus groups was meant to create avenues to engage the retail 
pharmacists directly on what really mattered in day to day practical environment, convergent 
themes if you will, as to put forth recommendations.  
 
Sequencing of the action cycles thereafter provided the ability to establish the baseline opinions 
of the participants and discuss in detail the important themes (Chapter four). Over time, a set of 
seven themes dominated the discussions.  
 
The evaluation of the data availed throughout the action cycling required an integrated design 
(Chapter five). This type of design availed a transformative thinking process to understand or 
relate the quantitative and qualitative data (Sandelowski et al, 2006). A mixed methods matrix 
was developed and critical to the overall sensemaking of the overall findings. The effort assisted 
in comparing what is often viewed as incomparable as to reveal root causes. These themes, or 
“chunks” (Henning, 2011, p.3) aligned within the categorizations previously noted. Thereafter, 
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this extensive analysis and assimilation opened up the pathway for conclusions and the set of 
recommendations for practical application (Chapter six). 
 
As this research was limited to that of three action cycles, further research to continue to 
understand and validate the ongoing important themes is recommended as to create a ‘continuous 
improvement protocol’ that would modify and enhance recommendations over time. 
 
2.0 Literature Review 
 
2.1 Search Methodology 
 
Key words used for the search strategy included medication adherence, action research, chronic 
disease, technology, financial assistance, and pharmacy. 
 
The literature review commenced with random searches throughout the library and ultimately 
narrowed to two main databases in that of Pubmed and Google Scholar as these provided the 
most pertinent responses. Consideration was also necessary of other relevant publications that 
are often not available through library resources including reputable industry sources such as the 
Center for Disease Control or industry associations. Content was identified, evaluated, and 
determined if useful over the entire thesis period and added periodically. As medication 
adherence is a global issue, much of the literature content was outside of the Canadian 
environment, but still highly relevant.  
 
To critically refine the analysis and arrive at a deeper level of discovery of the concepts and 
arguments which would eventually lead to a set of smart recommendations, it was important to 
focus on the subset constructs of medication adherence related technology and financial 
assistance. This narrowed the search significantly and aided in pursuing evidence-based material.    
 
Hundreds of articles within the search results were systematically assessed as to ensure a 
complete, and in depth, coverage of the relevant material. The search databases availed many 
overlapping articles. Articles found not utilizing action research methodologies included a broad 
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range of quality resources, many of which were disease-specific or meta-analyses. Unfortunately, 
literature utilizing the critical search frame of action research AND medication adherence held 
significantly less results. Results showed a ten-fold higher quantity of non-action research versus 
that of action research articles. Furthermore, the criteria of sourcing articles by adding 
‘pharmacy’, ‘technology’, or ‘financial assistance’ became even further limiting. This was not 
surprising and highlighted a gap in the use of action research in previous work within the subject 
area.  
 
It was important to understand the context of duplicates within the literature search. Consensus 
has not been established on a simple method of how to identify duplicates as they are often 
variable across different databases and further improvement to methodologies in doing so is 
needed (Qi et al, 2013). As such, duplicates were manually pulled out throughout the screening 
phases. 
 
Search Inclusion:   Medications for Chronic Diseases 
   Academic Journal Articles: Both Independent and Meta-Analysis 
   Reputable Consulting Publications 
   Articles 2000 - 2019 with limited exceptions 
  



















The concept of individuals not taking their medication as prescribed has arguably been around 
for as long as medicines have been available with a central component being the patient. 
Donovan & Blake (1992) argued that lack of progress regarding medication adherence could 
likely be attributed to the perspective of the patient. Unfortunately, nonadherence is a key reason 
for less than optimal clinical benefit (Rybacki, 2002). Vermeire et al (2001) concluded, during a 
comprehensive review of three decades of research on the subject matter that poor adherence is a 
major healthcare problem. Furthermore, the authors found that there was no measurement 
standardization (Vermeire et al, 2001). Krueger et al (2005), in yet another review, also 




The theoretical framework of this research can be best described as ‘transformational’ (Clark & 
Wilson, 1991) in which the participants utilize their fundamental beliefs and understanding 
surrounding reasons for medication nonadherence, challenge norms or convictions on underlying 
themes, and transition to actionable recommendations that may be used in the practical setting. In 
this sense, the context was critical as the human actor, the patient, is unique and host varying 
backgrounds. As such, the theoretical frame entailed “critical reflection central to perspective 
transformation” (Clark & Wilson, 1991, p.75) which led to practical and actionable 
recommendations. The development of these potential solutions may arguably be ‘relatively 
minor’ when comparing to the broader context of the WHO five categorizations (Sabate, 2003) 
or even the 200 subset variables (Vermeire et al, 2001) that have been studied over the years. 
Nonetheless, as a scholarly practitioner, I suggest a similar argument in that the extensive 
knowledge (Ramsey, 2014) which already exists, and which we have been trained to rely upon, 
has provided little change or improvement in medication adherence rates over decades.  
 
Furthermore, singular reliance or acceptance of such knowledge compromises progress. Gogovor 
et al (2019), for example, notes in a recent Canadian article that “non-adherence to prescribed 
therapies”, in hope of a medication benefit plan funding all citizens, as a potential existential 
challenge. New perspectives and inquiry (Ramsey, 2014) are necessary to attempt to generate 
practical recommendations in the pursuit to achieve such important goals. The recommendations 
put forth as a result of the efforts by the participants, the retail pharmacists, are practical and 
actionable. Their discovery was a direct result of the three action cycles and emergent from the 




Ho et al (2009) describes medication adherence as whether patients comply to the medication 
instruction as prescribed. It is important to note that this reference, along with most others, take 
into consideration the use of medications only and excludes behaviors associated with other 
important factors that contribute to adherence and clinical outcomes such as diet, lifestyle, and 




“In the 1970’s, the term compliance came into use, and was defined as the degree or extent to 
which a patient follows or completes a prescribed, diagnostic, treatment, or preventive 
procedure” (Capgemini Consulting, 2011, p.4). Dunbar-Jacob et al (1991) note the term 
‘adherence’ and ‘compliance’ may be regarded as interchangeable. Although this understanding 
had no effect on the research, it may be important to recognize in order to synthesize the various 
ways differing researchers address the concept. Further, medication adherence is often broken 
down into two concepts, adherence and persistence (Ho et al, 2009), whereby adherence refers to 




The significance of medication nonadherence is far reaching; not only from the patient’s clinical 
perspective but also economically, due to both direct and indirect costs. Challenges to adopt 
ways to promote adherence are faced by the healthcare providers in pursuit of the best outcomes 
(Spoelstra et al, 2014). The WHO advocates, for longer therapies, nonadherence is a world-wide 
problem (Ruppar et al, 2015) and further stated that it is a major public health issue due to half of 
patients being nonadherence. 
 
Economically, the impact is difficult to determine although researchers agree upon significant 
direct and indirect financial costs, given that “medication nonadherence is considered 
responsible for 33 – 69% of medication-related hospital admissions, 23% of all nursing home 
admissions, increased use of expensive, specialized medical resources, unneeded medication 
changes, unexplained treatment failures, and repeat office visits” (Technologies for Optimizing 
Medication Use in Older Adults, 2011, p.13).  
 
Gurwitz et al (2003) note that 90% of seniors use at least one prescription per week. Of this 
number, “a significant portion (12%) of patients will not take possession of dispensed 
medications” (Technologies for Optimizing Medication Use in Older Adults, 2011, p.13). For 
those that do fill their prescriptions, although it is difficult to generalize poor compliance rates, 
“30 – 50% of all patients, irrespective of disease, prognosis or setting” (Vermeire et al, 2001, 
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p.334) will non-comply with their medication regimen. This is also supported a WHO 
assessment noting, “approximately 50% of patients do not take their medications as prescribed” 
(Brown and Bussell, 2011, p.1). Ozok et al (2011) also found that rates among seniors for 
nonadherence were above 60% and likely lower due to the fact that their assessment was based 
on patients self-reporting, making it closely parallel to previous studies. 
 
Overall, concerning the prevalence of medication nonadherence, research is consistent in that 
failure rates above 50% in any condition are common. Further compounding the problem, Ho et 
al (2009, p.3032) note, “because of the variety of data sources and adherence measures, it is 
often difficult to compare adherence rates across studies and conditions”. Young (2008) also 
notes that medicines are often not used properly in terms of underuse, overuse, and misuse 
highlighting a multitude of issues given the consideration of the human factor associated with the 
subject matter. 
 
2.5 Categorizations, Macro and Micro Frames 
 
Inherent in the WHO five formal categorizations as the root causes of medication nonadherence, 
inclusive of the health system, condition, patient, therapy, and socioeconomics (Figure #2), lies a 
numerous subset of factors that highlight the context of the larger problem, including an aging 
population, literacy levels, a patient’s ability to pay for medicine, and the behavioral 
complexities of the patient, to name a few.   
 
 
Figure #2: WHO Categorizations of Factors relating to Medication Adherence  




Within these five categorizations, a list of associated subsets of influential variables exists. 
Complicating the subject matter relative to these variables, and depending on the individual, 
medication adherence may be viewed as either unintentional or intentional (Stegemann et al, 
2012), further clouding the path to any solution. Gurwitz et al (2003), for example, emphasize 
that medication nonadherence will likely grow due to an aging population who tend to take more 
medications over time. Furthermore, significant literature exists in associating the ability to pay 
for medications with rates of adherence as noted by Cutler and Everett (2010, p.1553) in that 
paying “out of pocket for medication clearly affects adherence; people use more drugs when the 
prices of the drugs are lower.”  The patient variables are numerous. 
 
The rich picture (Figure #3) outlines the overall action research scope. In other words, the macro 
frame. Within this broader perspective, there are several micro considerations for the reader. 
Furthermore, each micro consideration is arguably, in its own right, quite complex, even for the 
professionals that operate directly within those environments. Within this research, at a 
minimum, the reader has to blend an understanding of at least six overlapping micro frames 
including:  
 
1. Underlying concepts within medication adherence,  
2. Chronic diseases,  
3. the professional structure and stakeholder process of which the participant (retail 
pharmacist) operates within,  
4. the action research process,  
5. the context of the author’s role within the research, and  
6. the ‘Locus of Action’ in which the focus of the attention lies in order to potentially avail 




Figure # 3  Rich Picture Experience of the Author and Participants 
 
The concepts within medication adherence are broad ranging. For the research, not only was the 
five WHO categorizations considered, but two other topics added that would normally be known 
as subsets within those categorizations. Within in this realm, although over 200 variables have 
been studied over the years, little has changed in terms of medication adherence improvement 
rates. Furthermore, measurement of such rates is varied, limited, and entails many gaps in 
quality. This has led to a broad range of a fairly rigid set of opinions and paradigms by 




Theoretically, medication adherence encompasses all diseases that require a medication 
prescription. Diseases may be further defined into those that are short term or acute, or those that 
are life-long or chronic. Notably, chronic diseases take up the vast majority of prescription 
volume globally. Furthermore, the WHO report that chronic diseases are prevalent within 57% of 
the world’s population in 2020. Fortunately, the progress and evolution of medication treatment 
of many of these chronic diseases continues to improve by the advancements of specialty 
medications. These medications are known to be more complex, require higher levels of 
maintenance and patient touch points, and are increasingly more expensive.  
 
Retail pharmacists are only one of several stakeholders in the healthcare structure and process 
that a patient enters when they require treatment that potentially leads to a medication 
prescription. Direct interaction with physicians and pharmacists is the known practical aspects of 
the engagement, but other stakeholders are involved including the innovators and manufacturers 
of medications along with those that may fund those medications such as private or public 
payers. Collectively, all stakeholders are integrated within the day to day process. 
 
The research process, upon which this thesis is guided, is one of ‘action’. Participants entered the 
process by way of a survey in order to determine a set of opinions and beliefs, ‘knowledge’ if 
you will. This garnered a convenience sample. This foundation set the stage for the subsequent 
cycles that moved from a foundational knowledge focus to that of ‘attention’ whereby, through 
the use of focus groups, the participants could engage ideas, inquire, and navigate relations 
(Ramsey, 2014).  
 
As the author, I found myself in dual roles of an insider and an outsider. Although I had 
extensive industry knowledge and experience, while being known as an innovator for the 
pharmaceutical and pharmacy industries, it came with limitations. My role as an outsider in 
spearheading the project was limited to research design, methodology, setup of the action cycles, 
facilitation, and data collection. My direct opinions and input within the subject matter 
conversations where avoided and focused on an understanding of the data collection as to 




Within this thesis, at the heart of the locus of action, is the retail pharmacist. Their practical work 
setting is nestled within a micro frame that overlaps the others. For these professionals, they are 
employed by pharmacy organizations with both professional and commercial interests, while at 
the same time associated with pharmacy associations that have prioritized their individual 
interests as the core mandate. However, it is the direct contact with the patient that triggers that 
ability to potentially garner insight as to the important underlying factors that contribute to 
medication nonadherence. It is within that immediate human interaction that this trusted, 
influential stakeholder within the process is able to center on “deliberative attention rather than 
knowledge” (Ramsey, 2014, p.6). It was this form of scholarly research that has provided the 
setting to step aside of the day to day tasks, pose the questions, and create the conversations that 
enabled the epistemological practice for interactive and generative perspectives. This led to the 
smart recommendations. 
 
2.6 Human and Societal Impact 
 
Capgemini Consulting (2011, p.8) note the ever-growing importance of medication adherence, in 
referencing the World Health Organization, the US National Institutes of Health, and the 
National Council on Patient Information and Education, each of which took positions stating that 
poor adherence is a “significant public health issue” and becoming more severe at a huge cost to 
the healthcare system. Overall improvements in medication adherence may have a larger effect 
on healthcare than the advances of medications themselves (Brown and Bussell, 2011).  
 
In a more recent comprehensive review Cutler, Fernandez-Llimos, Frommer, et al (2018) 
analyzed 79 studies adapting a formalized methodology, the Drummond checklist, across 14 
diseases to provide an economic evaluation of the extent of the problem. There findings note the 
costs relating to “all causes” (Cutler, Fernandez-Llimos, Frommer, et al, 2018, p.1) of 
medication nonadherence had a range of $5,271 - $52,341 depending on the disease. And 
because approximately half of all adults globally have some form of a chronic condition (Center 
for Disease Control and Prevention, 2016), the societal costs are enormous citing annual amounts 




Krueger et al (2005) along with Osterberg and Blaschke (2005) represent the majority of 
literature supporting the notion that medication nonadherence increases the chances of morbidity, 
mortality, and costs. Gurwitz et al (2003) emphasize that nonadherence will likely grow due to 
an aging population who tend to take more medications over time. Unfortunately, the use of 
interventions to help improve adherence are “rare in routine clinical practice” (Ho et al, 2009, 
p.3028). Given that the population’s demographic is aging, the issue of medication nonadherence 
may become a greater problem due to a correlation between chronic disease and older human 
subjects. Kung et al (2008) report that 70% of deaths in the USA involve chronic conditions and 
highlight that over 25% of the same population manage multiple diseases. 
 
Health outcomes and economic risks are high in that low adherence rates are a concern which 
undermines much of the benefit of medications that are readily available (Vermeire et al, 2001). 
Urquhart (1996) further notes that compliance provides a connection between process and 
outcome during care. Krueger et al (2005, p.320) note, “improving adherence can result in 
decreased consumption of medical resources” while referencing significant research in 
numerous diseases, and argue “it is clear that increasing adherence to medication regimens can 
improve clinical and economic outcomes for patients on long-term therapy.” 
 
Anticipated higher medication costs in future years suggest the need for improved levels of 
adherence in order to show a positive risk benefit and to lessen the financial impact. 
Economically, the impact to society can be considered significant. Although an agreed upon 
financial amount in the research has not been determined, all researchers conclude upon 
significant amounts. Osterberg & Blaschke (2005) estimated the societal economic impact to be 
$100 billion annually. Other authors such as Donovan & Blake (1992) argue that the financial 
impact may be even higher and that this burdensome sum of $100 billion is estimated to be 
imposed in the USA alone. 
 
Rapoff (2010) quantified the cost of less than optimum adherence rates associated with increases 
of $2 - 8000 per patient. DiMatteo (2004) notes increased odds of 2.9 times for quality outcomes 
for adherent patients versus those that are not. 
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2.7 Factors that affect medication adherence 
 
Significant amounts of literature exist relating to medication adherence and its broad range of 
underlying factors. Unfortunately, the perspective of action research on the subject matter was 
found to be less available and historically driven by academic interests utilizing non-action 
research approaches or commercial organizations who put forth reputable publications. The lack 
of volume within the subject matter area utilizing action research resulted in limited literature 
surrounding the locus of action. Specifically, that of action research of medication adherence 
with retail pharmacists relating to technology and financial assistance. The results sourced were 
limited to narrowed pathways relating to various cultures, minorities, patient variations, and 
much smaller study sizes. This limitation of articles found relating to action research created 
significant gaps in the understanding of medication adherence in the practical sense and opens up 
opportunities for future action research in the area. 
 
There are many avenues of action research to pursue as the subsets of medication adherence 
variables are extensive, and arguably as complex as the human actor themselves. Consistent with 
the WHO’s categorizations, many researchers assimilate the thinking to that of logical factors 
such as age, gender, race, language, residence proximity to one’s healthcare provider, and 
disease (Roberts et al, 2014). The list of factors goes on and on hence, the rationale for past 
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Ho et al (2009) Medication Adherence:  It’s 
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Patient, Therapy, & 
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Zullig et al (2014) A health literacy pilot intervention 
to improve medication adherence using Meducation 
technology, Patient Education and Counseling, 95, P. 
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non-adherence by disease groups: a systematic review. 
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Health System  Law et al (2018) The consequences of patient charges 
for prescription drugs in Canada: a cross-sectional 
survey. CMAJ 
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Gogovor et al (2019) Non-Adherence to Prescribed 
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Focus on Healthcare in Canada. Healthcare Quarterly, 
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apps:  Potential benefits to patients and providers.  
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Granger & Hayden (2011) Medication Adherence:  
Emerging Use of Technology, Current Opinion 
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Linn et al (2013) 1 + 1 = 3? The systematic 
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tailored multimedia intervention to improve medication 
adherence, Patient Education and Counseling, 93, P. 
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and Health Care Utilization Among Patients with 
Chronic Disease Who Were Enrolled in a Pharmacy 
Assistance Program. NCMJ, Vol. 75, No. 5, P. 310 -
318. Citations: 26 
 
Zhu et al (2018) A Descriptive Study of Patients 
Receiving Foundational Financial Assistance Through 
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Managed Care, Vol. 24, No. 5, PP. S80. Citations: 2 
 
Lee et al (2016) A retrospective study of direct cost to 
patients with the use of oncology medications for the 
treatment of multiple myeloma. Journal of Medical 
Economics, Vol. 19, No.4, P.397 – 402. Citations: 9 
 
Clifton et al (2018) Financial impact of patients 
enrolled in a medication adherence program at an 
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measure of MPR still used as 
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2.7.1 Patient  
 
Brown and Bussell (2011) cite several patient-related factors that have an impact on adherence to 
medications, including lack of understanding of their condition, lack of involvement in treatment 
plans, low literacy levels regarding medical topics, individual beliefs and attitudes toward health, 
motivation, medication costs, lack of transportation, and wait times to see a healthcare provider. 
Ho et al (2009, p.3031) add examples, stating “patient factors associated with medication 
adherence include younger age, nonwhite race, and depression”. Common rationale for 
medication nonadherence is often patient related involving forgetfulness, being away from the 
primary residence, or simply occupied with other responsibilities (Reynolds et al, 2004) noting 
that reasons may be relatively basic. Agreeing, Brown and Bussell (2011, p.8) suggest that 
patients “recall as little as 50% of what is discussed during the typical medical encounter”. It is 
understandable that rates of medication nonadherence are at such a high percentage. 
 
Relating to a patient’s knowledge and misunderstanding, Berkman et al (2011) & Gazmararian et 
al (2006) both found that low literacy of health knowledge contributed to nonadherence. Parker 
et al (2003) note that health and medication information is put forth to society at the grade ten 
reading level suggesting that literacy interventions could be a viable way to improve medication 
adherence. This may have some merit as Zullig et al (2014, p.288) found that “a health literacy 
intervention may be a feasible mechanism to improve cardiovascular related medication 
adherence and outcomes” during a trial in which patients self-reported their medication 
adherence at three months. 
 
Vermeire et al (2001, p.335) highlight that “patients must believe that they are vulnerable or 
susceptible to the disease or its consequences, that they actually have it, and that the 
consequences of the disease on their well-being could be serious”, although Donovan & Blake 
(1992) put forth that research relating to adherence has only just begun to take into consideration 
the patient view. This notes the slight shift in the difference between compliance and adherence 




Krueger et al (2005, p.336) provided evidence that certain patient backgrounds pertaining to 
“sex, ethnicity, and marital status” were thought to play a minor role on medication adherence, 
while those of “age, low literacy, lack of insurance coverage, and homelessness had most 
consistently reported negative impacts” (Krueger et al, 2005, p.336). Krueger et al (2005, p.336-
337) further noted that a “patient’s belief that a medication will work or is working is directly 
related to treatment adherence”, as was “the level of English language proficiency or low health 
literacy”. 
 
The uniqueness of personalized methods to address nonadherence must take goals into 
consideration which should vary depending on the strategy and patient (Mrosek, Dehling, & 





Ho et al (2009, p.3031) note “conditions that are asymptomatic and chronic in nature that 
require long-term therapy have also been associated with nonadherence”. Morris & Schulz 
(1992) along with Griffith (1990) report an association between low compliance and chronic 
conditions. 
 
Baily et al (2013) emphasize the importance of medication adherence in that management 
requires several phases such as understanding, organization, and monitoring. Because each 
medical condition may have its own nuances, it is important to take these cyclical phases into 
consideration. For example, Fenton (1994) notes a 3.7 times relapse risk on average of non-
adherent patients versus adherent in schizophrenia. This enhanced risk may be different than that 
of other diseases such as cardiovascular disease or diabetes, and research with a broad range of 









Claxton et al (2001) note an “inverse relationship between number of daily doses and rate of 
compliance” while assessing adherence. In their systematic review of 76 studies they found that 
once-daily dosing was associated with higher adherence versus other more complex dosage 
regimens and concluded that compliance is better across varieties of medication classes, citing 
that inadequate compliance results in poor control in several disorders.  
 
An association exists with low compliance and factors such as treatment duration and the number 
of medicines (Vermeire et al, 2001). Krueger et al (2005) also found that when the number of 
medications increases, adherence decreases, particularly with 4 or more medicines. With regard 
to therapy-related factors, Ho et al (2009, p.3029) note the“complexity of the regimen and the 
perceived or experienced side effects can impact adherence”. Complex medication regimens and 
lack of communication are associated with nonadherence, especially for the elderly (Vermeire et 




From a medication adherence perspective, a patient’s social status, economic situation, and 
environment may have an impact on their likeliness to adhere. Economically, Cutler and Everett 
(2010, p.1553) note that paying “out of pocket for medication clearly affects adherence; people 
use more drugs when the prices of the drugs are lower”. Ho et al (2009, p.3031) suggest 
“research is needed to better understand the association between adherence and healthcare 
cost”. Roberts et al (2014) note that high drug costs are a barrier to clinical improvements 
amongst low-income patients. In a study retrospectively reviewing 265 patients who utilized a 
pharmacy program offering financial assistance, they found that patients were approximately 
50% adherent to their medications and suggested future research take a longer view of pharmacy 
assistance programs to enhance adherence (Roberts et al, 2014). The authors identified that 
although many of these programs are starting to be implemented, little is known about their 




Zullig et al (2013) supported that claim by reporting that during their research nearly half of the 
164 participants mentioned cost as a reason for nonadherence. Unfortunately, patients were left 
to cope with the pressure of compensating high drug costs, doing so in many ways such as 
seeking out lower priced medications, borrowing funds, and reducing their usual spending on 
other necessities such as food (Zullig et al, 2013). Although it was noted that patients are likely 
to alter their day-to-day lifestyle in order to afford medication costs, surprisingly, during the 
multivariable analysis, confirmation of financial stress as a predictor of medication nonadherence 
wasn’t clear, leaving it difficult to separate the subjective and objective factors (Zullig et al, 
2013). 
 
Krueger et al (2005, p.319) suggest “multifaceted interventions that target specific barriers to 
adherence are most effective, because they address the problems and reinforce positive 
behaviors”. One variable outlined in their research affecting adherence is a patient’s “inability to 
obtain and pay for medications”. Hsu et al (2006) noted that patients with caps on their drug 
benefit plan showed higher nonadherence. Taira et al (2006) discusses a relationship grade 
between copayment and adherence. Consistent with these findings were Cole et al (2006) who 
recognized that with higher drug copayments came small decreases in medication possession 
ratios among patients. This suggests that patients will delay the purchase of their medication as it 
directly relates to out of pocket expenses. Ho et al (2009) note that due to the evidence 
associating nonadherence with medication costs, more studies are necessary in this area in order 
to improve upon and increase knowledge of any relationship between lowering costs and 
improving adherence.  
 
Petry et al (2015), over a 12-week period, studied 29 patients utilizing self-recorded videos in 
which a financial reinforcement was used to earn rewards. Results suggested that cell phone 
technology, along with the positive reinforcement of a financial reward for compliance, might 
increase medication adherence. Furthermore, Capgemini Consulting (2011) proposes taking an 
interventional cost-related approach to combatting medication nonadherence by providing 




During a focus on social status and environment, DiMatteo (2004) extensively reviewed the 
literature concerning the importance of social support relating to adherence with 122 studies 
dating from 1948 – 2001 and found a correlation between support and adherence and that 
patients in cohesive families are more adherent than those is situation of conflict. He further 
denoted the importance of categorizing social support into either structural support, such as 
marital and cohabitational, or functional support, referring to emotional or cohesive state. 
 
Patients lacking practical support during treatment with medications show at least 65% 
nonadherence (DiMatteo, 2004). Vermeire et al (2001, p.335) further note “social factors, such 
as a positive attitude by others in the community improve compliance”. Krueger et al (2005, 
p.336) highlight the importance of “family members, friends, or caregivers whom provide to help 
patients adhere to their medication regimens”, having a positive impact relative to the size of the 
immediate group, and that that when too many people were involved adherence often suffered. 
Ho et al (2009, p.3031) note examples of “socioeconomic factors such as lower education and 
health literacy have been correlated with nonadherence”. 
 
2.7.5 Health system 
 
Ho et al (2009, p.3031) note, “nonadherence is not solely a patient problem but is impacted by 
both care providers and the healthcare system”. Relationships and specific attributes such as 
trust and support were shown to have a positive affect within the healthcare system (Krueger et 
al, 2005). Ens et al (2014) highlighted that provider-patient relationships demonstration of 
quality communication and awareness improved adherence. 
 
Concerning the situational complexity, Ho et al (2009) discuss examples of health system-related 
factors such as educational interaction and counselling during discharge, inpatient versus 
outpatient medication regimens, conflicting information, bureaucracy associated with drug plan 








Brown and Bussell (2011) highlight the contribution of high drug costs or copayments, lack of 
information technology or connectivity between healthcare providers, and a system that is 
overburdened in many countries with medication nonadherence. Pharmacists may be an 
important link to addressing some of these issues; although Svarstad et al (2003) reported mixed 
results and patient outcomes when studying the use of written communication between the 
pharmacist and patient. Overall, more interactivity or communication resulted in improved 
outcomes, but results varied greatly depending on the amount of time spent with the patient, 
workload, and type of pharmacy environment. This may be a field of research that requires more 
attention. 
 
Xu, Chomutare, & Iyengar (2014) conducted a meta-analysis of 40 studies and found that the 
most common form of a persuasive attribute for medication adherence interventions were those 




Anon (1997) notes that disease, process, setting, and therapy all influence adherence. Findings 
from that research highlight the doctor-patient relationship and its importance to compliance, 
although it is recognized as difficult to assess. Vermeire et al (2001, p.335) suggest that there 
seems to be a relationship between the “quality, duration, and frequency of interaction of the 
patient and doctor”, although a consistent set of facts has yet to emerge. Krueger et al (2005) 
further supported this theory in that care providers effect adherence it in a positive way. 
Unfortunately, physician’s insight to recognize nonadherence is lacking (Osterberg & Blaschke, 
2005). 
 
Sleath et al (2000) assessed the perspective of physician and patient interaction but were unable 
to associate adherence with specific patient demographics, although they did advocate the 
importance of the physician-patient principles of respecting the patient, providing proper 
rationale for treatment, discussing a plan, creating a nonthreatening environment, and ensuring 
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an emotionally significant and collaborative approach. These principles were meant to enhance 
the physician-patient relationship with the intent to improve adherence.  
 
Brown and Bussell (2011) note several physician-patient related factors that may contribute to 
medication nonadherence, including issuing complex drug regimens, lack of explanation, poor 
communication, and the failure to connect information between healthcare settings such as the 
hospital and primary care environment. 
 
Research-based findings emphasize the importance of strengthening the doctor-patient 
relationship as a means to improve compliance (Vermeire et al, 2001). King and Peck (1981) 
argue that in order to enhance patient compliance the care-giver should have three goals in mind:  
improving patient comprehension, patient recall and patient motivation. These goals imply 
strong communication practices between the doctor and the patient. Vermeire et al (2001) 
highlight a subset of actions to support this intent such as initiatives to enhance friendliness and 
approachability, to ameliorate presentation of information, types of medications prescribed, and 
advise on techniques to ensure the correct dosages are taken. Chesney (2000) also focuses on this 
argument in his research and adds that improvements require clarity in treatment and fitting to 
the patient’s lifestyle. Further support comes from the notion that, from a present-day perspective 
and considering the ever-increasing use of technologies, it is likely that technology such as 
smartphone apps will eventually be prescribed as part of a patient’s treatment regimen (Dayer et 




Capgemini Consulting (2011) highlights the substantial advancements within technology in 
recent years including mobile health (mHealth) smartphone applications, smart pills containing 
microchips, electronic pill bottles, remote patient monitoring, self-diagnostic tools and customer 
support call centers. Despite optimism toward technology, Granger & Hayden (2011) note that 
although many studies have been pursued to evaluate technology and interventions in helping 
improve upon adherence, most have shown only mixed results. Haynes et al (2008) note that 




Krueger et al (2005) noted many initiatives directed at the Physician, Pharmacist, Patient, 
disease-specific groups, and other healthcare providers during a comprehensive assessment of 
the literature including various drug utilization reviews, point of care activities, computerized 
prescriber order entry activities, personal digital assistants, and actions involving electronic 
health records. The authors emphasized that there is no one approach to ensure adherence. 
 
Various forms of medication adherence technologies exist and can be categorized into either 
single, multi, or advanced functioning along with others that integrate into alternative health 
management capabilities (Technologies for Optimizing Medication Use in Older Adults, 2011).  
Single-functioning technologies are generally associated with medication fills, reminders, and 
dispensation. These are the most commonly available. Multi-functioning technologies add a 
reporting capability to single functions, while some of the more advanced functioning 
technologies are associated with patient ingestion, metabolizing and adjustment of medications 
(Technologies for Optimizing Medication Use in Older Adults, 2011). 
 
Yelena & Hommel (2014) emphasize the importance of recognizing the matching of various 
technology to particular problems. For example, Capgemini Consulting (2011) suggests that 
digitizing patient records will have a lasting impact on shaping the future of medication 
adherence, inclusive of electronic medical health records and trends that will help provide 
information leading to customized intervention designs.  
 
In theory, reminder technologies such as pill calendars and unit-of-use packaging should help 
prevent nonadherence, particularly unintentional nonadherence (ie. the patient simply forgets to 
take their medication); however, as stated by Dayer et al (2013) these systems can be 
cumbersome for complex regimens and minimally involve the patient in the self-medication 
process. Most traditional reminder systems do not actively involve patients with the adherence 
reminder process or offer patients access to their own adherence data (Dayer et al, 2013). 
Technologies that engage the patient in their self-medication regime, such as Short Message 




With the wide variety of digital interventions available to aid medication adherence, it is 
important to consider both intentional and unintentional nonadherence. In an evaluation of the 
effectiveness of RTMM (real time medication monitoring) combined with SMS reminders, 
Vervloet et al (2011) note, a patient’s increased awareness of a benefit will likely not lead to 
improved adherence if they unintentionally nonadhere. Furthermore, a reminder to patients to 
take medicines who have chosen intentionally not too may not be helpful. This statement 
supports the idea that a multi-faceted approach to the technologies is required in order to 
successfully improve upon medication adherence. The combination of education, data access, 
and reminders should work together to help patients’ understanding and/or forgetfulness and 
assist in reducing nonadherence.  
 
Although technological innovations are exciting and promising, it is important to remember the 
human aspect of medication adherence, and not put the technology ahead of the patient 
relationship. Riekert and Rand (2002) may put it best in saying technology will not replace a 
relationship, listening, and understanding. This notion is supported by Park et al (2014), who 
argue that medication adherence monitoring will be successful if patients and caregivers work 
together and communicate effectively in the clinical setting. Consistently, researchers agreed that 
no matter the technology, a healthy patient-healthcare provider relationship is key to maintaining 
a relationship conducive to proper medication management. 
 
SMS (Short Message Service) / Text 
 
Yelena & Hommel (2014) note the potential of using text messaging as a means to improve 
medication adherence as there is significant increase in usage and costs are sustainable over time. 
Early research looks promising in this approach. Park et al (2014) implemented a systematic 
review of phone interventions and assessed 29 research publications and found that 18 of the 
studies identified improvement in adherence using text messages. Negative results were usually 
associated with basic and repetitious content while positive results were associated with a variety 
of educational and motivational content tailored to the individual patient. Vervloet et al (2012) 
found, over a six-month trial with 104 patients using real time medication monitoring (RTMM), 




A study by Huang et al (2013) examined the effectiveness of SMS reminders as a digital 
intervention to determine whether they increased medication adherence. The objective of this 
study was primarily to analyze the impact of medication reminders on delayed and missed doses, 
and secondarily to determine patient satisfaction and demand for text message intervention. 
Huang et al (2013) assert that SMS messaging is simple and cost-effective and a method for 
reminding patients to take their medication. In the study, 83.1% of participants in the 
intervention group reported that SMS reminders were helpful for preventing missed or delayed 
doses, and 73.7% of participants in the intervention group considered SMS intervention to be of 
value for disease management. 
 
Huang et al (2013) findings determined that SMS medication reminders could be an easy and 
effective way to improve medication adherence; particularly in short-term medication regimens, 
as the study followed patients for only one week, and long-term adherence may be more difficult 
to maintain. Similarly, Vervloet et al (2011) suggest that SMS text messaging improves 
medication adherence and can be effective in measuring adherence in the short term. Both 
researchers believe that more research is required to determine long-term success.  
 
The simplicity of SMS text messaging sets it apart from other more complex digital interventions 
such as mobile health applications due to its compatibility with different types of 
telecommunication and, according to Thakkar et al (2016), ease of administration and 
automation using a computerized program. Unlike smartphones, SMS messaging is relatively old 
technology that can be used by mobile phones of all kinds, and is common across all 
demographics, cultures, and socioeconomic groups. SMS medication reminders can include 
personalized content such as motivational messages, educational and medication-specific 
information, humour, etc. which can encourage patient engagement (Thakkar et al, 2016). 
 
In 16 studies examined by Thakkar et al (2016), the majority of patients reported moderate to 
high satisfaction with SMS messaging as an aid to medication adherence. When asked, the 
majority of patients would have liked to continue receiving text messages. Overall, it was 
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determined that SMS interventions may have the potential to improve adherence within chronic 
diseases. 
 
The meta-analyses by Thakkar et al (2016) found that most participant dissatisfaction surrounded 
lack of privacy and confidentiality due to loud notifications, and inconvenient SMS timing. 
Huang et al (2013) found that participants who took several medications were inconvenienced by 
receiving multiple notifications, and that most patients preferred to receive reminders 30 minutes 
before the prescribed dosage was to be consumed. A potential solution to these challenges is to 
offer patients customization of notifications, giving them the option to choose timing, content, 




In recent years, there has been a groundswell of smartphone applications in the pursuit to 
improve medication adherence, essentially attempting to tailor to the lifestyle of the patient and 
the common everyday use of the smartphone device. This is especially so in developed countries. 
Generally, for patients, these devices are inexpensive, scalable, and accessible (Dayer et al, 
2013). However, Yelena & Hommel (2014) note, their overall effectiveness has yet to be proven 
and suggest the importance of more research in this area as to assess interventions such as 
networking and gaming. Furlow (2012) highlighted this lack of research, stating that regardless 
of the growth of mobile applications, most have not been tested. Further research is required to 
garner knowledge in how smartphone applications may have a positive impact on improving 
medication adherence rates in both acute and chronic diseases (Dayer et al, 2013). 
 
Miller and Himelhoch (2013) describe the influence of new technologies on adherence in recent 
years as showing promising results within several conditions. Their study assessed 100 patients 
using a survey to evaluate willingness to use smart phones for the promotion of medication 
adherence. Over one quarter of subjects indicated they would use the mobile phone to help 




Using smartphone applications (apps) for the management of adherence to prescribed medication 
regimens could give patients a one-stop shop for tailored interventions. Apps offer a 
technological interface which consolidates multiple features such as reminders, medication 
information, activity logs, and connectivity with digital monitoring hardware. Smartphone 
accessibility adds efficiency and convenience to each mode of intervention, while engaging the 
patient and offering greater ease of access to valuable medical information. Further empirical 
analyses of the use of smartphone apps to aid in adherence is required (Dayer et al, 2013).  
 
According to Dayer et al (2013), one key inclusion for a successful smartphone application is an 
educational component. This education has traditionally been part of the professional-patient 
interaction and relationship. To improve efficiency, the application may consolidate a patient’s 
user information and streamline the educational process (Dayer et al, 2013). 
 
A recent qualitative study carried out by Morrissey et al (2018) examines the patient’s 
perspective while using MiBP (a Smartphone application consisting of medication reminders and 
home blood pressure monitoring via Bluetooth connection). Patients expressed feelings of 
empowerment when visiting doctors for follow-up appointments due to new knowledge 
surrounding their health and condition. Personal access to blood pressure data was easily 
retrievable in the form of graphs outputted by the app in accordance with BP monitor readings, 
which motivated patients to better understand the technology and its functions. This access to 
information could also make an asymptomatic condition more easily understood (Morrissey et al, 
2018); however, some asymptomatic and more stable patients reported having less use for the 
apps (Hallberg, Ranerup & Kjellgren, 2015).   
  
Negative findings from Morrissey et al (2018) include patient reports of anxiety driven by a lack 
of understanding of the technologies, and concerns surrounding the privacy and safety of data. 
These issues increased patient anxiety when using the MiBP app for self-monitoring and it was 
determined that more information would be needed to explain app compliance to privacy 
standards. Providing reassurance for some of these concerns could be as easy as a conversation 
between doctors and patients explaining data interpretation and recourse (Fletcher & Jensen, 
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2015); a conversation made easier by the availability of home-monitoring BP data and mHealth 
app databases. 
 
It should be noted that the median age in Morrissey’s study is 65, and that technological 
competency for this demographic may be lower than that of the average adult smartphone user. 
In a study on the effects of SMS reminders for outpatients who were prescribed more than 7 days 
of medication, Huang et al (2013) found that patients ages 65 years or older were less likely to 
experience an increase in timely doses compared with those aged 20 - 34 years, suggesting that 
older patients may resist change. Further investigation is required to determine MiBP’s influence 
on overall medication adherence; however, this particular study demonstrates the potential for 
patient engagement and involvement in their own condition. 
 
Electronic Monitors of Adherence 
 
Electronic monitoring (EM) of medication adherence comes in many forms including, but not 
limited to, electronic health records, medication events monitoring systems (MEMS) such as 
microchips in pill bottles and blister packages, wirelessly observed therapy (WOT) with 
ingestible sensors, mechanisms for metered dose inhalers (MDI), audiovisual reminder functions 
(AVRF), condition-specific monitors, and various combinations of multimedia and mobile phone 
utilities. (Park et al 2014). EM is considered to be a high-quality form of adherence measurement 
due to its accuracy and is preferred over less reliable methods such as patient self-reporting (Linn 
et al, 2011).  
 
Electronic Monitors “record the date and time that medications were removed from the device or 
the medication was administered” (Yelena & Hommel, 2014, p.923) and have shown to increase 
usage in order to capture prospective and objective longitudinal data. These innovations may 
help by assessing the methods patients take medications. However, EMs are often expensive to 
purchase and, from a situational perspective and depending on the relative price of the 
medication, may not be practical (Cramer & Mattson, 1991). There may also be questions as to 
who pays for the EM and what payer scenario might be most cost beneficial. This data is often 
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used to compare against medication adherence in patient self-reports as well as prescription 
refills in pharmacy (Yelena & Hommel, 2014). 
 
In a randomized controlled trial, patients of various socioeconomic backgrounds participated in 
six months of blood pressure self-monitoring using a telemonitoring service. Findings indicated 
that home telemonitoring does cost significantly more in services charges, patient training, and 
supplementary professional consultation; however, these costs could even out over time as a 
result of overall health condition improvement (Stoddart et al, 2013). According to Stoddart et al 
(2013), telemonitoring in primary care showed higher effectiveness during the six months after 
start and could be recuperated over the longer run as a direct result of prevention. 
 
In corticosteroid therapy for Asthma patients, MDI paired with AVRF were deemed to increase 
medication adherence by 18%. However, it should be noted that adherence rates are typically 
lower in clinical practice than in a research environment (Charles et al, 2007). Although further 
study is required, Charles et al (2007) report that the MDI monitoring system, when paired with 
dynamic audiovisual reminders, does have opportunities to address nonadherence within chronic 
diseases. 
 
Regarding EM methods of assessing adherence, Hansen et al (2011) found that, statistically, data 
records regarding prescription refills using electronic pill bottles were higher as compared to 
patient self-reports, prescription refill records, and pill counter lids which all provided similar 
outcomes. Furthermore, Demonceau et al (2013) found that EM interventions are potentially 
effective methods to improve adherence noting the dosing information is an important 
contributor. 
 
As stated by Park et al (2014), electronic devices have the ability to time stamp certain data, 
offering caregivers and pharmacists/physicians the opportunity to recognize nonadherence 
patterns such as the ‘white coat effect’, which occurs when a patient takes proper dosages and/or 
over-compensates for nonadherence only in the short timespan leading up to appointments with 
their provider. Unfortunately, like most forms of electronic equipment, electronic devices are not 
 
 55 
immune to malfunction. Hardware failures and damage due to accidental or intentional misuse 
have been reported (Park et al, 2014).  
 
One disadvantage of EM is that, despite time and date signatures, there is no way to determine 
whether or not the medication was actually ingested, or if pill dumping (disposing of multiple 
pills in order to fake adherence) had occurred (Park et al, 2014). Additionally, the most 
commonly studied EM capabilities are limited to pill container technologies and are not 
applicable to liquid medications and/or injectables (Riekert & Rand, 2002). This field of EM 
requires further research in order to determine long-term results. 
 
Although these dynamic technologies are exciting and offer many ways to monitor and improve 
upon adherence, it is difficult to determine their effectiveness. Longitudinal studies are required 
to assess patient satisfaction and the potential impact of these methods of digital intervention 




Cressey notes that the microchip technology has recently been introduced for predefined 
therapeutic regimens whereby, upon ingestion, a telemonitoring communication is issued to 
record medication intake (Stegemann, 2012). Research has yet to show the significance of this 
technological advancement, though according to Avery and Liu (2011), smart pills show promise 
to safely revolutionize medication treatment. Avery and Liu (2011), however, raise the point that 
pharmaceutical companies may shy away from the research and development of such ingestible 
sensors due to regulations and high-cost technological requirements.  
 
Compared to other forms of EM, ingestible biosensors are unique in their ability to detect near-
exact time of consumption of medication (Chai et al, 2015). Sensors may detect adherence gaps 
and issue interventions. This data is valuable to the long-term pursuance of patient adherence, as 
interventions occurring at the exact time of nonadherence may be more effective than those 
occurring pre or post missed dose. Giving patients access to their own precise adherence data 
from ingestible biosensors could provide them with the insight needed to invoke positive 
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changes in attitude and behaviour surrounding their medication regimen, ultimately resulting in 
better adherence (Chai et al, 2015). 
 
Eisenberger et al (2013) studied the Ingestible Sensor System (ISS), with its combination of 
ingestible event markers (IEM) and an adhesive personal monitor (APM) used to measure 
medication intake by ingestion-activated micro sensor which transmits data to the APM, then to 
a mobile phone via Bluetooth. The ISS was determined to be highly accurate in detecting time, 
type, dose, and number of medications a patient took. However, reports of skin irritability from 
the APM were one downfall, along with connectivity problems between the monitor and mobile 
device (Eisenberger et al, 2013). 
 
Illness-Specific Medical Devices 
 
In recent years, several sophisticated devices with features to promote medication adherence and 
management of the disease have appeared on the commercial market (Yelena & Hommel, 2014). 
These include electronic devices such as blood glucose monitoring and blood pressure 
measurement systems. Limited research has been done on the utility of home monitoring 
systems. 
 
Research in hypertension management has shown potential for success in patient-centered, 
multifaceted programs including self-monitoring, reminder systems, and presentation of 
educational information, with the combined use of Smartphone applications and wireless BP 
monitors. Timely data output gives patients a better understanding of their own hypertension 
activity, demonstrating the effects of lifestyle practices on hypertension and better preparing 
them to participate in discussions at the doctor’s office (Morrissey et al, 2018). 
 
According to Hallberg et al, (2015) the patient’s ability to see immediate effects of lifestyle 
changes on blood pressure by viewing BP monitor reading outputs on an mHealth app, was 
reported as an eye-opener. Patients noted it taught them a lesson relating to the amount of 
forgetfulness. Other patients reported gaining a greater understanding of activities and lifestyle 
choices affecting their condition after interpreting BP monitor outputs, offering them more 
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control over their health. Immediate and visible results from patient’s own bodies served as 
much more motivation than receiving suggestions from magazines or websites, particularly 
advocating for exercise. This awareness may encourage patients to better adhere to their 
medication regimen (Hallberg et al, 2015). 
 
Conversely, Morrissey et al (2018) found some reluctance from participants to engage with the 
home BP monitor. Lack of know-how to interpret high readings was said to have caused 
unnecessary anxiety and could potentially lead to needless doctor visits. With regards to this 
technology, prior to self-monitoring, it is essential that the patient fully understand the 
technology’s operation, function and capabilities before attempting at-home use. The patient 




The internet and electronic reminders offer optimal technology for putting forth customized 
interventions as it may assess barriers (Linn et al, 2013). The authors assessed medication intake 
behavior using an online preparatory assessment, along with tailored text communication, and 
found that 65.6% of patients viewed this type of intervention as positive. 
 
Sajatovic (2015) conducted a study utilizing sensor automation in a pill cap and monitored 
remotely with an incentive component. Some of the challenges for patients included managing 
multiple types of adherence techniques simultaneously, hence recognizing a downside to more 
complex adherence interventions. 
 
Laffer and Feldman (2014) evaluated the use of 17 medical videos to determine which forms of 
technologies help patients best adhere to certain regimens and found that patients rely more on 
reminder systems such as utilizing cell phones and calendars rather than medical videos. 
Although photo and video of medication ingestion can lower personnel costs for healthcare 
professionals, they require frequent communication with patients which can be considered time 




Linn et al (2011), in a systematic literature review, determined that adherence may be improved 
using individualized internet interventions. The customizability of web-based platforms is 
beneficial to patients, while the opportunity to collect data and monitor patient adherence is 
valuable to healthcare providers (Lin et al, 2011). Tailored internet interventions can be used in 
coordination with current treatment and/or adherence practices, offering insight which can 
improve the outcome of the patient’s entire regimen (Lin et al, 2011). 
  
In a review of multimedia interventions for over-the-counter medications, Ciciriello et al (2013) 
found that, despite low quality of evidence, multimedia interventions were effective in educating 
patients on their medication. By means of written word, diagram, photos, audio, animation or 
video, consumers can access detailed information more easily than traditional methods, and that 




Self-Directed technologies include electronic monitoring, video, telephone calls, and mobile 
phones used as a direct intervention to improve adherence. These digital interventions (DI) 
generally require more participation from the patient and promote self-management of a 
medication regimen. Patients using these technologies to aid adherence may require more 
assistance from their healthcare provider (Morton et al, 2016), and may rely more heavily on at-
home support systems or caregivers.  
 
As noted by Morrissey et al (2018) in regard to self-monitoring combined with a novel 
Smartphone application it helped form part of the doctor-patient relationship which confirmed 
the patient’s need for physician support during self-management. This need is viewed by some as 
a potential burden, as self-management sometimes demands more time and assistance from 
healthcare providers (Morton et al, 2016). 
 
Walker et al (2014) found, in a study of 33 patients with heart failure, that self-directed 
technology in the form of MyMedSchedule.com did not significantly improve adherence to 
medications. Barriers attributing to lack of improvement included age, medication cost, complex 
 
 59 
medicine regimens, motivation, and social environment (Walker et al, 2014). Technologies like 
photo and video logging of medication ingestion require a greater level of patient engagement 
and more frequent communication between patients and their healthcare providers (Park et al, 
2014). These methods, when properly executed, can confirm timely medication intake but further 
research is required to determine long-term results. 
 
One benefit of self-directed digital intervention is the potential for positive reinforcement and 
encouragement due to increased involvement in the patient’s own health care. In Hallberg et al 
(2015) study of at-home blood pressure monitoring for patients with hypertension, they 
determined that a self-management effort provided perceived benefits leading to awareness and 
influenced blood pressure. Similarly, Morton et al (2016) concluded, after a meta-ethnography 
review of published studies, that patients reported higher satisfaction with care received and felt 
more connected with healthcare providers after using various methods of self-directed device 
integration to manage their condition. This review determined that patients who were self-
managing were more likely to engage in lifestyle change behaviours (Morton et al, 2016). 
 
Prescription Refill Monitoring 
 
Granger & Hayden (2011) note that pharmaceutical databases within the retail pharmacy setting 
offer insight into patient-level refill patterns. In general, this resource has been associated with 
analysis using medication possession ratios (MPR) and linking the information to that of 
reminder interventions thereafter. Interventional programs that have been pursued include 
database triggers, telephone reminders, picture cards to address low literacy, and physician alerts. 
Unfortunately, most of these programs have shown limited success or significant benefit 
(Granger & Hayden, 2011) in improving long-term adherence rates. A known limitation of this 
type of technological method is that it cannot confirm that a patient who filled their prescription 
at pharmacy and has possession of the medication has, in fact, used the medication (Sabate, 
2003). 
 
Arguably, pharmacists are properly positioned to engage with patients at optimal intervals 
relative to other healthcare providers (Calvert et al, 2012), as they have front-line access to 
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prescription refill information on patients. Unfortunately, the health system lacks a cohesiveness 
regarding patient information as pharmacists do not have the same level of insight into patient’s 
medical history as physicians would. Pharmacists do not normally engage the prescribing 
physician to assist in resolving adherence problems (Calvert et al, 2012). 
 
Refill monitoring, in contrast with EM alternatives, is fairly inexpensive. It is beneficial as an 
indirect method of adherence measurement because it can be done without informing the patient, 
which may increase the accuracy of results (Balkrishnan, 2005). Prescription data is easily 
attainable by the pharmacist, but patients who frequent more than one pharmacy may limit 
traceability of prescription refills; therefore, a unified pharmacy system is crucial to successful 
refill monitoring (Balkrishnan, 2005). 
 
Techniques for Measuring Adherence 
 
The various techniques considered in the pursuit to quantify adherence rates can be categorized 
as either direct or non-direct measurements. Vermeire et al (2001) makes this distinction in that 
direct measurements are often used to detect chemical markers in the body fluid”. Non-direct 
measurements are used more frequently in the relevant literature and include activities such as 
self-report interviews, diaries, and pill counting (Vermeire et al, 2001). Each categorization has 
been noted to have their own drawbacks as either deterioration or improvement in patient health 
outcomes can be attributed to other non-medication related factors beyond the scope of 
measurement. 
 
The ability to measure medication adherence rates is challenging (Brown and Bussell, 2011). 
The prediction of adherence has no stable factors (Sabate, 2003); however, an accurate measure 
is considered of the utmost importance if a change in the patient’s regimen is required to ensure 
an optimal outcome (Sabate, 2003).  
 
Brown and Bussell (2011) further highlight three different approaches: subjective, objective, and 
biochemical. Subjective approaches include actions such as simple asking the patient, family, or 
caregiver questions about the medications a patient is taking. This can be considered a self-
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report. Unfortunately, accuracy in subjective measures has been problematic. Healthcare 
providers tend to overestimate the success rates (Dimatteo & DiNicola, 1982), while patients 
vary in whether they follow or deny treatment advice (Spector et al, 1986).  
 
Objective measures include means of measuring adherence which involve counting pills or 
assessing pharmacy refill data. Objective measures might seem to be a preferred method over 
subjective measures, but they have their own drawbacks such as counting or timing inaccuracies 
(Matsui, 1994). A common method of measuring and quantifying medication adherence in recent 
years has been the use of electronic prescription data using pharmacy processing systems (Ho et 
al, 2009). Brown and Bussell (2011) also recognized the potential of electronic medical records 
and electronic prescribing to improve adherence. Two perspectives are often considered. Firstly, 
medication possession ratio (MPR) and secondly, proportion of days covered (PDC). Essentially, 
the ability to measure prescription refills and frequency can be correlated with health outcomes 
(Ho et al, 2009). The intention of MPR is to identify delayed filling on initial prescriptions and 
the refilling of future prescriptions (Brown and Bussell, 2011).   
 
An early limitation to MPR is that, in order to capture all medications and refills patients are 
prescribed, they are required to obtain medications in a closed pharmacy network (Ho et al, 
2009). This hinderance has improved in recent years, as many retail pharmacies have become 
linked and the closed pharmacy system has broadened. A further limitation to the tracking of 
electronic prescription data is that it only measures when the patient fills the physician order but 
is unable to track when the patient actually takes the medication in terms of time of dose (Ho et 
al, 2009). The concept of medication reconciliation (Brown and Bussell, 2011) seeks to create an 
accurate and collective list of all medications a patient is on and their respective uses. 
 
Biochemical measures require blood and urine tests to detect medication levels (Brown and 
Bussell, 2011) by adding non-toxic biological markers to the medication.  Unfortunately, this 
method of measurement also has its drawbacks, considering other influential factors such as a 




Using the medication possession ratio (MPR) measurement perspective viewing at prescription 
refill data at pharmacy adherence is generally considered at 80% (Ho et al, 2009), but it is also 
agreed upon that the MPR depends largely on the medication, formulation, and state of disease. 
Osterberg & Blaschke (2005) emphasize that no consistent standard exists that constitutes 
appropriate adherence referring to some trials that require greater than 80% acceptance and 
others that require greater than 95% depending on the disease condition and severity. 
 
Medication Possession Ratio is defined as: 
MPR = (# of pills Dispensed in Time X / # of pills Prescribed for Time X) times 100.  
(Brown and Bussell, 2011).  
 
Another important subset of MPR is the duration of interval episodes between refills. Ho et al 
(2009) suggests that pharmacy records should also assess refill frequency and date of last 
dispensation. This may facilitate a method to recognize medication nonadherence. 
 
Achieving accurate measurements of adherence is merely the beginning of solutions needed to 
help improve medication adherence. Granger & Hayden (2011) find that technological 
interventions without active human insight are ineffective regarding rate improvements of 
adherence. Granger & Hayden (2011) also note that in-person interaction complimented by 
automation of a reminder have the most effectiveness. 
 
Krueger et al (2005), during a comprehensive review, was able to categorize several intervention 
tactics aimed at helping to improve adherence to medications, including theory-based methods 
which target knowledge and information, disease-based methods which target knowledge on the 
disease, dosage simplification, reminders, hospital discharge programs, one time discussions, and 
self-care initiatives. 
 
It has been determined that interventions addressing adherence have shown modest results (Ho et 
al, 2009). Haynes et al (2008) noted singular interventions have been seen to be less effective 
than a multi-tiered approach, recognizing the multifactorial set of reasons for nonadherence. 
Deber (1994) suggests, as a means to improve adherence to medication regimens, that individual 
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patient autonomy is critical and participation in the process mandatory. Given the increase in a 
patient’s ability to retrieve information on their own health diagnosis, and possible solutions 
through various advancements in technology and the Internet, Deber (2014) does maintain a 
strong argument. 
 
Overall, the ability to measure medication adherence rates can be deemed an estimate at best.  
Many of the tools used to promote adherence are not available in all countries. Furthermore, no 
individual measurement strategy has been proven to demonstrate optimal and consistent results. 
Hence, a multi-method approach (Sabate, 2003) that combines many of the strategies and tools 
highlighted may seem the best avenue to pursue from a broad population perspective.  
 
2.7.7 Financial Assistance provided by the Pharmaceutical Industry 
 
Many medications that have been developed in recent years for diseases such as cancer, multiple 
sclerosis, rheumatoid arthritis, and HIV are generally more expensive for the healthcare system.  
Most of these medications are considered ‘specialty medications’ and the higher costs associated 
with them can present barriers to medication access, leading to patients non-adhering to the 
medicine regimes (Zhu et al, 2018).  
 
Studies consistently show that the higher cost of medications leads to lower adherence rates due 
to the patient often having to pay more for their portion of the prescription, therefore delaying or 
avoiding taking their medicine as prescribed (Zhu et al, 2018). The patient payment requirement 
is known as the copay or coinsurance portion, and has been rising in recent years. In fact, in the 
United States during 2015, specialty medications accounted for 75% of all the new growth 
related to spending and of 36% of the total cost (IMS Institute for Healthcare Informatics, 2016). 
This is expected to continue for the foreseeable future and is viewed as a great burden to the 
payers within the healthcare system, most notably, when it comes to indirect costs such as poorer 
clinical outcomes leading to patients not being able to work or lower productivity outputs. 
 
It is believed that financial assistance provided to patients with higher medication costs to 
compliment or assist in the payment of their copay portion may help to lower the direct and 
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indirect impact on the healthcare’s fiscal burden. Pharmaceutical companies which develop, 
manufacture, and sell these specialty medications, along with retail pharmacy stores, have 
commercial incentives to provide financial assistance in this capacity in order to ensure that the 
patients have access to the medications they provide. Studies suggest a connection between the 
patient's out-of-pocket (OOP) costs for specialty medications and the outright abandonment of 
the medicine regimen, resulting in intentional medication nonadherence (Streeter et al, 2011 and 
Gleason et al, 2009). Further evidence put forth by Dusetzina et al (2014) demonstrates a 
connection between higher copay costs for patients and nonadherence or discontinuation of use. 
 
Although financial assistance programs do exist, research continues to show medication 
adherence rates at approximately 50% within chronic diseases for patients who had used such 
programs. Roberts et al (2014) concluded, after following 866 patients with a chronic disease 
who participated in a Pharmacy Assistance Program, that although inpatient or emergency room 
resource requirements were lower, actual adherence to their medication regimens remained at 
50%. In this study, the benchmark for a patient to be deemed adherent was 80%; a consistent 
level of adherence across much of the research. This may suggest that the basic availability of 
the PAP, leading to financial assistance for the patient in obtaining the medication, may not only 
be the determining factor in influencing the patient to adhere to the medication regimen. 
 
Patients who have the ability to enroll in variations of financial assistance programs are able to 
lessen the cost burden generally associated with specialty medications (Garner, 2010).  
Unfortunately, there remains a gap in terms of clinicians providing information regarding such 
available programs leading only a small portion of the patient base in actually gaining access to 
the funding (Piette et al, 2004). Although, Zhu et al (2018) research suggest further research in 
the area of medication adherence and financial assistance, the coordination of information 
leading to matching those organizations whom provide fundamental financial assistance to the 
patients who need it most given the current high cost and trending newer of medications may be 
the critical link to patients not only accessing the medications but in turn adhering the regimens 





2.8 Potential Research Gaps, Barriers, and Inadequacies 
 
Research gaps continue to exist regarding the understanding of how to manage, coordinate, and 
assign interventional medication adherence approaches given the multitude of factors involved.  
Noting the complexities and variations of medication nonadherence, Brown and Bussell (2011) 
suggest, opportunities for improvement must be multifactorial. During this research, retail 
pharmacists determined and agreed that engaging the human actor, from either the patient or the 
healthcare provider’s perspective, presented many barriers and inadequacies. We are all humanly 
different and act in a variety of ways depending on the situation as it relates to either the delivery 
or acceptance of care. 
 
Kumarasamy et al (2005) note that perceived barriers to patient’s medication adherence may be 
classified into ‘themes’ such as cost and social support. Surprisingly, given a patient’s action to 
seek out medical help, the research also denoted a rarely seen concept of the benefits of not 
adhering to the medication regime, claiming that some patients are concerned with broader 
aspects inclusive of side effects. In other words, some patients intentionally associated 
medication nonadherence with a benefit to themselves. This again highlights the web of 
complexity dependent on the patient.  
 
Cost as a barrier to medication adherence was noted as one most frequently discussed factors and 
included several subset themes such as financial hardship due to life’s other necessities, self-
driven drug ‘holidays’ or intervals without taking the medication to help avoid financial 
hardship, and worry regarding future ability to buy medications (Kumarasamy et al, 2005). 
 
Kumarasamy et al (2005) further highlight the importance of social support outside of the 
healthcare system. Depending on the disease state, there may be varying levels of support with 
respect to a patient’s family, friends, and the community around them. This often impacted the 
medication adherence rates as the social support network could not only remind the patient, but 
sometimes directly assist in the administration of the medication, or even offer financial help in 




Measurement methods of medication adherence are generally classified as self-reports put forth 
by the patient, counting the number of pills, prescription refill frequency, biological monitoring, 
and various forms of electronic monitoring. Each of these categories has its limitations (Garfield 
et al, 2011, Cramer et al, 1989 & Claxton et al, 2001). Self-reporting by the patient relies on 
accurate memory and recall of the action taken. Counting the number of pills in a bottle or 
package may be unreliable due to miscounts or lost pills. Monitoring prescription refills simply 
recognizes when the prescription has been filled and medication has been dispensed at the 
pharmacy and is not representative of when a patient actually takes the medicine. Biological 
monitoring is often deemed impractical or invasive, while electronic monitoring is only effective 
in recognizing when the patient opens the medication container. 
 
Validation of reporting systems may not always be an accurate measure for recognizing 
medication nonadherence. Self-reporting methods such as pill counting, electronic monitoring, 
and the testing of blood levels all have an element of patient reliance, emphasizing the 
importance of awareness that the information is only as good as the accuracy of data put into the 
system. 
 
Ho et al (2009) reference several studies that demonstrated improved adherence rates, focusing 
on interactive voice technology, pharmacist-led interventions, education, reminders, and follow-
up with the healthcare provider. Unfortunately, management personnel are needed to oversee 
coordination. This increases cost of implementation (Ho et al, 2009), in turn, presenting 
challenges given the numerous barriers involved. Though a daunting task to pursue, research 
gaps exist regarding the complexities of how to manage, coordinate, and assign interventional 
medication adherence approaches given the multitude of factors involved.  
 
Research suggests no one solution improves adherence versus any other (Vermeire et al, 2001). 
Various aspects of medication adherence have been researched including those not only related 
to patients, but also clinicians such as physicians and pharmacists, leading to a wide body of 
potential solutions inclusive of not assigning blame, less frequent dosing regimens, recognizing 
the importance of health literacy and attentiveness (Brown and Bussell, 2011). Zygmunt et al 
(2002) note that concrete problem solving and methods to motivate patients were prevalent 
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features of good programs, while targeted programs were more effective than broad-based 
programs. This area of identifying the correct intervention after a thorough assessment of the 
patient’s situation may warrant further investigation.  
 
Electronic technological advancements in the past decade, along with the shear pace of 
innovation, require further research on their interventional impact on clinical and practical 
application. Several advancements have been noted in this literature review, each with its own 
potential for more comprehensive offerings as they continue to develop and improve yearly.  For 
example, a research gap exists regarding the use of electronic data within retail pharmacy and 
tracking patient’s refill rates over time. Historically, this data has been compared to patient self-
reports only. Moving forward, this same refill data may act as a control arm in studies with a 
comparison to many of the other means of medication adherence noted in this review. Little or 
no research exists in this area. 
 
From a similar perspective, Kronish and Ye (2013) note that, although researchers and clinicians 
often use an 80% medication possession ratio to determine satisfactory adherence to 
medications, the reference can be traced back to a small trial of scant research which has been 
done to identify whether an 80% threshold as a marker for categorizing adherence was sufficient 
for all diseases. They suggest that this lack of a specific measure might cause a void in 
knowledge, although most researchers take for granted the 80% cutoff point. As such, the same 
pharmacy data may be used to pursue new knowledge regarding medication adherence and 
various diseases. 
 
Brown and Bussell (2011) note that because influences on adherence are often complex and 
varied, methods of improvement must be multifactorial. Arguably, research gaps concerning 
medication adherence are numerous given the multifaceted background and human actor 
component. Vermeire et al (2001) argue that inadequacies of compliance research have been a 
result of assuming the patient should be a passive participant without active involvement in the 
instructions. With the abundance of medical information in today’s society and the availability of 
certain technological advances, this assumption may be challenged in the pursuit of solutions to 
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improve adherence and compliance. Furthermore, Vermeire et al (2001) proposes that, going 
forward, adherence research should focus on the rational motivations of behavior. 
 
Traditional methods of assisting patients to adhere to medication regimes include the basic non-
technological strategies such as physically having the medications in one’s possession, storing 
them in a convenient place as to cause notice, and depending on family and friends to remind 
patients. In these cases, the perceived consequences of not adhering to the medication regime are 
noted as disease progression, side effects, and quality of life (Kumarasamy et al, 2005).    
 
Technological advancements in the past decade such as the use of the internet to connect directly 
with the patient using email and SMS text messaging, as basic examples, requires further 
research efforts in order to determine their impact during practical application. This thesis 
pursued action research in an effort to generate new knowledge gathered from those on the front 
lines of healthcare, and has produced a set of smart recommendations towards improvements.  
 
Given the shear pace of innovation, and beyond the scope of these recommendations, there is the 
potential to explore how technology, financial assistance, and diseases requiring specialty 
medications are intertwined in how patients adhere to taking their medications.  
 
2.9 Literature Review Summary 
 
Within the review of existing literature regarding medication adherence, many conclusions may 
be drawn. Perhaps most dominant is the ‘urgency’ of improving medication adherence. The 
WHO’s statement that adherence improvements may be more effective than specific medical 
treatment advances (Brown and Bussell, 2011) certainly highlights the importance. Canada is not 
immune given 37 percent of the population has some form of chronic illness (9000 Points of 
Care, 2013). Furthermore, one of the largest health insurance organizations in Canada report that 
5 percent of hospital admissions and 5 percent of physician visits are directly related to 
medication nonadherence (Sun Life, 2014). Although this is true, the ability to notably increase 
adherence rates is a difficult task given the various diseases it affects and the multifactorial 




This literature review highlights several aspects of medication adherence, including the nuances 
of various terminologies in order to enable the synthesizing of available literature, the prevalence 
of the issue as a whole, various categorizations of related factors, and the overall societal impact.  
Furthermore, it has focused on the many factors that have an effect on medication adherence, 
ways to measure and improve it such as recent advances in technology, along with potential gaps 
in knowledge that exist. 
 
A common theme in the research recognizes that medication adherence is a multifactorial 
concept. Krueger et al (2005) may be representative of most researchers who determined that no 
single approach to improving patient compliance is enough to ensure or guarantee a positive 
result, and suggested that any attempt involve the patient in the process. Today, patients are seen 
as partners during the interaction. Noteworthy conclusions of Krueger et al (2005)’s 
comprehensive review included the importance of patient-centric initiatives such as proper 
education, an understanding of what to expect, clarity of possible barriers and how to navigate 
them, patient-specific regimens, close supervision, follow-up and rewards, mutual agreement on 
treatment goals, good social support, less complex treatment regimens, and individual 
counseling.   
 
This vast array of solutions for improving upon medication adherence seems like a daunting task 
to assess. Still, alternate ways of thought and specific approaches relating to adherence are 
needed (Krueger et al, 2005). The implications for practice and managerial professionals within 
retail pharmacy may be far reaching. If implemented for the long run, and embedded within the 
day to day process flow for the healthcare professional, it may be possible to improve upon 
medication adherence rates. This remains to be discovered and beyond the scope of this study 
future research is recommended to determine firstly, the extent of practical change that has 
happened in terms of recommendation adoption and secondly, are there improvement in the rates 
of adherence.  
 
If the answers to both these questions are positive, the next step would be to formally expand 
upon the scope of the practice geographically and continue to develop improvement processes to 
 
 70 
the recommendations themselves. Furthermore, the implications from a theoretical and research 
point of view will require continued assessment. As technology along with the use of alternative 
methods to financially assist the patient to pay for medications continue to innovate, these 
advances will need to be tested as to determine how best to utilize them in the pursuit to improve 
upon medication adherence rates.    
 
In order to generate new knowledge, action research requires “an intent to change the 
organization” (Easterby-Smith, Thorpe, Jackson, 2012, p. 155), in this case an entire Canadian 
industry from both the patient and professional perspectives. This is a massive undertaking given 
the unlimited variables involved in medication adherence. The possibilities go beyond that of just 
patient and retail pharmacists and may be envisaged to other aspects of healthcare. Comparably, 
the recommendations put forth as part of this study may be as clear as those put forth by the 
WHO as to better utilize the medications already developed in order to improve upon health 
outcomes. In other words, in Canada, we already have great tools to treat diseases requiring 
specialty medications. Better utilization is required with respect to adherence and instructions. 
Without argument, enhanced utilization of what currently exists would fit with local norms, 
values, and practical application. 
 
That said, the recommendations put forth by retail pharmacists in Atlantic Canada calls for a 
level of new knowledge by asserting the information which already exists within the toolbox of 
the profession. In doing so, the new knowledge and contribution to the practice of pharmacy may 
not be a giant leap in the advancement of medication adherence rates but a small and important 




This chapter outlines the action research framework along with ethical considerations that were 
necessary to design a study that would capture enough data to garner deep considerations by the 
participants of what would enable a set of practical recommendations. The research sought to 
create a new level of understanding through an attempt to change the situation being investigated 




This action research project takes a mixed-methods approach whereby the data collection process 
pursues a “partnership design” (Easterby-Smith et al, 2012, p.62), combining both 
constructionist and positivist epistemological approaches through the use of an online survey and 
two focus group sessions respectively. Attention to ‘importance of themes’ set the direction for 
the cognitive activity as to connect established opinions, practice, and contextual implications of 
the data findings (Ramsey, 2014). The data collected was isolated during each cycle and 
evaluated separately before moving onto the next cycle in the sequence. Preliminary findings 
during each cycle were presented at the commencement of each subsequent cycle in the 
sequence.  
 
The appropriate methodological choice for this research was important as the objective was to 
not only highlight the story of a very complex global problem, but narrow the purpose into a 
deep exploration and understanding of retail pharmacists’ opinions regarding medication 
nonadherence in an attempt to put forth recommendations that had the ability to evolve. The 
journey of a mixed-methods approach was pursued as the intent was firstly, to establish a 
baseline of existing ideas, context, and opinions by the utilization of a survey. This was the 
existing knowledge component of the research. And secondly, move to an activity of scholarly 
practice through the use of focus groups whereby “attention is the key cognitive” (Ramsey, 
2014, p.7).  The methodological choice established the baseline norm and then let the 
participants drive the attention to active practice.  
 
This research method of choice is defended in that the methodology required the ability to garner 
provisional insight or knowledge (hence the survey), reflective moments, a test environment, 
logic input, evaluation, and ongoing improvement throughout subsequent action cycles. In 
advance of the decision, it was important to fully understand the objectives of the overall 
research. Firstly, how would I establish the provisional insight? A survey was sequenced to 
commence the research utilizing the five WHO categorizations while adding two additional 
broad topics to inquire about the existing paradigms of the frontline practitioners. This was by no 
means the only methodology that may have been pursed at the start of the field research, but did 
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serve its purpose in informing a framework basis to proceed with general knowledge that the 
participants could understand.  
 
Ramsey (2014, p.16) discusses the importance of “a practice of inquiry” as one of three subset 
domains of attention within managerial research and the action it involves as a formalized 
method to determine and test ideas towards arriving to a place of emergent sense making instead 
of being purely analytical. This scholarly practice research was focused on engagement, inquiry, 
and navigation of the themes or ideas of interest and was reflected in the methodological choice. 
 
The situational ‘context’ was not only critical to the choice of research methodology, especially 
during the action cycles as a foundation for reflection, but also to mapping the terrain. In order to 
map the terrain in a scholarly fashion, it was critical to engage the intellectual imagination of the 
retail pharmacists within a “robust, intentional, and evaluative inquiry” (Ramsey, 2014, p.15). 
The depth of the participant’s contextual competence aided in the ability to highlight the issues. 
Arguably, this level of insight, was only recognizable by practicing front-line professionals as to 
what the discoveries, or limitations, might be.  
 
Enormous amounts of knowledge relating to medication adherence is available and well 
established. Adherence rates, lack of change, and similar solutions are common language across 
the academic literature. Significant reference and acceptance are given to the existing knowledge 
base relating to findings established by reputable researchers and authoritative bodies such as the 
WHO. Arguably, what is lacking is scholarly, rigorous practice that attempts to pursue “ongoing, 
skeptical and evaluative testing of actions” (Ramsey, 2014, p.18). In other words, what is the 
challenge to this knowledge?  
 
Mapping of the terrain set out to identify themes of importance and attempted to interpret what 
resonated in detailed communications with patients. The forty themes isolated by the participants 
provided the robustness within the rigorous inquiry while the action cycling allowed for the 
“intentional and evaluative” (Ramsey, 2014, p.15-16) insight to narrow the importance of 






The considerations and reflexive critique by retail pharmacists formed at a level of interaction 
through “knowing in action” (Ramsey, 2014, p.8) assisted in determining the two specific 
recommendations put forth as an output of this thesis. Varying levels of ‘importance’ of each of 
the forty different themes generated by the research helped isolate those that were a priority in 
order to assert lasting change of medication adherence rates. In doing so, the retail pharmacists 
brought concentrated attention to integrating ideas into practice. The recommendations would be 
intentional and purposeful.  
 
As a result of connecting theory to practice, the patient’s ability to fund their medications, 
monitoring of prescription refills, and the timing of discussions with the patient surrounding their 
medications were the central concepts once the bridging of ideas, inquiry, and navigating the 
relations had taken place.  
 
Upon the formulation of the two recommendations during the final action cycle with retail 
pharmacists in Atlantic Canada, I had the opportunity to test plausibility on a broader scale in 
order to assess the potential for practical application on the front lines of healthcare. Separate 
meetings took place with the Canadian Pharmacists Association, which represents 60,000 
membership pharmacists, and the Neighborhood Pharmacy Association, which represents the 
chain drug stores which account for approximately 75% of the Canadian prescription volume. 
Although none of the specific underlying findings in this study were disclosed so as not to 
impact the integrity of the research, the topic of medication nonadherence as major problem was 
discussed. The smart recommendations were put forth as a potential positive and practical 
offering and each organization supported this action moving forward. This subtle market test was 
an indicator of acceptance by those that are attentive to the profession, and a measure of 







Table #3: Demographic Profiles of Participants 
 
 
The research sought to develop practical solutions for those on the front lines of healthcare 
directly working with patients every day. With the ability to pursue continuous cycling, forward 
thinking, and rigor towards the same, change may happen. This was the objective in this action 
research as it took in the perspective of practicality in a ‘how to’ (Elliott, 1991) approach, 
centered around the opinions of retail pharmacists.  
 
Choosing to implement a mixed methods methodology fit the techniques required to garner a 
baseline of current believes and knowledge regarding medication non-adherence and the ability 
to use that baseline to lead into the deeper conversation and evolvement of new knowledge. The 
baseline of current opinions put forth by the participants taking on a positivist paradigm meant 
that as the observer I was independent, and given concepts of the WHO predetermined for basic 
units of analysis during measurability generalization could occur. The online survey fit these 
requirements. The transition into the cycling of focus groups thereafter would be able to utilize 
the survey outcome data whereby the philosophical perspective would then border on a move to 
the epistemology of relativism, in order to compare and generate opinions and new insights, to 
that of nominalism that enabled invention, participatory critique, engagement, shared 
experiences, sense-making, and the possibility of new knowledge and actionable 




The ‘sequence’ and starting point regarding the methodological design was critical as to put forth 
study aims, optimally utilize the data, and analyze or interpret the findings before a set of 
recommendations could be determined. However, dominance of both perspectives was given 
equal weighting and became critically important within the ‘integrated’ data analysis utilizing the 
Mixed Methods Matrix (Overall Findings, Table #4).  
 
The ontological perspective was also an important consideration. Given that the patient is at the 
root cause of the concept of medication non-adherence which is socially defined, viewed, and 
experienced differently by different people a relativist paradigm was required. Also, a relativist 
paradigm across the whole research project was a must “if ontologies are very different there 
will be no way of resolving the confusion” and “if they are close enough then resolution may be 
possible” (Easterby-Smith, Thorpe, Jackson, 2012, p.64). This was also a good choice from the 
pharmacist vantage point as their views were assumed to be different from one professional to 
the next depending on backgrounds, status and practical pharmacist-patient experiences. 
Furthermore, as pragmatism “argues that knowledge and understanding should be derived from 
direct experience” (Easterby-Smith, Thorpe, Jackson, 2012, p.344) and noting that the objective 
of the study was to put for recommendations it would be important to take a pragmatic approach 
to commence without inhibiting creative ideas and discussions thereafter. 
 
Data assimilation posed challenges as integration of both methodologies is ‘difficult’ at best 
(O’Cathain et al, 2010). Heading into the study, I realized that this may have led to a limitation 
in garnering new knowledge as to put forth future recommendations. It may have presented 
barriers in this synthesis (Voils et al, 2008). Fortunately, some researchers argue that there are 
methods, when adopted adequately, which provide pathways to synthesizing the data. I chose an 
integrated design put forth by Sandelowski et al (2006, figure #27) in an attempt to answer the 
research question regarding medication adherence.  
 





AR Cycle 1 - Online Survey | AR Cycle 2 – Focus Group One | AR Cycle 3 – Focus Group Two 
 
 
The participants did not have input into the design of the three cycles. Furthermore, the research 
was considered participatory action research as it sought to make change as a result of 
collaboration and reflection in settings outside the practical work place as to focus on the deep 
consideration of the factors and possible solutions of medication non-adherence. The inquiry was 
based on practical experiences of the participants. 
 
The concept of cycles during the action research highlights the continuous process to plan, act, 
observe, and reflect (Kuhne & Quigley, 1997) in the formal context. The individual 
epistemological approaches support the methodology design choice and requirements during 
specific times during the study. The terms cycles and either the online survey or focus group 
sessions may be used interchangeably depending on the context of the writing and the AR 
sequence above. Beyond the broader explanation of the framework, the chapter provides an in-
depth explanation of the action cycles 1, 2, and 3. 
 
3.1 Action Research Framework 
 
Based on a preliminary assessment, the five WHO’s categorizations of Patient, Therapy, Disease, 
Socioeconomics, and Health Related Systems relating to reasons for medication non-adherence 
would be the ‘core’ of the AR Framework. For the purpose of this research, the current available 
knowledge within these WHO categorizations was best suited to the research goals. Furthermore, 
this core would be further enhanced by breaking out two subset groupings that existed within the 
five formal categorizations to that of their own. The two groupings of ‘technology’ and ‘financial 
assistance provided to patients’ warranted further review in order to assert their role within the 





 As the researcher, I decided that these seven categorizations would optimize setting up a 
structured approach, without bias, to determine the current views and opinions of retail 
pharmacists in Atlantic Canada. An online survey during cycle 1 to commence the study, was an 
appropriate means to outline a solid baseline. This design highlights the importance of the survey 
results serving the requirements of focus group sessions thereafter. Hence, cycles 2 and 3 were 
qualitatively driven as to “demonstrate generalizability, and to provide deeper insights that 
explain why things take place” (Easterby-Smith, Thorpe, Jackson, 2012, p.63).   
 
The choice of a mixed methods approach and subsequent framework was not meant to highlight 
any of the “long-standing tension” (Easterby-Smith, Thorpe, Jackson, 2012, p.1) of either 
method but complement each other during the scope of the project. This is consistent with the 
notion that for many important questions within management research that there are times when 
both methods would be not only acceptable, but optimal (Easterby-Smith, Thorpe, Jackson, 
2012). Furthermore, although there is debate on the use of mixed methods approaches, for the 
requirements of this study, I sided with those that argue in favour in order to “increase validity 
and generalizability of results” (Easterby-Smith, Thorpe, Jackson, 2012, p.61). 
 
The online survey structure was set up to align with the seven chosen categories. The instruments 
used in the research included a survey via SurveyMonkey (SurveyMonkey.com), an online 
software tool. Thereafter, small private focus groups to create discussion and an open dialogue 
were pursued. For data capture during the cycling of meetings throughout the focus groups, field 
notes, journaling, and audio recordings were used to assist in collection. This not only enhanced 
the quality of data during post-meeting assessments and early analysis, but also served as 
preparation for future meetings as part of the cycling process. 
 
The intent of the action research framework was to create an environment whereby retail 
pharmacists in Atlantic Canada were able to focus their attention away from routine professional 
tasks and guide the discussion and thought process directly towards medication adherence. The 
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desire was that the participants would gain a comfortable and relaxed feeling with their own 
professional colleagues in order to create a forum for them to express their views. The opinions 
formed through engagement in research project were intended to provide enough data to enable 
the formal drafting of recommendations. If appropriate, these recommendations would be given 
to pharmacist colleagues along with other healthcare providers to assess and potentially 
implement in the practical setting thereafter. Furthermore, it could be possible that any of the 
smart recommendations may set the stage for third-party interest, commercial or otherwise, to 
pursue those actions that bring into reality the day-to-day set of professional tasks required to 
help improve medication adherence rates in the practical setting.   
 
The goal was that the formalized smart recommendations, put forth by the practicing 
pharmacists, would become entrenched in the approach relating to matters of medication 
adherence at the point of care within retail pharmacies. It would need to become part of the 
protocol rather than an afterthought or an unachievable task on a list of competing priorities 
during a busy day in the retail pharmacy setting. As outlined in Figure #3, the action research 
process suggests to plan, act, observe, and reflect (Kuhne & Quigley, 1997), so too does the day-
to-day operational aspect of long-term progress of medication adherence.   
 
Overarching guidelines of the Research  
 
1. Create an approach with the participants that keeps them comfortable to communicate but 
also challenges them to engage colleagues on the topic. 
2. As participation was voluntary, ensure to provide an environment that promotes emotion 
and passion in order to engage them and encourage them to speak freely on the subject 
matter. 
3. Encourage collaboration within the profession for the good of the patient, even though 
most participants will be employed with competitive organizations. 
4. Celebrate the ability to be self-critical of conversation in order to build commitment to 
progressing towards a set of smart recommendations. 
5. Explore direct examples of failures and successes.  
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6. Implement short cycles with small groups in order to slow the speed of progression. This 
will keep the subject matter at the forefront of the minds of participants. The research is 
not expected to find a set of complete solutions to medication nonadherence. Progress is 
the key and any set of smart recommendations should be able to be improved upon after 
the action research.  
7. Keep the cycles moving. Ultimately, there should be no end point in the pursuit of 
improvement to medication adherence rates.   
 
 
Figure #4: Action Research Process as a Conceptual Model 
 
Each of the cycles built upon its antecedent by informing the participants of the preliminary 
input and results put forth by themselves and regional colleagues. This not only provided the 
ongoing feedback required to move through the cycles but continued to demonstrate themes 
necessary to investigate further and open up new discovery. This process was meant not to lead, 
but rather to open up the thought process and enable a deeper dive into the unknown given the 
comfort the participants felt in expressing their views and opinions (Easterby-Smith, 2012). 
These data collection techniques were used to ensure quality and accuracy.  
 
Polyangulation, or by viewing the realities in multiple layers and dimensions (Raul AM, 2014) to 
compliment multiple realities (as in triangulation) assisted in the interpretation and 
comprehension of the data collected by the end of the third action cycle. This approach made 
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sense in relation to the recommendations and in terms of practical implementation. This 
consideration was taken given the social realities and potential shifts in the interpretation of 
discussions from one cycle to the next. Medication adherence is complex, given the human actor 




The online survey, cycle 1, ran from September 6th – October 9th, 2017. Preliminary survey data 
analysis took place from October 10th – 30th, 2017. Thereafter, cycle 2 (focus groups) took place 
from November 1st – 22nd and cycle 3 between November 28th – 30th, 2017 respectively. Ongoing 
data analysis took place during the week between both focus group sessions. It is important to 
note that the mid-cycling analysis took place not only to view data upon collection but to use that 
data to reflect and plan as part of the action research process. Data from cycles was discussed 
and reviewed as part of the opening of the ongoing sequenced cycles. 
 
A total of 115 participants engaged in whole or part of the survey from across the four targeted 
provinces. This number of participants represented 3.7% of the 3108 total licensed pharmacists 
in Atlantic Canada (NAPRA, 2019). The survey garnered a convenience respondent sample 
which was the optimal outcome as to evaluate the current general opinions of retail pharmacists 
and set the stage for discussions. This convenience sample was a non-probability sampling 
method which did not aim to get specific with correlation or probability of any of the sample 
elements. The sample was meant to be convenient, as the provinces are located in reasonable 
geographical vicinity to where I live, and simply evaluate the current opinions of retail 
pharmacists in Atlantic Canada without providing probability statements or detailed statistics. Its 
value to the study was to enable the baseline opinions within the categories chosen relating to 
what is currently known in medication adherence without limiting the ability of future cycles to 
create their own pathways or categorizations of new discovery. 
 
Data from the focus groups were coded manually rather than automated using any form of a 
software tool. This traditional approach involved myself, as the researcher, to assign a manual 





My role as the researcher 
 
My role as the researcher, considering both the important topic and interest within it, came with 
some advantages in that, although I wasn’t a pharmacist participant and assumed without bias in 
terms of facilitation, I was seen as part of the collective group discussion. Furthermore, I was 
seen as objective in my role during the setup of the research meetings, discussion facilitation, 
and journaling. As well, my background related to their industry allowed me, to understand 
much of the sensitive information and discussion without having to stop and ask for clarification. 
There was a level of knowledge relating to their profession, albeit assumed, leading into the 
discussions. 
 
Unfortunately, many of the attributes I brought as the researcher, may have created bias towards 
any of the interpretation during the conversation. It may be possible that some of the content 
leading to findings would have been inaccurate as a result of misinterpretation. Furthermore, as 
novice researcher, I may have focused on the larger discussions rather than those that may have 
been a deeper one-off which could have led to new knowledge. In other words, the routine 
conversations may have been overlooked especially given the limited amount of cycles during 
this research. This limitation may as well not have provided the time necessary to establish 
optimum levels of trust. This is an unknown. 
 
As an insider, I was comfortable with the duality of roles as I took on the perspective of a 
researcher, although knowledgeable in the subject matter, limiting my discussion and opinion 
other than facilitation and clarification of the participant’s communication. Furthermore, there 
were no notable conflicts of interest. Any perceived commercial or political stances assumed 
during the early introductory phases of the sessions, based on varying employers, where quickly 
dismissed at commencement thus supporting the professional aspects of their profession and 





3.2 Ethical Considerations 
 
Participants in either of the quantitative or qualitative methods of the study had minimal potential 
for any personal or professional risk. The importance of privacy and confidentiality played a 
critical role in the consideration of methodological choice (Brownlow & O’Dell, 2002), meeting 
settings, presentation structure and research flow. No personal data was needed within the 
enrolment for the online survey and as such informed consent was appropriate. Given that 
individual data requires reasonable protection from risk of loss, access, the ability to change, or 
viewing (Elgesem, 1999) this note leading into the online survey was bolded and implied consent 
was assumed based on the participant proceeding to fill out the survey thereafter: 
 
Please respond to these questions openly and truthfully. All results will remain 
confidential and will only be reported in aggregate form. No individual personal 
identifiers will be reported in order to protect your confidentiality and privacy.  The 
data will only be available to the researcher. 
 
The survey invitation and survey questions are presented in Appendices D and E respectively. 
Data collected during the survey were stored in the SurveyMonkey system: 
 
SurveyMonkey Website privacy policy: surveys are stored in a SAS 70 Type II certified Sungard 
data center protected with biometric access controls, a firewall that restricts access to all 
outgoing ports (except 80 and 443 as is customary), QualysGuard network scans run weekly, 
McAfee HackerSafe scans run daily, and data backups run hourly.  
 
In keeping with the important ethical principles (Easterby-Smith, Thorpe, & Jackson, 2012) for 
focus groups, great care was taken to determine the venue, setting, and discussion flow. 
Independent focus group meetings were conducted in closed settings in order to ensure privacy 
and confidentiality. All participants were provided participation information sheets in advance of 





Limited personal data was required. Questions were asked regarding the professional background 
individually and presented in the collective context. For Consent forms and Participation 
Information Sheets refer to Appendices A and B respectively. An example of the copy of the 
Focus Group invitation is presented in Appendix C. Presentations during both focus groups are 
available in Appendices F and G respectively. 
 
As with any type of collected or stored electronic data, even given significant safeguards for 
protection, it is reasonably possible for any form of information exchange through electronic 
communication to be hacked or accessed by external parties, the participants were made aware of 
this risk. If this were to happen, minimum or no harm would occur as a result as all data 
collection omitted any individual or personal identifiers including that of the participant or 
patient. These types of identifiers were unnecessary for the purpose of the study. 
 
All data collected during this action research was be kept on a secure, encrypted flash drive. This 
will be done for up to a five-year period. The flash drive is password protected and will be 
accessible in the researcher’s private office and residence. This office is locked at all times when 
not being used. Upon five years of storage the secured flash drive will be destroyed. 
 
3.3 Action Research Cycle 1: Online Survey 
 
Survey Design: Utilizing the WHO categorizations relating to Medication Adherence 
 
The WHO has identified five broad domains that are categorized in relation to medication 
adherence including Health System, Socioeconomic, Patient, Disease, and Therapy. Not only 
does the WHO refer to these domains from their perspective, research generally falls within one 
of these five areas, or at the very least, a subset list of associated variables which would fall 
within any one of said areas. For the purposes of this study, these domains are considered to be 
reasonable given the WHO’s status and reputation. Furthermore, there was no challenge on the 
baseline list of these categorizations as the qualitative component during the focus group 
sessions would provide the avenue to discover other themes. The challenge or pursuit of new 
knowledge was devoted to uncovering practical applications to improve upon medication 
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adherence put forth by frontline retail pharmacists.  
 
A survey of 24 questions provided a non-probability convenience sample from 115 retail 
pharmacists across Atlantic Canada. The survey captured the demographic profiles of the 
participants within the first ten questions and, for the remaining questions, focused on the ‘level 
of importance’ of subset factors categorized within the seven broader dimensions outlined within 
the title of the thesis. Importance of factors was determined by rankings of the participants 
whereby a software survey tool, SurveyMonkey, was used to implement a design with a 5-Point 
Likert Scale. Importance of themes were ranked whereby 1 stood for “Not Important”, 2 
“Somewhat Important”, 3 “Important”, 4 “Very Important”, and 5 “Extremely Important”. 
Thereafter, responses were grouped into three categories: 1) “Not Important/Somewhat 
Important”, 2) “Important”, and 3) “Very Important/Extremely Important” to facilitate analysis. 
 
Participants were invited to participate in an online survey through each of their provincial 
associations membership databases. An email request including the survey introduction, my 
personal background, research purpose, and link to the survey were included. Reminders were 
sent out periodically to ask members of the association to engage with the survey.  
 
Respondents were well educated with almost all having a university undergraduate degree at 
minimum. Most had a large amount of experience working in a pharmacy setting with a third 
working in their current job function for 10 years or more. The vast majority spent considerable 
time dealing with their patients, with almost half spending more than 30 hours with patients on 
an average week and almost half seeing at least 45 patients on an average day. Nearly half of the 
participants worked for a Chain retail pharmacy while almost two-thirds of respondents worked 
in an urban environment. The age range was split down the middle with just over half under 40 
years and the other half over 40. Female respondents far outweighed the survey with almost 
three-quarters.  
 
To summarize, the participant demographics suggest that those responding to the survey should 
have considerable and reliable insight into the patient populations they serve on a daily basis. 
Increasingly, many of these patients entering the pharmacy have diseases requiring specialty 
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medicines given the growth of these types of medicines within recent years.  
 
3.4 Action Research Cycle 2:  Focus Group Session 1 
 
Three separate sessions were required for this focus group based on geographical considerations 
as participants were spread over three of the four provinces. Each session pursued a two-hour 
interactive discussion and was journaled and audiotaped. Each session garnered several pages of 
hand-written notes used to capture verbatim quotes, statements, and interactive subtle cues. The 
journaling by use of field notes was relied upon extensively for analysis post-focus group 
sessions. The audiotaping was used to confirm what was written and used only as a secondary 
backup for clarification if necessary.  
 
Notably, the non-verbal communication was important as it provided a level or helpful measure 
of importance during that conversation or subtopic. Although observation of the non-verbal 
communication was not scientifically driven, it did take into consideration such things as body 
movements, posture, tone, and facial expressions to assert a level of importance of the noted 
discussion points. The observation of non-verbal aspects was considered casual and not formally 
documented other than imbedding in the importance level. The informality of the non-verbal 
observation was based on casual perception and understood to be a limitation given the insider’s 
perspective.  
 
Furthermore, many subtopics were given ample time in order to dig deeper on the underlying 
issue. The liberty to flow into various themes provided the understanding and breadth of 
possibility to put forth suggested changes leading to the set of smart recommendations.   
 
Themes were assessed based on ranking of importance (high, med, low) by way of manual 
coding which is often used in qualitative research. This provided a means of “quantitising” 




The total participants for the first of two focus groups across all four Atlantic provincial regions 
were 10. This included 5 from Prince Edward Island, 3 from New Brunswick, 0 from 
Newfoundland and 2 from Nova Scotia.   
 
Although Newfoundland participants showed interest during the online survey portion of the 
research, little interested was shown to be involved during the focus group sessions thereafter. 
The survey data from Newfoundland respondents came from a vast amount of geographical 
locations and the focus group session was to be set up within the largest urban setting. Although 
it is unclear why no participants came forward, it is possible that the distance to travel may have 
been a limitation. As a result, action cycle meetings were not set up in Newfoundland. For the 
collective focus group session exclusive of Newfoundland, three separate meetings had to be set 
up based on the geographical locations of the participants. This created a significant amount of 
effort in the planning and execution of each individual meetings and data collected from each 
were grouped together. 
 
Participants from the three provinces came from a variety of workplace backgrounds including 
chain pharmacy, banner pharmacy, niche or specialized pharmacy which focuses almost 
exclusively on patients with diseases requiring specialty medicines, and pharmacy independently 
owned or with a hospital background. With the exception of one participant who had over ten 
years of experience, all participants had a minimum of 20 or more years practical work 
experience on the front lines, directly with patients.   
 
Written notes during each focus group session captured both verbatim comments and opinions 
throughout the groups.  Though difficult to capture, nonverbal body language was attempted to 
be recorded during the discussions as to assist in validating the true meaning of the groups’ 
communication. For example, was ‘groupthink’ a part of the broader meaning or was there true 
consensus? The sessions were also audiotaped in order to verify the intent and translation of the 
discussion points. 
 
Regarding the interview and facilitation skills of myself as the researcher, there was no formal 
background training in the aspect of qualitative research interviewing. However, I had been 
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previously trained in the field of behavioral event interviewing for employment purposes and had 
spent decades in people management which often included formal interviews, facilitation, and 
presentations. Although not trained in the profession of pharmacy, I had over 25 years of direct 
experience interacting with pharmacists as my customer within the pharmaceutical industry. As 
such, I did not encounter any difficulties during the sessions. Furthermore, the focus groups were 
conducted in the English language and attention during discussions could focus on both verbal 
and nonverbal points of discussion. 
 
3.5 Action Research Cycle 3:  Focus Group Session 2 
 
Participants who had been involved in the first action cycle were given priority to participate in 
the second focus group or action cycle 3. As with action cycle 2, a total of three independent 
meetings were set up based on geography in closed settings as to ensure privacy and 
confidentiality. Furthermore, two new participants joined the group and were provided 
participation information sheets upfront and formal written consent was discussed and obtained 
prior to the session commencement.  
 
The implementation of this focus group was consistent with that of Cycle 2. Again, themes were 
assessed based on ranking of importance (high, med, low) by way of manual coding. 
 
Collectively, the data was formally assessed by an ‘integrated’ analysis utilizing the Mixed 
Methods Matrix (Overall Findings, Table #4) to arrive at the overall findings. Within the 
analysis, treatment of data throughout each cycle focused on important themes. As mentioned, 
Cycle 1 utilized a quantifiable approach with a Survey and ‘5-Point Likert Scale’. Cycles 2 and 3 
level of importance rankings were determined with ‘manual coding’ by myself as the researcher 
and based on observation. The final seven themes of most importance, or those that garnered 
deliberate attention (Ramsey, 2014), required a consistent level of ‘high’ ranking throughout the 
cycles in order to be considered generative as they directly laid out the foundation for smart 
recommendations. 
 
The total number of participants across all provincial regions for action cycle 3 was eleven as 
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one participant dropped off in Nova Scotia. As such, this session included four from Prince 
Edward Island, three from New Brunswick, zero from Newfoundland and four from Nova 
Scotia. The two new participants from Nova Scotia were easily able to engage in the discussion 
as there was a brief overview of the first focus group session results and agreement was gained 
on the themes and issues that were arising. This slight change from one focus group to the next 
had no effect on the findings. Again, although Newfoundland participants showed interest during 
the online survey portion of the research, little interested was shown in being involved during the 
action cycles thereafter. As a result, a session was not set up in that province.  
 
Consistent with the cycle 2 focus group, participants were noted to have come from a variety of 
workplace backgrounds including chain, banner, specialty and independent pharmacies. Of the 
total participants in the third action cycle (focus group), 9 had participated in the second action 
cycle (focus group). The other 2 were new participants but engaged quickly and agreed with the 
themes developed from the survey and prior focus groups.  
 
Overall, this chapter binds together the action research framework regarding epistemological and 
ontological perspectives, ethical considerations, my role as an insider, and methodological 
approaches during each cycle. The choice of a mixed methods approach seemed justified for this 
study. Arguably, from either of the philological stances, there will be advantages and 
disadvantages along with varying receptivity of the study direction by participants. The most 
significant issue evolved around how to evaluate the data. Based on a review of different 
approaches, an integrated analysis often used in health research was chosen.  
 
The following chapter takes a deeper dive into each of the action cycles data analysis 
methodology and reflection before leading into the complete evaluation of outcomes. 
 
4.0 Story of Cycles of Action, Reflection 
 
The recommendations put forth as an output of the key findings, consistent with actionable 
knowledge as a DBA requirement, determine that action is needed now although confidence 
levels will be lower in the pursuit of practical change. Reasonable judgement has prevailed 
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throughout the three action cycles in order to submit that further long-term cycling is required as 
to embed the processes of natural day-to-day work flow and evaluation directly into the practical 
settings or industry context.  
 
This chapter provides an overview on how the action cycles were designed, processed, and 
implemented. Reflection between each action cycle provided space to commence with the 
preliminary analysis and sensemaking as well as develop the status content for the opening of 
future cycles. Cycle 3 also led to the evolvement of actionable recommendations given the 
important themes and new knowledge that was developed. 
 
As noted by the Rich Picture Experience of the Author and Participants (Figure #3), participants 
in the action research, retail pharmacists at the forefront of interactive patient care, were within 
the locus of action. Their position within the environment is not only unique, but demanding 
given their place within the healthcare system structure and process, at the forefront of 




Working Environment - Structure 
 
Prior to entry into the profession, pharmacists are trained in the profession of medication 
dispensation with an underlying set of standards around a broad range of clinical, ethical, and 
practical domains. This not only outlines their role within the clinical process inclusive of other 
stakeholders, but considers important aspects of the environment such as the significant number 
of patients with a chronic disease and how medication adherence is a dominant factor. 
Participants did note that although other aspects of the retail pharmacy environment were 
highlighted and acknowledged during education and training, the conflict of the ‘professional’ 
and ‘commercial’ expectations were less of an emphasis and were assumed to be understood. 
Participants felt that this conflict impacted the concept of ‘time’ available within a busy retail 
setting. Furthermore, participants acknowledged the lack of training around the importance of 
 
 90 
communication directed towards medication adherence behavior modification aside from 
formalized medication instruction and counselling.      
 
Role and Integration - Process 
 
Retail pharmacists bridge their background of professional training in the commercial setting 
with integration into a generalized process cycle which involves other stakeholders including the 
patient, physicians, pharmaceutical manufacturers, public and private payers, and a variety of 
other healthcare practitioners. Their interaction within this process involves multiple levels of 
knowledge and skillsets. Two-way communication can be noted at any stage of the process, but 





During the action research cycles, the participants were asked to consider the retail environment 
and work flow processes they operate within and move from a set of opinions and beliefs, 
founded upon existing “knowledge” (Ramsey, 2014, p.6), to that of practice inquiry. During the 
transition from Cycle 1, driven by a survey, to that of the subsequent cycles 2 and 3 focus group 
sessions, the participants moved from the knowledge paradigm to a focus on deliberate attention 
(Ramsey, 2014).  
 
Observationally, the stories of action noted the conversations as purposeful and generative 
whereby participants moved from a position of guardedness, given their framed positions within 
the structure and being employed by various and competing organizations, to that of 
understanding the research methodology and intent directed towards workable solutions. As an 
insider, I sensed the barriers of their differences breaking down very early in the process as 
understanding of the action research intentions increased, along with the realization of the 
importance of the effort. They engaged in the topic individually, rarely guarded, with passion for 
generative discovery that might lead to improvements of patient lives. Over time, the focus group 
sessions became more relaxed, friendly, with consideration of a common purpose through shared 
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experiences. The effort manifested itself in evolving themes known to be ‘important’ within the 
practical setting. 
 
As the Author 
 
My experience within the action research focused on setting up and executing the cycles in a 
structured and formalized approach. This included detailed attention to facilitation, clarification, 
and interpretation. Given that this was my first research project, I leaned heavily on the 
educational training and understanding I developed throughout the DBA degree. Fortunately, my 
industry experience and knowledge significantly help guide my actions during the preparation 
and facilitation of each cycle.  
 
Given my personal background, and that of the research methodology, I took on a pragmatic 
mindset, not committed to a singular philosophy or reality. My intent was to facilitate a quality 
research project while, at the same time, not leaning on the academic structures I was generally 
accustomed to. Rather, I let the conversations focus on the attention to detail that led to small, 
progressive steps forward. Conversations were generative in nature. The intent was to “change 
the organization” (Easterby-Smith, Thorpe, Jackson, 2012, p.155) by utilizing the resources of 
those on the front lines of a practical setting.  
 
My stories of action are reflective of my insider and outsider roles within the research. The cycle 
1 survey overwhelmingly put me in the position of an outsider. Independent decisions relating to 
the quantitative approach, within the mixed methodology, were mine alone. These included the 
survey content questions and structure, implementation with the assistance of the provincial 
pharmacy associations, and analysis. The experience within the focus groups was much different 
as I felt the dual roles were prevalent. As an outsider, the sessions entailed detailing pages of 
hand-written notes in order to capture important conversation, quotes, and subtle cues to their 
meaning. My role as a facilitator often consciously kept me in check so as not to cross the line 
into the capacity as a participant. My observational skills were critical to compliment my 




The insider role was notably important to the interpretation of non-verbal communication. It was 
within this role that the intimate understanding of the conversations took place and required 
consideration of the observational techniques assessing body movements, posture, tone, and 
facial expressions. As such, the observation of non-verbal aspects was considered casual and not 
formally documented other than imbedding in the importance level. The informality of the non-
verbal observation was based on casual perception. Furthermore, many subtopics were given 
ample time in order to dig deeper on the underlying issue. The autonomy to flow into various 
themes provided the understanding and breadth of possibility to put forth suggested changes 
leading to the set of smart recommendations.  
 
My experience as an insider was constantly top of mind. I was comfortable in the role and 
actively conscious and mindful of my position within the research setting. I took on the 
perspective as a researcher, an observer, and a facilitator.  As I was knowledgeable in the subject 
matter, during the conversations, I limited any participation of my personal opinion or input. 
Actively, my outsider actions were focused on interactions to that of organizing, session setup, 
facilitation, and details clarification. 
 
Assertions made as a direct result of the action cycling from a starting point of ‘existing 
knowledge’ garnered during the survey (cycle 1) to that of ‘attention’ provided by practical 
inquiry during the focus groups (cycles 2 and 3) led to a set of themes that were the foundation 
of two recommendations. The assertions that were dominant throughout each of the cycles were 
discussed with the participants at the commencement of each cycle in order to ensure any 
assumptions or perceptions by the author were correct. This action not only validated the 
dominant assertions but provided a critical linkage to the recommendations as an output of the 
thesis and practical inquiry. 
 
During the survey, 32 predetermined themes were provided. Each of these themes were 
considered significant variables by the author in terms of medication adherence leading into the 
survey. Based on rankings of importance, five themes emerged as dominant that were directly 
related to (assertions) the future recommendations. These themes continued their important 




Cost and how to access funding for medications (four themes) and prescription refill monitoring 
(one theme) were highlighted as assertions or necessary considerations that supported the 
recommendation:  
 
Establish a Centralized Repository of Information regarding access and availability of Patient 
Assistance Programs. 
 
Numerous quotes by the participants provided the foundation for assertions leading to the 
recommendation. All direct quotes are not listed below. Those listed below are representative of 
the assertions made that supported the recommendation. 
 
“We need knowledge and insight to be the patient assistance program advocate.” 
 
“The individual pharmaceutical manufacturers don’t advertise the programs broadly. It would 
help if they all went on.” 
 
“Pharmacists feel stretched in terms of time allocation on finding what programs are available 
and in terms of navigating the system.” 
 
“Programs vary. Offerings are different. Forms are different. It is very time consuming to do 
this.” 
 
“With respect to medication adherence, we need to take the financial burden away.” 
 
“How do we navigate the system with the huge cost to these meds?” 
 
“Some patients access the programs. Some don’t, based on not knowing how. This is creating a 




Eight other themes were added during the focus groups and contributed to the breadth of 
discussion and brought the total thesis themes to 40. Interestingly, two additional themes ranking 
of high importance were highlighted during the focus group sessions. Although not considered as 
part of the dominant themes based on the requirements of importance ranking across the whole 
research project, the assertions were the foundation for the consideration of one of the two 
recommendations.  
 
Those additional themes revolved around the importance of ‘time’ necessary to discuss 
medication adherence with patients and the ‘timing’ of those conversations. Those assertions 
supported the recommendation:  
 
Increase the emphasis and support for a national standardized approach of medication 
reviews as it directly relates to timeliness, content, funding, training, and implementation. 
 
All direct quotes are not listed below. Those listed are representative of the assertions made that 
supported the recommendation. 
 
“Pharmacists have little time for medication adherence discussions and should be compensated 
for more than just counting pills.” 
 
“Unfortunately, the majority of education at pharmacy is when a person is sick. They have to 
absorb all the information at once. They are terrified, sick, and wanting to go home. How does 
that improve medication adherence?” 
 
“Medication reviews need to take place when the patient is not sick or stressed in order to create 
the human connection.” 
 
“A personal connection… medication reviews are critical to this. Making it a basic principle 
should be paramount.” 
 




“IDR software can identify when patients need a refill and would improve medication 
adherence.” 
 
“Often, when a patient asks one question it creates others and a patient opens up.” 
 
4.1 Action Research Cycle 1: Online Survey (Sept. 6 – Oct. 9, 2017) 
 
Participant invitations for the online survey were directed at retail pharmacists in Atlantic 
Canada, which includes the four provinces of Newfoundland, Prince Edward Island, Nova 
Scotia, and New Brunswick. These participants had some experience working on the frontlines 
of pharmacy with patients with diseases requiring specialty medicines. These pharmacists were 
generally members of local provincial associations that act on their behalf to support the 
professional development and economic interests of its members to advance the practice of 
pharmacy in their designated geographical area. Through upfront telephone discussions and 
formal written requests to each of the Directors of the provincial pharmacy associations in 
Atlantic Canada, approval of the online survey issuance to their membership was acquired. The 
survey was issued by the pharmacy associations using their own membership databases.  
 
The formal request provided the thesis title, the researcher’s personal background, intent of the 
research, a SurveyMonkey (survey software) web link, a privacy statement, and an invitation to 
voluntarily enroll into action cycle focus groups thereafter. Formal approval and endorsement 
were received through acceptance by the pharmacy association Directors of each province to 
email their membership requesting participation in the survey, and to complete the survey. Refer 









Pharmacists membership in each of the four provinces included: 
 
Prince Edward Island    195 
Newfoundland    726 
New Brunswick    879 
Nova Scotia    1308 
Total Atlantic Provinces  3108 (3.7% of the total membership) 
 
Phase I of the thesis research commenced September 6th, 2017 with dispersion of the online 
survey. This component of the research which represented action cycle 1, and the quantitative 
aspect, was placed first in sequence, followed by action cycles 2 and 3 representing the focus 
groups scheduled for November, 2017. Action cycle 1 was intended to provide a convenience 
sample. Reminders to the pharmacy association’s membership went out after two weeks in order 
to encourage the participants to engage in the survey and increase the overall number of 
respondents. The survey closed October 9th, 2017. Although the respondent numbers counted 
115 participants for the survey’s duration, which did not provide a statistically significant 
representation of the broader group, the survey was considered a success.  
 
With 115 respondents, the online survey provided a convenience sample intended to garner 
primary information which determined presentation content for the introduction to focus group 
action cycles 2 and 3. The respondents represented a cross section of participants from the 
profession including a background mix of age, gender, tenure in the industry, and associated 
employers. The inference of the data collected is assumed to be representative of the broader 
retail pharmacist population within the geographical area. As statistical significance of the data 
was not required an analysis of this was not pursued. The design methodology of the 
questionnaire and data analysis was meant to provide a foundation for discussion purposes of the 
subsequent cycles in an attempt to align with answering the research question and creating 






4.2 Action Research Cycle 2: Focus Group Session 1 (Nov. 1 – 22, 2017) 
 
Participants were determined using two methods; firstly, if they indicated on the final question of 
the online survey, which was sequenced prior to the focus group action cycles, that they had 
interest in further involvement in the action research, and secondly, if they responded to the 
formal invitation issued through their provincial pharmacy association. Priority was given to 
those who responded first who had working experience directly related to daily engagement with 
patients with diseases requiring specialty medicines. For action cycle 2, based on geographical 
considerations, three separate sessions where required. The same was also necessary for action 
cycle 3 discussed in the next section. 
 
Action research cycle 2, the first of two focus group sessions, opened with a presentation to 
provide an overview of the online survey results. As previously noted, the survey was sent to all 
pharmacists in each of the Atlantic Canadian Pharmacy Association memberships prior to the 
session. This survey not only provided high-level results including opinions of professional 
pharmacists relative to the five WHO categorizations, but also addressed technology and the 
provision of financial assistance provided by the pharmaceutical industry through the use of 
electronic cards. This was intended to set the stage for formalized thought pathways that could be 
pursued during the focus group meetings.  
 
Presentation of the research objectives, researcher’s background and role, process and action 
research cycles, and high preliminary results of the online survey was implemented. This was 
provided not only to formalize the design and methodology of the research but to provoke 
themes and discussions around medication nonadherence in the participant’s own practical work 
settings. Furthermore, it also provided a loose structure or “steered conversations” (Easterby-
Smith, Thorpe, Jackson, 2012 p.133) to direct conversational engagement. Throughout the 
discussions, open probes following the organized format of a “topic guide” (Easterby-Smith, 
Thorpe, Jackson, 2012 p.133) were used to engage the audience and create opportunities for in-




As all participants had common backgrounds, though mostly working for different organizations, 
participants seemed comfortable in expressing opinions. This allowed for the emergence of both 
generally known but also unforeseen areas of discussion. Common themes were recognized and 
pursued in order to dig deeper into the root causes of medication nonadherence. These themes 
were important in the manual coding as to assign discussion points accordingly. Overall, the 
settings and forum provided an environment for the participants to which they may not have 
otherwise been exposed, given the busy pace within the practical setting and limited time to 
discuss the issues surrounding medication nonadherence outside of the workplace. Assumingly, 
they felt relaxed and were able to put forth their experiences, views and opinions without threat 
(Easterby-Smith, Thorpe, & Jackson, 2012). 
 
Given the action research cycle process, participants were instructed that it was necessary not to 
jump to conclusions, definitively attempt to match theories for medication nonadherence to 
solutions, or put forth final recommendations at that point, but rather openly pursue broad 
concepts or themes in order to bring out multiple thoughts and ideas. It was highlighted that the 
first action cycle focus group session was set up with the intent to explore a deeper 
understanding of the root causes of medication nonadherence from their own practical setting.  
 
Thereafter, data collection across the common themes was assimilated across the broader set of 
sessions before going into the second set of formal focus group discussions.    
 
4.3 Action Research Cycle 3: Focus Group Session 2 (Nov. 28 – 30, 2017) 
 
Themes which began forming during the previous two cycles were assessed based on a manual 
coding, often used in qualitative research, using the measure of importance with that of low, 
medium, or high based on my informal perception. This was implemented as to avail the ability 
to compare data across the whole study in an integrated fashion. The observational data collected 
grouped the themes into 1. Either of the seven themes that originated within the survey, or 2. 
Other themes. Other themes of importance were captured only during the qualitative sessions and 
included surprise themes, two of which were consistently rated ‘high’ across both focus group 
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discussions and eventually played a critical part in the development of the smart 
recommendations. 
 
To commence this session, a brief overview of the original presentation was provided which 
included the research objectives, researcher’s background and role, and process. Furthermore, 
action cycle 3 began with the provision of an in-depth summary of the common themes 
discussed during action cycle 2, the previous focus group session, in order to create an 
environment in which to dig deeper on the root causes of medication nonadherence. These 
themes were given priority during action cycle 3. One further objective of this action cycle was 
to attempt to coordinate development of a set of smart recommendations to be put forth by the 
participants based on the themes generated during the action research. 
 
4.4 Methodology Discussion 
 
Surprisingly, action research focused on deliberative attention by retail pharmacists to generate 
intentional and purposeful outputs surrounding medication adherence is, essentially, very 
limited. Researchers have consistently used empirical methods for decades while those involved 
in the day to day delivery of healthcare to patients have generally accepted, not only the process, 
but also the results. This highlights a significant gap in the overall research focus and the reliance 
on traditional methods. Argyris (1996) argues that interventions are unable to be pursued when 
‘operational’ definitions are unknown that utilize underlying tacit and explicit knowledge to 
discover the intervention. I strongly agree.  
 
Who best to engage, inquire, and navigate through the underlying considerations of medication 
nonadherence other than those practitioners that are one on one, face to face, within the center of 
gravity, with the PATIENT? It is based on this strong foundation, that I defend the reliability of 
the participants, their commitment, and involvement in this research. As the author, I ask, “Why 
hasn’t significant effort within action research been afforded such an important topic already 




This is a ‘real problem’ in a system that requires ongoing planning, assessment, adjustment, and 
evolvement. The basic concept of what numerous academic researchers suggest as solutions 
focused on a ‘multifactorial approach’ requires a constant ongoing set of cycles on many 
different narrowed pathways within medication adherence. The participants in this research, 
retail pharmacists, need to be congratulated on their energy and attention to detail on pursing 
workable solutions or a formalized set of smart recommendations. For those individuals, entering 
the action research was not mandatory. It was the pursuit of a better understanding that led them 
to this point by asking the tough questions and digging deeper on the emergent thoughts. It was 
about challenging the status quo, knowing full well that, although efforts may avail 
improvements, the road ahead within the practical setting will always require unique attention 
given the patient, a human actor, is each unique to their individual needs. 
 
 
5.0 Evaluation of Outcomes 
 
5.1 Overview and Analysis 
 
The required sequence of the partnership design and action cycles directed that the online survey 
was to be implemented first and the two sets of focus group sessions to follow thereafter. The 
online survey was issued simultaneously across each of the four Atlantic Canadian provinces 
through the provincial retail pharmacist’s industry body known as pharmacy associations. Each 
provincial pharmacy association issued a communication invite to their respective membership 
utilizing their own individual databases. 
 
Research Sequence  Action Cycle 1: Online Survey 
                     Action Cycle 2: Focus Group Session One (three groups) 
   Action Cycle 3: Focus Group Session Two (three groups) 
 
The dominance of both methods used in the research was equal in regards to their individual 
importance for the overall data collection, although the focus group sessions did require more 
time and resource. Both the first and second focus group sessions required multiple meetings due 
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to geographical locations of the participants. The first focus group, as well as the second focus 
group, had participants in the respective provinces of New Brunswick, Nova Scotia, and Prince 
Edward Island. This element of the data collection and design required significant amounts of 
travel between the provinces, along with an enhanced level of coordination relating to the 
meeting settings and scheduling.  
 
5.2 Action Cycle 1: Online Survey 
 
The online survey constituted a convenience respondent sample in order to capture the current 
general opinions of retail pharmacists in Atlantic Canada. Consistent with the thesis objective, 
the online survey was utilized to garner a perspective on the impact of the current WHO five 
core categorizations of medication adherence factors, while simultaneously adding the constructs 
of both 1. technology and 2. pharmaceutical industry-initiated financial assistance. Altogether, 
this uncovered seven underlying pathways or themes which contributed to a set of data that 
would be presented to the focus group participants at the commencement of action cycle 2 and 
continue throughout the second and third action cycles. 
 
Overall, the online survey appears to have captured input from a diverse group of 115 retail 
pharmacists in Atlantic Canada. In general, the four targeted provinces, as the geographical base 
of all survey participants, appear to have a fairly homogenous population within Canada with 
respect to socioeconomic and health-related factors. Furthermore, it is not unusual to see the four 
Atlantic provinces grouped together in national or collective reporting of many types such as 
health, employment, education and immigration issues, given that the population represents 
roughly nine percent (Statistics Canada, 2017) of the national total.  
 
Upon completion, there was a slight under-representation of Nova Scotia within the survey 
respondents relative to the population. This under-representation of Nova Scotia should not be a 
negative factor, as a random-representative sample with statistical significance was not an 
objective of the study’s design. Rather, a convenience respondent sample was the optimal 
outcome of the online survey as to evaluate the current general opinions of retail pharmacists and 
set the stage for conversation, along with early feedback elements, for the focus group sessions 
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in the second and third action cycles.  
 
The target participants for the action research using the mixed methods approach are front-line 
retail pharmacists. This group represents two-thirds of respondents of the online survey. The 
other third of respondents are middle and senior management, formally educated and trained 
pharmacists, and presumably would have some previous experience on the front-line of retail 
pharmacy in Canada. Respondents are also well educated with almost all (93%) having a 
university undergraduate degree at minimum.  
 
The respondent sample also had a large amount of experience working in a pharmacy setting 
with approximately half in their current job function for 10 years or more. Furthermore, they also 
spent considerable time dealing with their patients, with almost half spending more than 30 hours 
with patients on an average week and almost half (42%) seeing at least 45 patients on an average 
day.   
 
5.2.1 Discussion of Quantitative Results 
 
The following dataset of questions 1 through 10 represents results of the characteristics of the 
convenience sample taken. 
 
Q1. What type of retail pharmacy do you currently work in? 
 




As noted in Figure #5, among those pharmacists who responded to the online survey, most 
worked for a Chain Retail Pharmacy (n=46; or 42.2% of the respondents), followed by Banner 
Retail Pharmacy (n=35; 32.1%), and Independent Retail Pharmacy (n=22; 20.2%). The 
remaining 5.5% (n=6) worked in other types of retail pharmacies. Chain retail pharmacy in 
Canada represents the corporately owned entities which comprise the largest volume of stores 
within the commercial pharmacy environment. The majority of these large ‘box’ stores are 
owned by publicly traded companies. ‘Banner’ retail pharmacies represent a group of stores with 
the same published name for the purposes of promotion and group buying, but are independently 
owned and operated. Independent retail pharmacies are, in general, individually named, owned, 
and operated. These are privately owned.  
 
Q2. In which province in Atlantic Canada is the Pharmacy located? 
 
Figure #6: Pharmacy of Participant’s Employment location 
 
As noted in Figure #6, the survey responses proved interesting with strong representation from 
New Brunswick, Newfoundland and Labrador, and Prince Edward Island (PEI) with 
approximately 36%, 28%, and 23% respectively. Unfortunately, Nova Scotia, which represents 
the largest population in Atlantic Canada, faired lower with just over 12% of the total survey 
respondents. Having the largest population in the region, one would have expected to see the 
greatest participation among Nova Scotian pharmacists. This does not affect the overall desired 
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intent of the convenience sample. Relatively, the population in 2017 came in at approximately 
40% for Nova Scotia, 6.7% for PEI, 23% for Newfoundland and Labrador, followed by New 
Brunswick with 32% (Statistics Canada, 2017). Consequently, one may have expected a much 
higher result in responses from Nova Scotia. Nonetheless, the overall capture of 115 respondents 
from Atlantic Canada was sufficient in providing a convenience sample with ample quantitative 
data to articulate the opinions of retail pharmacists. This data would serve as the leading 
information into the second action research cycle in that of the focus groups. 
 
Q3. Is the Pharmacy located in an urban or rural setting? 
 
Figure #7: Urban or Rural Pharmacy Location 
 
As noted in Figure #7, almost two-thirds of respondents (n=71; 63.4%) worked in an urban 
environment, with the remainder working in a rural setting. This was considered adequate in 
terms of data collection from respondents as essentially all of the major services provided within 
the provinces for diseases requiring specialty medicines are found within larger urban areas. A 
good example of this would be ‘infusion clinics’ whereby patients would be provided their 
specialty medicine under the care of a controlled clinic staffed by several types of healthcare 
professionals. Thereafter, even for patients living outside the urban setting, it is assumed that 








Q4. What is the highest level of education you have completed? 
 
Figure #8:  Participant’s Educational Level 
 
Since the early 1980s, the minimum requirement to practice the profession of pharmacy in 
Canada required an undergraduate degree in Pharmacy from one of ten accredited universities 
along with the completion of a national board examination. Prior to the 1980s, some provinces 
accepted the completion of programs from technical, college, or trade schools. As noted in 
Figure #8, the survey results are consistent with this educational requirement with the vast 
number of respondents in that of approximately 72% originating from a person with either an 
undergraduate degree or technical school. The remaining 28% represented other pharmacists 
with both undergraduate and advanced masters or professional degrees. 
 
Q5. What is your age? 
 




As noted in Figure #9, a slight majority of respondents were aged under 40 years (n=59; 52.7%) 
with the balance of approximately 47% over the age of 40. This respondent rate was important 
because it generally reflects the level of experience within the profession. The majority of 
diseases requiring specialty medicines are deemed chronic and associated with an older 
demographic. With this in mind, it was important that the respondent have a considerable amount 
of experience as to assess the rationale for medication nonadherence within their own practical 
setting. 
 
Q6. Are you male or female? 
 
Figure #10: Participant’s Gender 
 
As noted in Figure #10, the survey yielded almost three-quarters of female respondents (n=81; 
72.3%). This was not surprising as the ratio of female to male pharmacists has been increasing in 
Canada. In 2011, female pharmacists represented approximately 60% of the total pool and were 
growing. During that year, female pharmacists in Atlantic Canada represented 71% for Nova 
Scotia, 66% for PEI, 54% for Newfoundland and Labrador, and 67% for New Brunswick, 









Q7. What best describes your current job function within the Pharmacy? 
 
 
Figure #11:  Participant’s Job Function 
 
As noted in Figure #11, the vast majority, two-thirds in fact, were Front-Line Staff Pharmacists 
(n=75; 67.0%), whereas 15 (13.4%) were Middle Management, and 17 (15.2%) were Senior 
Management. This was very important as the research required the vast majority of participants 
to have significant experience in dispensing specialty medicines to patients.  
 
Q8. How many years have you been within the current level of job function? 
 




As noted in Figure #12, the largest proportion of respondents have been in their current job for 
less than 5 years (n=33; 29.5%), followed by those between 5 to 9 years (n=23; 20.5%), 10 to 14 
years (n=22; 19.6%), and 30+ years (n=16; 14.3%). Corresponding to the availability of the 
majority of specialty medicines within the last ten years, this is a relatively new and important 
factor in health care with approximately half of the survey respondents having less than ten years 
of experience. In other words, it would be assumed that for pharmacists that entered the field of 
pharmacy over the last ten years, their day-to-day experience regarding the provision and 
counselling needs for patients with specialty medicines would seem normal. Twenty years ago, 
pharmacists would have had fewer options.  
 
Q9. How many hours do you spend with Patients during an average work week? 
 
Figure #13: Participant Hours spent with Patients per Week 
 
As noted in Figure #13, over half of respondents spent more than 30 hours with patients on an 
average week (n=59; 52.7%). This is considered significant in the scope of the average Canadian 






Q10. On average, how many patients do you interact with each day regarding their 
medications? 
 
Figure #14: Number Patients Participants see per Day 
 
As noted in Figure #14, the largest group of respondents interacted with 60 or more patients 
(n=33; 29.5%) on an average day, followed by those averaging between 30 and 44 patients 
(n=25; 22.3%) and those averaging between 45 and 59 patients (n=14). This reflects a fairly 
steady pace throughout a normal work week of five days, averaging twelve per day, which 
















Q. 11 Socioeconomic Related Factors 
 
Figure #15: Rankings of Importance, Socioeconomic Factors 
 
As noted in Figure #15, of the fourteen Socioeconomic factors identified by the WHO, a 
majority of respondents felt that eight were either ‘very important’ or ‘extremely important’ in 
the populations they serve. The high cost of care was considered to be most important (87%), 
followed by poor socioeconomic status (72%), poverty (72%), inadequate social support (60%), 
unemployment (59%), literacy (58%), inadequate family support (53%), and cultural and lay 
beliefs about illness and treatment (53%). Interestingly, sex of the patient, was not thought to 
play a significant role with 2% of respondents reporting it to be important or only somewhat 
important.  
 
Notably, the highest-ranking socioeconomic factor(s) directly associated with medication 




Q. 12 Healthcare System Related Factors 
 
Figure #16: Rankings of Importance, Healthcare system Factors 
 
As noted in Figure #16, The WHO lists eight healthcare system factors as predictors of 
medication adherence rates. Only 5 were perceived to be either ‘very important’ or ‘extremely 
important’ by a majority of respondents in the context of medication adherence within the 
population they serve. Inadequate reimbursement by health insurance plans was reported to be 
the most important (82%), followed by poor delivery of care education to the patient (60%), 
inadequate relationship between health care provider and patient (57%), inadequate health care 
providers (57%), and lack of training in changing the behavior of non-adherent patients (50%). 
Interestingly, but not surprisingly, the importance of reimbursement provided by health 
insurance plans ranked number one given the known high cost of newer specialty medications.   
 
Many private and public health insurance plans struggle to determine how to reimburse patients 
for such high-priced medications, regardless of their medical advancement, as it puts upward 
pressure on the plan’s financial cost. It is surprising that the other top-ranked factors relating to 
the healthcare system were focused on care delivery and included provider education, 
relationship, inadequacy, and training, suggesting the importance of the secondary human 
participant in the interaction; the healthcare provider. This demonstrates that communication 
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regarding the direction and importance of medication adherence is a ‘two-way’ street in that not 
only is the patient a human participant, so too is the healthcare provider. 
 
Notably, the highest-ranking health system related factor directly associated with medication 
nonadherence was related to the inadequate reimbursement by health insurance plans.   
 
Q. 13 Disease or Condition Related Factors 
 
Figure #17: Rankings of Importance, Disease Related Factors 
 
As noted in Figure #17, five elements make up the WHOs list of Disease or Condition related 
factors. Of these, a majority of participants responded that four were either ‘very important’ or 
‘extremely important’ in the populations they serve. Misunderstanding of the diseases was 
considered to be most important (66%), followed by co-morbidities (58%), previous treatment 
failures (54%), and then asymptomatic patients (56%) in ranking. Duration of the disease (49%) 
came in with slightly less than a majority, but was still viewed as a relatively important factor. 
 
Notably, with respect to disease or condition related variables directly associated with 
medication nonadherence, there was no dominant factor. A broader perspective arose implying 






Q. 14 Therapy Related Factors 
 
Figure #18: Rankings of Importance, Therapy Related Factors 
 
As noted in Figure #18, six factors make up the WHO’s list of therapy-related factors connected 
to medication adherence. Of these, a majority of respondents found that four were either ‘very 
important’ or ‘extremely important’ in the populations they serve. The adverse effects of 
treatment were considered to be the most important (84%), followed by complex treatment 
regimens (82%), misunderstanding about how to take the medications (70%), and duration of 
treatment (59%).  Only 29% of respondents thought that dietary restrictions played a very or 
extremely important role. 
 
Notably, with respect to therapy related variables directly associated with medication 
nonadherence, adverse effects of the medication were considered to be of utmost importance.  
This leads one to believe that perhaps many patients intentionally avoid taking their medications 








Q. 15 Patient Related Factors 
 
Figure #19: Rankings of Importance, Patient Related Factors 
 
As noted in Figure #19, the WHO’s list of patient-related factors concerning medication 
adherence is comprised of ten items. Of these, a majority of respondents reported that half (5) 
were either ‘very important’ or ‘extremely important’ in the population populations they serve. 
Forgetfulness was reported to be the most important (76%), followed by perceived 
ineffectiveness of the medication (61%), lack of understanding about vulnerability to illness 
(58%), misunderstanding of instructions for medications (57%), and lifestyle and health beliefs 
(53%). Only roughly a third of respondents believed that fear of addiction, alcohol use or drug 
use played a very or extremely important role.  It is interesting to note the concept of ‘non-
intentional’ medication nonadherence in that forgetfulness was ranked most important as 
opposed to the other perceived ‘intentional’ variables. This suggests the importance of both 
intentional and unintentional contributors to the broader issue when considering medication 





Notably, the highest-ranking patient related factor directly associated with medication 
nonadherence was forgetfulness. 
 
Collective: WHO Factors associated with medication adherence 
 
Q. 16 Based on your personal experience in the pharmacy where you work, what do you think 
are the FIVE most important sub-factors driving medication nonadherence? Responses to this 
question were limited to the answers of five subfactors. 
 
Figure #20: Rankings of Importance, Collective WHO Related Factors 
 
Respondents were asked to determine the five most important factors influencing medication 
adherence in the patient populations they serve. As noted in Figure #20, there was a total of 92 
participants who answered this question. The average score for each potential factor was 






The top ten most important factors in order of importance were: 
 
1. High cost of care 
2. Adverse Effects of the Treatment 
3. Inadequate reimbursement 
4. Misunderstanding about how to take medications 
5. Poor socioeconomic status 
6. Forgetfulness 
7. Complex treatment regimens 
8. Asymptomatic patients 
9. Misunderstanding of instructions 
10. Misunderstanding of how to take medication 
 
Summary of importance and responsiveness of 10 most important WHO factors 
 
Q.17 Of the five sub-factors you identified, please rank each in terms of their relative 
importance where 1 is the most important in driving medication nonadherence, 2 is the second 
most important, 3 is the third most important, and so on. 
 
The 10 most important factors influencing medication adherence among the patients served by 
survey respondents came from all five domains, with the Disease and Therapy related 
categorizations the most prominent. Several themes appear, the most important related to 
misunderstandings about the disease itself or the medications used to treat the conditions. The 
costs of medication are also important, whether they be direct costs, the ability to pay, or those 
costs offset by insurance plans or other forms of reimbursement. Also playing a role within 
complex treatments were patient factors, such as forgetfulness and fear of the drugs’ adverse 
effects, which were thought to heavily influence medication adherence.   
 
There was no clear suggestive correlation between the factors ranked most important in 
influencing medication adherence and those considered most responsive to targeted 
interventions. For example, while high cost of care ranked first in importance, it was ranked 
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fourth in responsiveness. Interventions aimed at correcting misunderstandings were considered 
to have the greatest potential for success, followed loosely by interventions aimed at reducing 
financial burdens of patients. Understandably, outreach efforts to educate patients or minimize 
costs would appear to have more promise than trying to alleviate forgetfulness, identify 
asymptomatic patients or change a person’s socioeconomic status.   
 
Responsiveness of 10 most important WHO factors to targeted interventions 
 
Q.18 Again, based on your own personal experience, of the five sub-factors you selected, 
which do you think would be the most responsive to change from targeted interventions designed 
to improve medication adherence, where 1 would be the most responsive, 2 would be the second 
most responsive, 3 would be the third most responsive, and so on? 
 
The factors reported to be most responsive to targeted interventions are listed in order:  
 
1. Misunderstanding about how to take medications 
2. Misunderstanding of instructions 
3. Misunderstanding of the disease 
4. High cost of care 
5. Complex treatment regimens 
6. Inadequate reimbursement 
7. Adverse effects of treatment 
8. Forgetfulness 
9. Asymptomatic patients 
10. Poor socioeconomic status 
 




Q.19 Many forms of technology have been used in recent years in an attempt to improve 
 
 118 
medication adherence. Some of these technological interventions are listed below. Please 
indicate whether or not you are familiar with the various interventions from a medication 
adherence perspective. Yes = green bar. No = blue bar. 
 
Figure #21: Rankings of Importance, Technological Interventions 
 
As noted in Figure #21, there were 92 respondents to this question. Ten technological 
interventions where presented that have been used to promote improvements in medication 
adherence. The interventions varied in terms of sophistication and the length of time they have 
been trialed. For example, telephone call reminders versus medication packaging microchips.  
 





1. Prescription refill monitoring using pharmacy software systems (92%) 
2. Illness-specific medical devices (e.g., blood glucose monitors) (90%) 
3. Telephone call reminders (83%) 
4. Smart Phone apps (79%) 
5. Online links providing education (77%) 
6. Email reminders (72%) 
7. SMS (Short Message Text) reminders (62%) 
8. Social Media (e.g., Facebook) (58%) 
9. Self-directed electronic monitors of adherence (40%) 
10. Medication packaging microchips (11%) 
 
Technological Interventions with the greatest impact on improving medication adherence 
 
Q. 20 Based on your personal experience in the pharmacy where you work, what do you think 
are the FIVE technological interventions that would have the greatest impact on medication 
nonadherence? Again, it is very important that you limit your responses to five technological 
interventions. 
 




As noted in Figure #22, there were 92 respondents to this question. Frequency of mentions was 
used to rank the technological interventions which were ranked from the greatest to least 
potential:  
 
1. Prescription refill monitoring using pharmacy software systems 85% (78 mentions) 
2. SMS (Short Message Text) reminders 77% (71 mentions) 
3. Telephone call reminders 73% (67 mentions) 
4. Smart Phone apps 64% (59 mentions) 
5. Illness-specific medical devices (e.g., blood glucose monitors) 50% (46 mentions) 
6. Self-directed electronic monitors of adherence (40 mentions) 
7. Email reminders (35 mentions) 
8. Medication packaging microchips (21 mentions) 
9. Online links providing education (18 mentions) 
10. Social Media (e.g., Facebook) (17 mentions) 
 
Technological Interventions with the greatest potential for uptake 
 
Q. 21 Again, based on your experience working with the patients you serve in the retail 
pharmacy where you work, please rank the technological interventions you identified in terms of 
their potential uptake, where 1 represents the intervention with the greatest potential uptake, 2 is 




Figure #23: Rankings of Greatest Potential Uptake, Technological Interventions 
As noted to Figure #23, there were 89 respondents to this question. An average score was used 
to rank the technological interventions from the greatest. The interventions were ranked from the 
greatest to least potential:  
 
1. Telephone call reminders 
2. SMS (Short Message Text) reminders  
3. Prescription refill monitoring using pharmacy software systems 
4. Social Media (e.g., Facebook) 
5. Medication packaging microchips 
6. Smart Phone apps 
7. Email reminders 
8. Illness-specific medical devices (e.g., blood glucose monitors) 
9. Self-directed electronic monitors of adherence 






Summary of Technological Interventions awareness and impact 
 
Of the 10 technological interventions, respondents were most familiar with prescription refill 
monitoring pharmacy software solutions and illness-specific medical devices, likely because 
these systems and products are ubiquitous in retail pharmacies. All pharmacies including chain, 
banner, and independents require electronic pharmacy software in Canada in order to process 
prescription claims, so this finding is logical in terms of proactively determining when patients 
are should refill a prescription.  
 
Familiarity of the remaining interventions, or lack thereof, appears to be related to the novelty of 
the intervention and level of sophistication. The technological interventions considered to have 
the greatest potential impact on improving adherence appear to be those that can be quickly 
directed towards the patient and are triggered by someone or something other than the patient. 
Pharmacy software systems immediately identify those who require prescription refills and may 
then issue SMS text reminders, telephone calls, and Smart Phone application notifications, all of 
which have the potential to prompt the patient at the appropriate time.  
 
Aside from pharmacy software solutions and medication packaging microchips, the 
technological interventions with the greatest potential for uptake are those that can be tailored to 
and launched on a smart phone, which most patients typically have on their person. From a 
proximity perspective, this may be the closest to the patient a solution can get for the time being. 
Presumably, telephone call reminders lead the way because the vast majority of Atlantic 




Financial assistance may be provided to patients within Canada in various ways. It may be in the 
basic method of simply issuing the appropriate funds directly to the patient as reimbursement for 
prior payments made toward one’s healthcare services, in this case medications. Alternatively, 
financial assistance may be issued directly to the service provider upon proof of the service by 
way of electronic funds transfer, credit card, or cheque. In recent years, the latter has been 
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enhanced by the provision of electronic payment cards provided by a third party, generally 
known to have commercial interest, such as pharmaceutical manufacturers, in which case the 
patient is able to access financial assistance similar to a public or private drug benefit plan. These 
electronic payment cards are predominantly given to assist in the funding of one medication 
whereas a public or private drug benefit plan would cover hundreds or even thousands of 
medications and/or services. Electronic payment cards for individual medication coverage are 
only able to be processed electronically through pharmacy software systems available in Canada. 
 
Q. 22 Based on your personal experiences or perceptions from the patients that you serve at the 
retail pharmacy where you work, please rate each of the factors in terms of their potential impact 
on improving medication adherence. 
 
 
Figure #24: Rankings of Importance, Financial Interventions 
 
As noted in Figure #24, respondents were presented with 4 electronic card types that either offset 
the direct costs of drug coverage or enable the patient to accumulate non-financial rewards such 
as devices to help manage the patient’s disease or non-disease related freebies such as gift cards. 
Respondents were asked to rate cards in terms of their potential to positively impact medication 
adherence among the patient populations they serve using a 5-point Likert scale, where 1 stood 
for “Not at All”, 2 “Very Little”, 3 “Somewhat”, 4 “Quite a Bit” and 5 “A Great Deal”. 
Responses were grouped into three categories: 1) “Not at All/Very Little”; 2) “Somewhat”; and 
3) “Quite a bit/A great deal” to facilitate analysis. The latter grouping was considered to be most 
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relevant. There were 88 respondents to this question. 
 
Financial Assistance (electronic payment cards) thought most impactful, in order of importance 
were:  
 
1. Financial assistance cards to help in the partial or full payment of a remaining balance of 
medication costs after coordination with the patient’s own private or public health 
insurance plan (78%); 
2. Drug Navigation service funded by the providers of financial assistance through the use 
of electronic cards to help access drug coverage from any source, i.e., disease societies 
(56%); 
3. An electronic card with the potential for other services of non-financial assistance 
relating to a specific disease (e.g., non-medication offerings such as a free blood pressure 
monitor (51%); 
4. The psychological aspect of using a card to access a ‘freebie’ similar to a gift card 
offering or a points schemes (regardless if the patient ever uses the freebie or whether 
points may be accumulated or not (32%). 
  
Financial assistance using electronic payment cards with the greatest potential for uptake 
 
Q. 23 Again, based on your retail pharmacy experience, please rank the electronic cards 
described in terms of their potential uptake among the patient population that you serve, where 1 
represents the intervention with the greatest potential uptake, 2 is the second greatest, 3 is the 




Figure #25: Rankings of Greatest Potential Uptake, Financial Assistance 
 
As noted in Figure #25, there were 86 respondents to this question and the average score was 
used to rank the potential of these interventions. Financial assistance (electronic payment cards) 
thought to have the greatest potential for uptake, in order of importance were:  
 
1. Financial assistance cards to help in the partial or full payment of a remaining balance of 
medication costs after co-ordination with the patient’s own private or public health 
insurance plan (average=1.2); 
2. Drug Navigation service funded by the providers of financial assistance through the use 
of electronic to help access drug coverage from any source, i.e., disease societies 
(average=2.5); 
3. A card with the potential for other services of non-financial assistance relating to a 
specific disease (e.g., non-medication offerings such as a free blood pressure monitor) 
(average=2.8); 
4. The psychological aspect of using a card to access a ‘freebie’ similar to a gift card 
offering or a point scheme regardless if the patient ever uses the freebie or whether points 






Summary: Financial Assistance 
 
Respondents thought that 3 of the 4 factors would benefit patients in some way through a 
medium of electronic payment cards. Most respondents viewed these factors as having the 
potential to improve medication adherence quite a bit or a great deal, including financial 
assistance to help in the partial or full payment of a remaining balance of medication costs after 
coordination with the patient’s own private or public health insurance plan. Interestingly, a drug 
navigation service, a means to assist patients in accessing financial assistance for medications 
from any source, also stood out has having a very clear majority with three-quarters of 
respondents (78%) in agreement.   
 
The ranking of potential uptake for electronic payment cards was consistent with the perceived 
impact on medication adherence. Financial assistance to compensate for partial or full payment 
of a remaining balance of medication costs was thought to have the greatest potential uptake, 
with an average score that was followed distantly by the other value using an electronic card. 
 
Q. 24 Would you be interested in participating in the focus group phase of this research? 
 
 
Figure #26: Interest in Participation in future Focus Groups  
 
There were 88 respondents to this question. Interestingly, as noted in Figure #26, 59 respondents 
(67%) expressed no interest in further participation in the qualitative component or focus group 
sessions of the research. This did not impact the overall results as, again, the online survey was 
intended to avail a convenience respondent sample. The remaining 29 respondents that did show 
interest in the focus groups or future action cycles established the foundation for a contact list 
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and were the first potential participants solicited once the meeting settings and dates were 
determined.  
 
5.2.2 Action Cycle 1 Online Survey Themes 
 
Medication nonadherence has been recognized for decades, even centuries. Throughout the 
previous findings in the literature search, it has been noted that there have been a vast array of 
underlying variables leading to formal categorizations put forth by organizations such the WHO. 
During this research, there were a multitude of rationalizations or themes regarding medication 
nonadherence discussed during each of the action cycles whereby participants were able to 
isolate general topics and provide further insight into their own practical environment.  
 
The online survey questions were determined prior to their issuance to the participants and 
disseminated through their provincial professional association’s membership databases. One of 
the downsides to such research using surveys is that, although at first glance an objective set of 
data may be perceived to provide optimal clarity into the underlying issues, potential data 
leading to new knowledge outside of the realm of survey questions may be omitted. The stand-
alone research of an online survey may not allow for data to arise that is outside of the 
methodological scope and questionnaire, in this case, the five categorizations of the WHO along 
with the addition of technology and financial assistance. This was taken into consideration as the 
online survey representing action research cycle 1 was meant to capture the baseline opinions of 
retail pharmacists regarding medication adherence at a point in time. 
 
During this first action cycle it was clear that the overwhelming factors put forth by the retail 
pharmacists directly associated with medication nonadherence were that of the cost of the 
medication and funding along with the ability to connect with the patient regarding their disease 
and treatment. The findings were consistent across regions. These factors dominated the ratings 
on ‘importance’ and provided the first insight into seven themes that would be established over 





5.3 Action Cycle 2 Focus Group Session One 
 
The qualitative approach using focus groups provided an excellent complement to the online 
survey. Several themes were discovered during the action cycle 2; the first of two focus group 
sessions. Interestingly, two of the seven themes were outside of the selected factors chosen to 
align within the survey questions. The seven themes included: 
 
I. Time constraints of the retail pharmacist 
II. Timing of the medication adherence consultation with the patient 
III. Cost of the medication and who provides the funding 
IV. Navigation to assist the healthcare provider and patient in optimizing available programs  
V. Optimal methods of engaging the patient 
VI. Uses of technology 
VII. Financial assistance provided by the pharmaceutical industry 
 
I. Time constraints of the Retail Pharmacist 
 
Effective time management required by retail pharmacists in Atlantic Canada in order to 
complete daily professional tasks is becoming increasingly challenging to achieve. Within the 
retail pharmacy setting, the pharmacist has a multitude of responsibilities. The fundamental set 
of priorities would surround the interaction with patients during the processing, filling, and 
dispensation of their prescriptions. Although the pharmacist is formally trained in the 
professional capacity of healthcare delivery, their ability to fulfill the commercial responsibilities 
of a pharmacist in the practical retail setting are of the utmost importance. In the vast majority of 
cases, the employer of the retail pharmacist has a commercial interest in ensuring the ability to 
process as many prescriptions as are available in supply. The professional responsibilities of the 
pharmacists essentially converge with the business requirements, and though rarely discussed, it 
can be argued that a conflict is enacted. However, in general, the professional and commercial 




From a medication adherence perspective, it is the professional responsibility aspect that it would 
fall under. As such, any reduction in the professional tasks as to provide the commercial interest 
within the retail pharmacy environment would be at the detriment of increased time necessary for 
communication to patients regarding medication adherence. The blend of professional and 
commercial time constraints during quotidian operations of retail pharmacies put increasingly 
more pressure on the pharmacists to implement other services such as a periodic and holistic 
medication reviews, which include medication adherence discussions, at later dates. In other 
words, it may mean that these important discussions will occur further into the future, if at all. 
Medication adherence discussions are often a key aspect of an overall medication review. 
Unfortunately, lack of such reviews supplemental to medication dispensation means less time 
spent discussing the importance of adherence.  
 
Compounding the problem of missed or delayed medication adherence discussions for patients 
with diseases requiring specialty medications is the fact that those diseases are known to be more 
complex, expensive, and requiring of increased resources from a care and maintenance 
perspective. There is an elevated need for follow-up and/or comprehensive medication adherence 
discussions with patients who have diseases requiring specialty medications, and this extra 
communication is deemed optimal in order to reinforce the instruction and improvement of care.  
 
Retail pharmacists during the focus group session continued to reflect on the importance and 
reinforcement of communication on medication adherence if optimal care is to be achieved. 
Often, instructions given during the initial medication dispensation and communication period 
may not be internalized or fully understood by patients. From an information provision point of 
view, the patient is likely dealing with emotional stresses due to the disease diagnosis. 
Information reception and retention capabilities of the patient may be lowered at this critical 
point in time. Even with this knowledge in mind, it was consistently agreed upon by the research 
participants, that there is limited time allocated for supplemental services such as medication 
reviews or deeper follow-up conversations surrounding medication adherence. 
 
Although participating pharmacists in the action research believe medication adherence 
discussions should be paramount in the services they provide, many pharmacies may not have a 
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standardized process, formalized timelines, or methods with which to do so. Furthermore, 
participants highlighted that there may be competing interests in terms of who should fund such 
a service. Should it be public and private insurance plans or, alternately, a third party such as the 
manufacturers of medications. Again, although the concept of time spent enhancing discussions 
regarding medication adherence is generally one perceived to be fundamental in a professional 
context, the practice of devoting time to it would require funding. Evidently, time has a monetary 
value; and, if the service were performed it would require compensation for the service. 
 
Currently, from the public payer perspective, individual provincial government bodies in Canada 
outline different criteria for broader services in which medication adherence discussions are 
provided. Payment allowances vary by province, suggesting that the services available to each 
patient, even if there was a consistent delivery mechanism put forth by the pharmacy providers, 
would differ across provinces. Participants’ opinions suggest that perhaps independent patient 
advocate groups are required to put pressure on the pharmacy profession to align and assign 
more time for counselling on medication adherence, regardless of who provides funding for the 
service.  
 
Overall, time required to complete the day to day professional aspects within the retail pharmacy 
are not only becoming more challenging but have to compete for commercial consideration when 
determining how to enhance the requirement of medication adherence discussions with patients 
utilizing specialty medications. 
 
II. Timing of Medication Adherence Consultations with Patients 
 
Research participants noted that, unfortunately, much of the in-pharmacy education and 
discussion regarding proper medication adherence with patients occurs shortly after the time of 
disease diagnosis. This is at a time when the initial prescription for the diagnosed disease is 
dispensed. Although this is required and an important timing of a discussion on how best to 
adhere to one’s medication, pharmacists recognize that this may be happening at a time when the 





Often, relating to the need for specialty medications, patients have just been diagnosed with a 
life-threatening or altering disease and are sick, scared, and simply want to go home to be 
comfortable. Pharmacists agree that this decreases the patient’s receptivity to information being 
exchanged on the importance of taking the medications properly. Furthermore, it is the same 
time at which a significant amount of information on the treatment and overall care is transferred 
using both verbal and paper methods to accompany the prescription. From the patient’s 
perspective, this period of emotional stress and/or trauma may be overwhelming and potentially 
impairing to their comprehension of the means necessary for optimal care and adequate 
medication adherence. 
 
During this action research, the question arose by the participants on what the true impact of this 
timing of communication really is at this most important time in the illness of the patient. 
Research participants agreed that the timing of a medication adherence conversation varies 
greatly from patient to patient and depends largely on a vast array of individual variables that are 
known subsets of the five WHO categorizations. For example, if a person has low health literacy, 
is their attentiveness affected by the timing of a conversation relating to their medication 
regimen? 
 
Timing of medication adherence communication is critical in order to provide the most optimal 
care required. Depending on the individual patient, and given the right timing, other questions 
may arise due to a more relaxed individual and/or environment. Research participants agreed that 
several things may come out in latter medication adherence conversations that may not have 
been discovered when the patient initially arrived at the pharmacy with their first prescription in 
hand, and that the patient is more opt to be stressed at that time. Factors such as the patronizing 
of multiple pharmacies for other medications prior to the present diagnosis, other known diseases 
or conditions, funding towards the medication, and the patient’s social status need to be 
considered. The more information a pharmacist has regarding the patient, the more it may 




The timing factor, or when best to interact with the patient at various stages of the disease, was 
emphasized by participants to be of critical importance to the overall success of patient 
communication. The attentiveness and mental receptiveness of the patient was also noted to be 
crucial to success. Pharmacists recognize that formal assistance and communication relating to 
medication adherence is only as good as the ability of the patient to receive, process, and 
understand it.   
 
III. Cost of the Medication and who provides the Funding  
 
The cost of specialty medications for diseases such as cancer, HIV, multiple sclerosis, and 
rheumatoid arthritis, to name a few, are known to be significantly higher than the average 
medication (IMS Institute for Healthcare Informatics, 2016). As the overall direct and indirect 
costs associated with healthcare are rising, including that of newer medications, it begs the 
question of how to fund these medications. Furthermore, if funding is provided by a public or 
private plan other than the patient, how much funding is provided? The concept of the growing 
availability of specialty medications over the last decade has generated new hope for many 
patients, but obtaining these medications is not a simple feat for most. This may have a 
substantial impact on medication adherence and the ability to improve upon rates. 
 
Availability of specialty medications:  
 
Newer medications, specifically those referred to as specialty medications, generally tend to be 
expensive. In 2015, these medications accounted for 75% of all the new growth in spending and 
36% of the total cost in the United States (IMS Institute for Healthcare Informatics, 2016). The 
research, development, and availability of these medications has become prevalent over the last 
decade and in the United States alone, the direct impact of which accounts for $105 billion 
annually (QuintilesIMS, 2016). 
 
The significant increase in cost of specialty medications and debate over who provides the 
necessary funding are major issues in the overall care of patients diagnosed with diseases such as 
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MS, cancer, rheumatoid arthritis, HIV, and many others. Inherently, this leads healthcare 
providers and patients to search for alternate ways to either access the specific specialty 
medications they are prescribed or seek out solutions that may provide a similarly desired 
outcome relating to their disease.  
 
Due to the high cost of specialty medications, healthcare providers such as retail pharmacists 
may look for ways to substitute these newer medications with older therapies which may be 
provided in the generic form, a biosimilar, or one which has similar clinical outcomes. The 
advantage is that most often these alternative medications have lower costs than the newer 
specialty medications. This is largely due, in part, to the many alternative medications that have 
lost their patent protection in Canada and may be produced by several manufacturers as long as 
those producers are able to provide the older medications in a bioequivalent form. Similar 
regulatory processes and pricing laws exist in developed countries around the world. 
Furthermore, many have been priced lower in any given market for competitive reasons. There 
are potential disadvantages of this phenomenon. Of note, when a healthcare provider makes a 
substitution for a medication within the same therapeutic class or with a generic equivalent of the 
same chemical, it is possible that the original & replacement medications may not be deemed to 
be comprised of identical molecules and may have slightly different effects from one patient to 
the next. 
 
Newer medications are often not considered as the first line of treatment if it is believed that an 
older, more traditional approach would suffice. Validation that the older medications are not 
optimal or should not be considered is a rarity given the paradigms that exist in healthcare. The 
decision to switch medications is left with the practicing physician who has the responsibility of 
caring for the patient. Over the years, healthcare providers have been educated and taught to be 
professionally wary of ‘me toos’ (generics and biosimilars) put to market by the manufacturers 
of pharmaceutical treatments. 
 
Often, the cost of a medication to the patient becomes a barrier to having the ability to prescribe 
certain kinds of medications, in this case specialty medications. This burden is negatively 
impactful. Not only from the patient’s perspective and who funds it but also from the prescribing 
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physician. If a medication is dispensed at a higher price point and the patient is unable to fund 
the full or partial amount they are responsible for, the physician may be forced to prescribe a 
lower-priced medication. Further complicating this variable in the decision-making process is the 
fact that prescribing physicians often do not know the specific prices of medications, although 
they may know if it is deemed expensive or not.  
 
Brand name medications from a single source within the given market are generally known to be 
more expensive during the period of their market exclusivity given patent rights versus that are 
non-brand medications. There is no formal system within the physician’s office for them to 
assess this key component of the prescribing thought process. Employees working in retail 
pharmacy in Canada have the ability to look up specific prices either manually or, most times, 
electronically. Unfortunately, by the time the retail pharmacist is required to do so, the 
prescription has already been issued by the physician and any substitution for an alternative 
medication requires the pharmacist to contact the physician to obtain approval for that change.   
 
How the funding for Specialty Medications is broken down: 
 
Many patients are unable to pay out-of-pocket for the full price of the more expensive specialty 
medications in Canada. Furthermore, the average household income in Atlantic Canada is 
relatively low compared to the average Canadian household income (Statistics Canada). For 
many patients, specialty medications may not be prescribed unless the patient has some form of a 
third-party drug benefit plan. Even then, the vast majority of patients do not have the ability to 
pay the patient co-pay portion of the prescription cost of most specialty medications due to their 
high prices. For example, if the patient portion or co-pay in Canada are 20% of the amount of the 
total prescription including costs of the medicine, applicable wholesale and retail markups, and 
the fee for processing or dispensing the medication, it may be inaccessible for the patient. One 
research participant quoted, “some people don’t have an extra $20,000 per year to pay for their 
medications”. The consensus provided from the broader research group was that these monetary 




Regarding specialty medications not covered by a third-party drug benefit plan in Canada, either 
public or private, often there may be the ability to file an ‘exception request’ to the plan provider 
for an individual patient assessment if the medicine should be funded based on unique 
circumstances. Unfortunately, these exception requests require a significant amount of forms to 
be filed out by the patient or healthcare provider including information on whether a lower 
priced medicine has been previously tried with unsuccessful results. This process may be viewed 
as a barrier to the provision of the specialty medicine due to the inherent creation of delays in 
amount of time the prescription will be written while waiting for a rejection or acceptance of the 
request.   
 
During the review and acceptance process of who funds the medication for the patient, the third-
party drug plan payers often formalize policies on the primary and secondary payer sequence if a 
patient has multiple plans. These policies are known as ‘payer of last resort’. For example, public 
plans provided by federal or provincial governments mandate the acceptance of their funding 
sequenced secondarily to that of a patient’s private plan. Similarly, when patients have access to 
multiple private plans, as is the case if a patient has their own plan but is also covered by their 
spouse or significant other’s plan, these plans implement informal policies in order to minimize 
their own funding outlay. Theoretically, this forces the premiums a patient has to pay for the 
private plan itself. 
 
Example for the payment flow of a prescription for which a patient utilizes both public and 
private plans for funding:   
 
Primary Payer = 80%, Secondary Payer = 20%, Third Payer = 0%. If a patient has both 
public and private drug plans, the first or ‘primary’ payer (in this example the private plan), 
pays a significantly higher portion than the second payer (the public plan). If a patient only 
has public plan coverage than the public plan funding would increase accordingly as they 
would hold the burden of the primary payer. 
 





Given that the newer specialty medications are generally priced relatively high, the question 
becomes not only who funds these medications but also, what resources are available to help 
those involved in patient care to navigate through the healthcare system and access the funding. 
The amount of time spent assisting the patient in attaining funding that is not readily available 
may be perceived to be significant, especially if that time spent lacks compensation for the 
service. For the busy retail pharmacist, allocating time to seeking such access to funding may be 
difficult as they are already at full capacity filling prescriptions for other patients and tending to 
the quotidian business of the pharmacy. A general consensus was made by the research 
participants that most commercial pharmacy operations have cut back on pharmacist personnel 
and those on the front lines are expected to do more with less. As the discussion regarding 
medication adherence commences with the first visit to pharmacy based on the initial 
prescription, it often is the case that the optimal communication necessary to ensure the patient is 
best equipped to fully adhere does not take place. 
 
Should funds be allocated to incentivize both the pharmacists and the patient to improve 
medication adherence? Participants in this research agree that if incentives were implemented, 
guidance and regulations would need to be drafted. Furthermore, barriers exist for the retail 
pharmacist in implementing such a service if there are no centralized repository systems or 
formal pathways to access the information necessary to provide the service. 
 
Navigation through the healthcare system to access services can be a major problem. Caregivers 
and healthcare providers often feel they lack knowledge and insight into how to be the patient’s 
advocate in many situations.  
 
Example 1:  ‘Where a patient lives’ relative to a core set of services for patients with 
diseases requiring specialty medications, such as MS and Cancer, is a major issue in 
healthcare delivery. If the patient lives in a small town 300 kilometers from the nearest 
available radiation treatment center, there is an assumed incremental cost for the patient 




Example 2: ‘Delays in approval for medications’ to be funded may impact patient 
care. For many of the specialty medications, these approvals require exceptional status 
forms to be completed and submitted. During the extra time required to process the 
exception request, a patient may have to seek other types of reimbursement avenues 
including private or commercial interest groups or, depending on the urgency, switch to 
other medications.  
 
The examples are numerous. Overall, the amount of energy and resources necessary to navigate 
the system, at a time when the patient is burdened with health limitations and stress, can be 
daunting. 
 




Varying diseases require different methods and frequency of communication regarding 
medication adherence. Each patient is different. Each healthcare provider, although assumedly 
trained in similar care delivery methods, act and communicate differently. Often, the human 
interaction partly depends upon the audience, regardless of the communication. Several services 
are provided at the various healthcare touchpoints inclusive of the family physician, the 
specialist, the disease clinic, and the retail pharmacy. Patients have many healthcare providers 
discussing various aspects of their disease. Different diseases required different approaches. 
 
For example, depending on the disease and the patient a stigma may be associated with going to 
any or all of the healthcare services provided. Nonetheless, it is critical to have a consistent 
message to the patient regarding their disease and treatment from all aspects of the healthcare 
system and the providers. If not, the patient potentially may become confused about which 






Conflicting roles of the pharmacist 
 
Although pharmacists in the professional context pursue making a positive difference in the 
patient’s care, it is also a profession, amongst very few, associated with a commercial entity 
driven to make a profit. Often, a pharmacist may be caught up in commercial productivity 
requirements of the business and time spent with individual patients is shortened in order to 
move on to the next patient. 
 
Pharmacy Operations and Training 
 
Formal pharmacist training on the optimal timing and methods used for facilitating an effective 
discussion regarding medication adherence does exist; however, this training assumes the 
pharmacist is practicing in an ideal environment. Unfortunately, it may have never been properly 
established on what a perfect environment is or what is the day to day reality. Furthermore, 
multiple sessions may be required to create an optimal situation whereby the patient has full 
understanding of the communication on medication adherence.  
 
In recent years, some pharmacies have attempted to redesign the operational flow of the patient 
experience when requiring a prescription in order to improve information retention and 
understanding. For example, there are separate areas for prescription drop-off, patient 
counselling, and prescription pick-up. The thought is that each of these services requires a 
slightly different type of patient engagement and, when tailored, can enhance the patient 
experience. Research participants agreed that there was a direct relationship with the level of 
personal connection the pharmacist has with the patient that assists in the understanding and 
importance of the aspects of medication adherence. Emotionally, it is a method of incenting the 
patient to better adhere to their medications. Pharmacists agree that patients are often 







Inpatient versus outpatient process flows 
 
Oral medications require lower amounts of patient interaction as opposed to injectable or 
infusion medications. Furthermore, oral medications are not monitored as closely as injection or 
intravenous products as they are not administered within the inpatient setting. With respect to 
inpatient services for injection or intravenous medications, when a patient has a disease requiring 
specialty medications there is an assumed increase in direct monitoring and care for the specific 
time at which a patient receives these medications. Inherent in this standard approach to inpatient 
care is the discussion of how a patient is to receive their medications as there are more healthcare 
professionals involved at the time of care. Much of the aspect of medication adherence is left to 
the healthcare professional. On an out-patient basis, for those patients receiving oral medications, 
there is generally less time allotted for the discussion on medication adherence as it is considered 
part of the normal upfront counselling when a medication is dispensed.  From the research 
participants’ perspective, the question arises, “shouldn’t we advise all patients the same when it 




It is unfortunate but necessary that one of the first questions generally posed to the patients while 
interacting with the retail pharmacist tends to be, “Do you have drug coverage?” Does this create 
a two-tiered system of those who have medication funding versus those that do not? Candid 
discussions with patients need to be pursued in order to help avoid financial hardship and take 
away subsequent burdens such as disease relapse, loss of work, or a multitude of other negative 
repercussions directly relating to medication nonadherence.  
 
VI. Uses of Technology 
 
New forms of technology that could assist healthcare providers, including pharmacists, in 
improving patient experience would be beneficial to all and could potentially increase the 






Pharmacy software in Canada currently facilitates prescription refill monitoring in order to 
indicate when a patient requires their next prescription. This information provides a trigger point 
at which to contact the patient as a reminder to pick up their medications. Inherent in this 
functionality is an indicator of medication nonadherence by the patient in that they have 
neglected to pick up their medications. Proactively, these systems are able to either provide a 
real-time notification or communication through the software or, alternatively, run a report on 
command. Although these types of software systems are broadly available, pharmacies that are 
more involved in diseases requiring specialty medications are more opt to use such a system, 
given the higher individual monetary value of the patient.  
 
Participants in the research noted that a centralized software system functionality is lacking that 
provides a convenient and productive method to isolate patients that should be provided a timely 
medication adherence discussion. This is left to the determination of the individual retail 
pharmacist and is added onto the long list of professional and commercial competing priorities in 
any given day. Certainly, software does exist that enables a notification to the user, the 
pharmacist, when actionable tasks are due. This functionality is only as useful as the ‘user’s’ 
proactive input efforts to the action.  
 
Research participants noted that formalized guidelines or algorithms may be of assistance 
regarding this often-neglected priority. Advanced functionality designed to assist in developing a 
formalized approach to scheduling medication reviews, including medication adherence as a 
significant subset, with the patient at a time when there is anticipated to be ample time and 
attention to review the patient’s full medication profile. This will potentially improve the effort 
when complimented by an environment in which the patient is relaxed, in order to create an 
improved communication connection. Timing of this effort is critical in order to set the patient 








In November 2017, the Food and Drug Administration in the United States approved the first 
medication that would include a digestible microchip to indicate that a pill has been swallowed. 
This form of technology, although potentially very useful, has yet to be proven in terms of 
patient acceptance. 
 
Voice technology (IVR), an automated software used within numerous industries including 
healthcare, can assist when a patient needs their prescription refilled. When prompted, the 
technology sends an automated telephone call reminder to patients. This type of prescription 
refill monitoring functionality does come with some downsides; some patients may not want 
unsolicited communication in any form. As such, research participants agreed that this form of 
technology still requires human intervention in order to customize an approach that focuses on 
those that are open to participation. Pharmacists believe that, although IVR technology is a 
beneficial tool to assist in contacting patients when a prescription requires a refill, human contact 
is the most optimal method. Unfortunately, most retail pharmacy businesses in Canada do not 
have time to schedule an outgoing call due to an already time-constrained working environment. 
Research participants concluded the optimal approach using IVR technology would be a 
combination of automated and direct human telephone calls with an emphasis on the individual 




It is possible that certain third-party providers, those generally with private and commercial 
interests, offering financial assistance through the use of electronic cards may put relief on the 
private and public payers if they have the ability to distinguish definitively who is providing that 
financial assistance. Although beneficial to the patient, the concept of being able to track these 
payments electronically is worrisome to the pharmacists as adding a third payer to the mix of 
eligibility may create a more rigid payer environment in the future in that each payer will 
continue to implement policies directing the pharmacists to sequence themselves as last payer or 
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‘payer of last resort’. Pharmacists suggested that this type of technology has not yet reached its 
full potential for being monitored or tracked in Canada. 
 
Privacy and Security 
 
Provincial and federal privacy legislation in Canada protects patient’s personal information; 
however, the implied consent of the patient allows for some level of internal sharing of 
information through technology in order to provide the service criteria during prescription 
processing. For example, during the processing of a prescription medication, it may be necessary 
to electronically submit a claim to public or private plan payers in order to determine if the 
medication will be funded by the patient’s individual plan. The same technology limited to 
provincial or federal privacy regulations may be helpful in identifying those patients non-
adherent to their medication regimens. This may then allow for the provision of various forms of 
assistance or intervention. Use of the same information by external parties may be a threat to 




Various forms of device reminders could be a unique solution in improving medication 
adherence. These types of notifications or device reminders are directly available on most 
smartphones and various tools specifically designed for this purpose. Good examples of these 
tools include automatic pill boxes or dispensers which are available in both the basic physical 
formats which provide a visual reminder, or more advanced forms with electronic functionality. 
Device reminders, as an added tool in assisting patients adhere to their medication regimens, are 
readily available within most retail pharmacies. These can be recommended by the pharmacists 
and are especially useful when a patient has multiple medications with different regimens. 
Furthermore, some pharmacies provide formalized services whereby the medications can be 
ordered online, packed, and delivered to the patient’s home. Ordering online and then picking the 
medications up via a drive-thru scenario is becoming a more viable option for patients that are 








Of the 34 million Canadians, those who are eligible for either a public or private benefit plan that 
funds medications are by far in the majority (Sutherland, Greg and Thy, 2017). It is estimated 
that approximately 5.2 percent of the Canadian population is not eligible for a public plan or 
enrolled in a private plan (Sutherland, Greg and Thy, 2017). This suggests the gap requirement 
for some form of medication funding is relatively small. Given the low percentage of those not 
eligible, this is true. Unfortunately, the vast majority of public or private benefit plans do not 
cover the total cost of the medicine and require co-pays or some form of partial payment put 
forth by the patient. This puts a financial burden on the patient, especially those in lower income 
brackets (Sutherland, Greg and Thy, 2017). The amount of out-of-pocket spending to make up 
the co-pay difference for which the patient is responsible varies greatly, is increasing, and is 
largely dependent on the patient’s plan design. Rationale for patients who self-reported not 
adhering to a prescribed medication cited expense of the medication or unaffordability as the 






As the demographic age increases, those requiring funding for medications will likely increase. 
This will, in turn, put pressure on the healthcare system and both public and private benefit plans 
are predicted to be harder to access in the future. This pressure on the healthcare system may 
result in healthcare providers such as the retail pharmacists and patients seeking out other 
methods to fund medications such as third-party commercial interests. Unfortunately, when it 
comes to those programs that offer financial assistance to patients on specialty medications, 
many healthcare providers and most patients are not aware of such offerings. Pharmaceutical 
manufacturers do not always formally advertise these programs in a broad-based perspective. As 





Research participants believe that the service of financial assistance to those patients requiring it 
should be universal. Unfortunately, the cost for a pharmaceutical manufacturer to do so may not 
be viable or sustainable. Furthermore, these types of programs may become more prevalent over 
the coming years as downward pressure increases on household income due to tightening of 
government provided pension plans and other income supplementing services. Population aging 
becomes a major problem on the government or public system when such a high percentage of 
the population enters their senior years at the same time, certainly a consideration of the ‘baby 
boomers’ generation. 
 
Though popular for those that are fortunate enough to access such programs, financial assistance 
provided by pharmaceutical manufacturers may sometimes be problematic. The vast majority of 
the manufacturers that offer these programs are those that have a patent on the chemical 
molecule, hence programs designed to commercially promote the sale of the molecule during the 
patent exclusivity period. Once the patent expires, retail pharmacists understand that there is risk 
involved with such offerings as pharmaceutical manufacturers may discontinue the financial 
assistance programs as their return on investment may decline due to other competing 
organizations vying for the same business. In this scenario, the patient may be left without the 
assistance they depended upon to fund the medication and be required to pursue pathways to find 
other supplemental funding or switch or discontinue the medication regimen. 
 
5.4 Action Cycle 3  Focus group Session Two 
 
The collective set of seven themes established during the first and second action cycles 
represented the discussion pathways for the commencement of action cycle 3 (the second focus 
group session). The commentary that follows is either reinforcement of what was discovered in 
the first focus group or new information added for each of the themes. 
 
I. Time constraints of the Pharmacists or healthcare professional (HCP) 
 
Retail pharmacists, during this research, agreed that varying levels of service are provided 
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regarding necessary communication on medication adherence. Aspects relating to the province of 
service, retail chain and individual pharmacist all affect the level and quality of attention to the 
communication. As medication adherence discussions are generally a component of a broader 
medication review, the question is posed “what is the expectation of a competent medication 
adherence discussion embedded in an overall review”? It was recommended that a discussion 
surrounding medication adherence, at a minimum, requires 10-15 minutes of time during a 
patient visit versus that of a broader medication management discussion which would require at 
least an hour and is believed to provide more of a ‘teaching’ scenario for a patient. 
 
Various topics may need to be covered in a discussion to reasonably expect to have patients 
consider the importance of medication adherence. This has been highlighted by the concept of 
prior research, noting the importance of a multifactorial approach given the varying human 
aspects of different patients. Topics may include indirect medication adherence assessment 
criteria not directly focused on the specifics of adhering to one’s medication regimen such as the 
cost of the medication, who provides funding for the medications, the quality of communication 
provided by the pharmacist, and timing of the conversation just to name a few. 
 
Conflicting time constraints within retail pharmacy in Atlantic Canada exist. Not only do retail 
pharmacists provide the services of medication dispensation, and all the regulatory and legal 
responsibilities that surround it, they are often also engaged in activities involving the non-
prescription service delivery of the store. In other words, activities that are non-prescription 
related and further away from the perspective of discussions relating to medication adherence on 
prescription medications. This again highlights the conflict that exist in retail pharmacies within 
Canada by addressing the balance of professional and commercial affairs. A simple example of 
the reinforcement of this mix is the basic physical layout of the vast majority of retail 
pharmacies. The dispensary area of prescriptions is at the rear end of the retail pharmacy. This 
calculated design forces the consumer, the patient, to pass through the front store area before 
being able to engage with the pharmacist. This further lends to the pressures of pharmacists to 
participate in the business aspects of retail pharmacy in that it is generally accepted that they are 
required to dispense a minimum number of prescriptions each day to maintain a profitable 
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commercial situation. Again, this highlights the connected responsibilities of both professional 
and commercial activities of the retail pharmacist in order to maintain a viable business. 
 
II. Timing of Medication Adherence consultation with the Patient 
 
The concept of the timing of a medication adherence discussion with the patient often becomes 
‘generalized’ as a subset of the broader medication review. This is blended if you will, or 
clouded into the other responsibilities in a wholistic medication review. This natural tendency 
seemed reasonable given the fact that formalized training and professional reference usually 
evolved around the broader review.  
 
Participants in the research felt that though patient-specific medication reviews inclusive of a 
medication adherence discussion should be conducted at least every six months at a minimum to 
create optimum care and direction for the patient. Unfortunately, this timing recommendation put 
forth by the participants is not consistent with the providers of funding for a medication review. 
Overall, the most common funding for medication reviews, from the provincial government, is 
limited to once per year and, by in large part, sets the stage for if and when these reviews take 
place. 
 
Funding for medication reviews varies from province to province.  Provincial funding in Canada 
at the time of this research has different payment provisions depending on the Province. Most 
provincial funding is provided for a one-time annual review; however, participants recommended 
that once a patient is diagnosed, and the initial prescription filled, a medication review should 
automatically be scheduled within six months. This conflicts with the current funding provincial 
provisions if the patient is unable to fund the service themselves. Overall, it was agreed that this 
type of a formalized schedule should be driven by the individual patient and disease 
requirements, not by funding provisions. Unfortunately, this aspect was determined to be 
conflicting. 
 
Other parameters were discussed. In what setting should medication reviews including the 
medication adherence discussion be completed? For example, should they be conducted in the 
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patient’s home versus in a professional healthcare setting? Consistently, it was agreed that this 
may be also patient and disease specific.  
 
Overall, research participants agreed that recommendations need to be put forth emphasizing the 
patient or disease requirements regarding medication adherence, a subset of the broader 
medication review. A multitude of questions arose relating to funding, where should the 
discussion take place, how should it differ from patient to patient, and if it would be preferable to 
take on a more formalized national scope. Ultimately, national guidelines supported by a central 
body may be the optimal outcome for such an important and impactful healthcare consideration.  
 
III. Cost of the Medication and who Reimburses 
 
Unfortunately, physicians do not have a competent level of knowledge regarding the price of 
medications and this sometimes creates a problem once a medicine is prescribed. For newer 
medications, physicians may have a general knowledge that because they are new and have 
molecule exclusivity relating to a patent, they are therefore more expensive. 
 
Patients are often not given a choice of which medications are prescribed due to the amount 
funded by their drug plans. Choice provisions generally come with limitations relative to 
funding. Some plans may pay 100% of the total cost of the medication and other plans may only 
pay 50%. This creates a situation whereby the prescriber, the physician, may be pressured to 
prescribe the medication based on what can be afforded given that the patient, in most cases, will 
bear the burden of a partial funding of the total cost. 
 
As physicians generally don’t know what medications are funded by any individual public or 
private benefit plan, they sometimes will issue two alternate medication prescriptions. Once the 
patient is at the pharmacy seeking a medication dispensation, the pharmacist can often identify 
which one is funded by using the pharmacy software system. This method notably lacks 
efficiencies for the healthcare system. The intent by the physician is that only one medication 
prescription is dispensed. Clearly, this may impact optimal care given that the physician may 
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have a preferred clinical choice of a medication for the betterment of the patient, but prescribing 
actions are impacted by funding. 
 





Retail pharmacies providing services for patients with diseases requiring specialty medications 
are assumed by the research participants to have more informational resources in place to 
provide direction or navigation on accessing medication funding over and above one’s individual 
public or private benefits plan. Unfortunately, this information is not readily available for the 
broader range of healthcare providers.  
 
Navigation through the current process 
 
The design of forms and eligibility requirements vary greatly from one financial assistance 
program to the next. Many forms are provided in the manual format only while others are 
available electronically. For those formats only available manually, simple ability to cut and 
paste information if medication funding is denied for use on another application is not an option. 
For those formats available electronically, the action may be cumbersome. Notably, by the 
research participants, accessing third party medication funding that lacks a streamlined process 
may be a daunting task. Although some help for financial assistance navigation does exist for 
diseases that are deemed more serious and life-threatening such as cancer and HIV, lack of 
centralize pathways affects productivity in the pursuit of such services. This begs the question, 
should other stakeholders such as healthcare associations or federal and provincial payers be 
seen as leading the action steps to provide a centralized drug navigation system? If so, do they 
even wish to be involved? Certainly, for the time being, these questions remain. Optimistically, 
moving forward, improved navigation may be enabled by modern day pathways such as the use 




V. Patient Engagement and Optimal Methods 
 
Training and Education 
 
Retail pharmacists are required to continue training and educational activities in order to hold 
their professional status and designation. This is often accomplished by pursuing professional 
credits through various training and educational offerings put forth by the federal or provincial 
pharmacy associations or conferences. Research participants noted that, in general, especially 
relating to pharmacy associations, these conferences do not include medication adherence 
discussions, but are more focused on ‘what’s trending’ in the industry at that time.  In the 
practicality and productivity sense, this is inconsistent with the opinion and advice of the WHO 
whom highlight medication nonadherence as one of the most significant threats to healthcare 
today. 
 
Minimal formal training exists regarding medication adherence in the educational curriculum of 
university pharmacy programs. Furthermore, minimal ongoing accreditation requirements for 
ongoing formal pharmacist training exist relating to medication adherence and the behavioral 
psychology surrounding it given the suggested pathway of a multifactorial approach. We need to 
remember as well, the retail pharmacist, as another human actor in the communication with the 
patient. Training, education, and effective methods of communication by the pharmacist are 
critical to the ability to create adequate levels of medication adherence moving forward. 
Patient engagement needs to be personal. Often, it requires a connection to personal interest. In 
many scenarios, cultural and language barriers may exist. Many considerations need to be taken 
into account during the development of any formal training programs.  
 
Proximity to Healthcare Services 
 
Atlantic Canada is a large geographical area. The vast majority of services for diseases that 
require specialty medications such as cancer, MS, and HIV are located in urban areas. For those 
patients that live in remote or rural areas, it often creates an added disadvantage due to travel 
times, coordination, and associated costs. Arguably, distance from major healthcare centers in 
 
 150 
the urban setting often leads to less than optimal care for many patients outside the immediate 
areas. Theoretically, where a patient lives may affect the quality of care they receive.  
 
Generally, research participants noted that, in Canada, we create less than optimal methods of 
care in that we are more opt to ‘fix’ problems rather than provide proactive methods or reward 
good behaviour such as adherence to medication. Clearly, this approach is costly and lacks 
productivity. Consistency and control of the message to the patient regarding medication 
adherence requires rigidity from all points of care, including that of the physician, pharmacist, 
and other healthcare providers.   
 




Pharmacy software continues to evolve. The advancements and evolution of Information 
Technology systems such as alert notifications and prompts for pharmacists when a patient has 
not returned to the pharmacy to pick up their follow-up prescriptions have improved over time. 
This is one indicator that given the concept of time and a specified dosage regimen for a 
medication, the patient is assumed to return to the pharmacy for sequential prescription 
medications on a calendar date. Using this indictor, known as prescription refill monitoring, the 
retail pharmacist is able to monitor prescriptions and reach out to the patient in advance to 
inform them that the prescription is ready for pick up. This assumes that the patient has not died 
or gone to an alternate retail pharmacy for those future oriented services. 
 
Unfortunately, for retail pharmacists and ultimately patients, these advancements in prescription 
refill monitoring are only as effective as the user’s desire to use them. If the user has other 
competing priorities at the time of use, the alert notification may be simply bypassed or 
overridden. Although automation may free up time for other services, any advancement in the 
ability to implement an improvement to medication adherence discussion is left to the decision of 




Privacy and Security 
 
Privacy laws vary slightly from the federal and provincial governmental levels. Furthermore, 
these laws differ greatly from province to province. How, then, does this play into the use of 
technology and provision of services, especially if a standardized approach to medication 
adherence is desired? These considerations are necessary given the concept of notifications to 
patients who haven’t provided formal consent to be contacted. Research participants agreed that 
careful attention to this issue is necessary if a more proactive engagement is pursued with 
patients regarding their adherence to medications once they have left the retail pharmacy after 




Not only is there a requirement by healthcare professionals to have more tools such as device 
reminders readily available, but advancements of the technological capabilities or attributes 
within those device reminders are also desired. This not only demonstrates progress in the 
movement to improve upon the ability to provide new services in medication adherence, but also 
creates a question of how to match the ‘individual’ patient, the central human actor in the mix, 
with the optimal device reminder. Certainly, not all patients have the ability to use technology at 
a competent level, let alone the desire. Hence, the need for a multifactorial approach to matching 
new technologies of device reminders to patients. 
 
Web and mobile applications 
 
With the advancements of technological offerings separate from healthcare requirements, more 
and more retail pharmacy organizations are opening up to use those technologies to provide their 
own unique and complimentary services such as web and mobile applications to create 
competitive advantage. This advances the services provided by the pharmacists but not without 
effort, as these such applications require professional and technological support of their own over 
and above the busy work environment which already exists. Questions remain, as each patient is 
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unique in their desire and competency to use such offerings, regarding who provides the time and 
follow-up support once a patient has accepted the offering.  
 
VII. Financial Assistance provided by the Pharmaceutical industry / Electronic Cards 
 
Demographics / Patient Variability 
 
Retail pharmacists agree that adherence to medication regimens will generally be affected when 
a patient needs to take a conscious action regarding their medications. For diseases that are 
chronic in nature, notably those that require specialty medications, the concept of the 
individuality of the patient will constantly be a present factor. Within the broader perspective, a 
patient may be deemed to adhere despite missing or delaying a medication dosage from time to 
time. For most patients, these infrequent or minor deviations from the prescription regimen may 
not have clinical consequences. Research participants agreed that the true impact will vary from 
patient to patient depending on the disease and medication, amongst many other variables. 
 
Repository of Information on Available Programs 
 
Unfortunately, no central formalized scenario or repository of information exists to inform the 
pharmacist on what financial assistance and patient support programs are available, nor how to 
access them. Pharmaceutical manufacturers have commercial intentions relating to the provision 
of such programs of availing financial assistance when a patient’s primary or secondary drug 
benefit plan does not fund the entirety of the medication. Availability and communication of the 
same are largely driven by the brand’s objectives, marketing strategy, and intention of the 
pharmaceutical manufacturer themselves. Furthermore, competitive aspects from one 
manufacturer to the next are important considerations. 
 
Financial Assistance: Electronic Cards as a Promotional Tool 
 
Given the significant lack information or a centralized repository, inconsistencies regarding the 
use, how to access, or availability of electronic cards exist. Several risks are also perceived by 
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retail pharmacist in enrolling patients into such programs. It is possible that since the 
organizations that fund these financial assistance programs have limited exclusivity on the 
timeframe of a particular brand patent that a program may end at any time. What are the 
implications of these stoppages for the patient and what repercussions will this cause? Research 
participants, though knowing that such programs will have a start and eventual end date, agreed 
that these factors are likely to create distrust and decreased confidence which undermines the 
overall offering itself. At the very least, adequate communication relating to program limitations 
including an expiration date written into the program agreement should be explicit.  
 
Overall consistency in the methodology and user experience of varying forms of financial 
assistance programs is limited. Separate from the use of an electronic card to facilitate payment 
to the retail pharmacy processing the prescription claim, some pharmaceutical manufacturers 
provide a reimbursement to the pharmacy using replacement inventory of the same medication or 
alternatively, through the use of credit cards. For those using electronic payment cards 
specifically designed for use in pharmacy software processing systems, the vast majority have 
program scope that would differ slightly from one to another including the application process, 
eligibility, payment levels, and duration. Research participants overwhelmingly agreed that the 
extensive limitations on program availability along with the different offerings create extra effort 
on the part of the retail pharmacists that most do not have time for, given their competing 
priorities.  
 
5.5 Preparation of the Research Findings 
 
Action research was conducted using a mixed methods approach. The objective was to determine 
an integrated design analysis utilizing both quantitative and qualitative data collection methods 
that could relate to each other (Sandelowski et al, 2006) with the intent of assimilating the 
findings, rather than a configuration. The approach commenced with the actioning of an online 
survey and, thereafter, sequencing a qualitative method utilizing focus groups. The aim was to 
enable a set of smart recommendations put forth directly by retail pharmacy practitioners. The 
recommendations, or practical solutions, are intended to assist in the improvement of medication 
adherence rates for patients with diseases requiring specialty medications. This practical research 
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effort desires to create new knowledge usable directly within the retail pharmacy setting in the 
future. The recommendations could be continuously enhanced and potentially utilized by other 
healthcare practitioners over time. Ongoing action research cycling of these efforts for the longer 
term would be beneficial. 
 
5.6 Field Methods  
 
Overwhelmingly, studies from both methodological approaches agree that integration of 
quantitative and qualitative views is ‘difficult’ at best (O’Cathain et al, 2010). This leads to a 
limitation or barrier in achieving enhancements of knowledge in the field of health. In order to 
implement a complete synthesis of both quantitative and qualitative methodologies during an 
analysis of field research, it is important to focus on both commonalities and differences. The 
difference in the methodologies, however, can be a significant obstacle in this synthesis (Voils et 
al, 2008). Not surprisingly, the ability to synthesize mixed methods research has been arguably 
unsatisfactory in the opinion of experts in both of the methodological domains. The ability to 
come to a single common, precise and detailed measure of qualitative findings equal to that of 
the numerical, narrowed dimensionality of quantitative findings (Buchanan, 1992) has been 
continuously debated.  
 
As seen in Figure #27, the synthesis summarization of the action cycles during this research was 
determined by an assimilation of the findings, including that of the online survey and focus 
group cycles. Through an integrated design (Sandelowski et al, 2006), understanding of the 
findings were combined for synthesis assimilation, rather than specific methodological approach, 
in an attempt to answer the research question or address similar phenomenon aspects of 





Figure #27: Designs for Mixed Methods Synthesis Studies (Adapted from Sandelowski et al, 2006) 
 
This research led to an interpretive assessment or attempt to make sense of the overall findings. 
The integrated design was pursued, versus that of either segregated or contingent designs, as an 
assessment tool supporting the ‘analysis’ of the overall findings. This effort assisted in 
comparing what is often seen as incomparable or combine the non-combinable (Sandelowski et 
al, 2006).  
  
5.7 Sense-making: Research Findings 
 
Significant amounts of empirical academic research exist surrounding medication adherence. A 
view from this vantage point has been highlighted throughout the extensive literature search 
during this thesis preparation. The aim of this thesis was to explore the opinions and 
recommendations put forth from the practical viewpoint of frontline practitioners; that of retail 
pharmacists. Field work of the research was completed in Atlantic Canada. The WHO five 
categorizations of Patient, Therapy, Disease, Socioeconomics, and Health Related Systems along 
with two additional constructs, Technology, and Financial Assistance provided to patients set up 




The findings from the online survey set the stage for opening up discussion during both focus 
group sessions. Significant effort was put forth to approach the data analysis from a holistic or 
aggregative perspective. Integration of both the quantitative and qualitative analysis was 
necessary to yield knowledge that collectively provides a greater summation of both methods 
versus that of analyzing either independently (O’Cathain et al, 2010). The technique used in this 
study was that of a ‘Mixed Methods Matrix’ outlined by O’Cathain et al (2010) as one of three 
techniques often used by health researchers to create new knowledge. 
 
Many ideas were discussed at length in order to reveal root causes of medication nonadherence. 
These created the pooled sub-topics, themes, or “chunks” (Henning, 2011). Considered findings, 
individual chunks aligned within the seven categorizations noted in the opening to this section. 
All qualitative data gathered during each of the focus group sessions was assigned or grouped to 




Coding during the survey utilized a Likert scale with ‘importance’ as the core determinant for 
analysis whereby ‘very important or extremely important’ measures were considered a High 
rating. The traditional method of Manual coding was used for the focus group sessions, aligning 
with the themes, utilizing High, Medium, and Low for consistency across the study and for the 
“quantitising” (O’Cathain et al, 2010, p.6) of qualitative findings. Manual coding was based on 
my perception as the researcher. Across the meta-themes, the focus was to identify the most 
important themes ranked high throughout both methodologies. Five themes stood out. It was also 
important to note ‘other’ themes that ranked high in either methodology as to help understand 
any discrepancies throughout the analysis. Furthermore, outside of the themes aligned to the 
seven categorizations or ‘chunks’, there were any other surprise themes that ranked high and 
brought into the discussions by the participants themselves. These themes were only possible 
during the focus groups sessions as a natural progression of the discussions around workflow the 




The approach to data integration is not meant to imply that it was unproblematic but rather to 
take a stance to have consistency in its evaluation. During the analysis portion it took on a 
“subtle realist” (O’Cathain et al, 2010, p.6) ontological position meant to aid the understanding 
without losing the appreciation of the importance of both methodologies. Although an insider, 
and while knowing so during the research, I accepted the facts as put forth by the participants as 
true and to ‘perceive’ their meaning to the best of my ability. 
 
5.8 Mixed Methods Matrix 
 
The assimilation (Mixed Methods Matrix, Table # 4) provides a synthesis of the findings 
collected throughout each action cycle. The integrated design (Sandelowski et al, 2006) provides 
a systematic method to logically understand both divergent and convergent themes based on 



























A total subset of 40 themes or factors relating to medication adherence were assessed between 
both methodologies throughout the action research. Upon reflection, but not surprisingly, it is 
important to note that the cycling evolved the themes which rose above the others as deemed 
important. There themes ranked important during the survey but fell off during the focus groups. 
Furthermore, other themes ranked important were not included in the survey were quickly 
brought to light during the first focus group discussion. This provided some validation that the 
concept of using both methodologies was a good choice and the perspective of cycling is an 
important tool in working towards solutions in a practical environment. 
  
The survey utilized a Likert scale to assess the quantitative findings. Furthermore, qualitative 
findings were coded for importance. With respect to the qualitative findings, a manual coding 
rating system was utilized based on the researcher's perception using a scale of importance of 
High / Medium / Low. The method of attempting to quantify the qualitative findings is a 
technique sometimes used in health research (Sandelowski, 2000). The technique is meant to 
assist in the integration through a formalized approach. It is not meant to imply that integration is 
unproblematic, but rather to take a positivism stance to the analysis versus that of assessing 





This action research sought to provide a set of smart recommendations put forth by the retail 
pharmacists. The recommendations are intended to contribute to the improvement of medication 
adherence rates regarding patients with diseases requiring specialty medications. As such, a 
convergence (O’Cathain et al, 2010) relating themes across the methodologies ranking high in 
either overall ‘importance’ or of perceived ‘responsiveness’ of the patient were considered. 
Seven themes emerged as dominant in relation to medication adherence. These include: 
 
a) High cost of Care (medications) 
b) Inadequate Reimbursement 
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c) The use of Technology for Prescription Refill Monitoring 
d) Financial Assistance provided by a third party 
e) Drug Navigation seeking funding or coverage of a Medication 
f) Time constraints of Pharmacist 
g) Timing of Medication Adherence discussion 
 
Interestingly, four of the seven dominant themes relate directly to the cost of the medication or 
how to identify the ability to fund the medication. This, overwhelming, highlights the importance 
and concern retail pharmacists view patients have in accessing their medications relating directly 
to the financial aspect of the medication purchase. Cost, funding, and means of finding help or 
information on how to access the medications are factors which are top of mind for most 
patients. The ability to utilize pharmacy software as a means to identify when a patient is 
required to refill a future prescription in order to issue notifications to the patient in advance 
along with concepts of timing were dominant themes considered non-financial. 
 
Other Themes of Importance 
 
Notably, time constraints of the pharmacist (f) along with the timing of the medication adherence 
discussion (g) were ranked of high importance during the qualitative component of the mixed 
methods research. Unfortunately, these themes were brought up during the focus group sessions 
in action cycles 2 and 3. They were not included during the questionnaire design of the online 
survey. This was one of the limitations of creating the survey questionnaire and of the 
quantitative approach, as the content is left to the best judgement of the researcher and may often 
omit critical topics that the participants consider important. Although not considered convergent 
themes across the methodologies, based on the criteria of being pursued, the notation regarding 
these themes is warranted as they were brought up by the participants as top of mind when 
rationalizing medication nonadherence by patients. Both themes considered ‘time’ as relating the 






Surprise Themes which did not Converge across Methodologies 
 
Five themes were rated highly in either overall ‘importance’ or perceived patient 
‘responsiveness’ during the online survey portion of the research, but surprisingly did not come 
up as an important discussion topic during the focus groups. Misunderstanding of the disease, 
adverse effects of treatment, complex treatment regimens, misunderstanding of treatment, along 
with misunderstanding of instructions were all themes, though reported to be important during 
the setup of the focus groups, that did not capture any discussion time during those sessions. This 
is seemingly unfortunate as all of these five factors highlight the importance of patient 
engagement and knowledge of how to help themselves to better understand and manage their 
disease. Nonetheless, although not considered as part of this integrated analysis, these themes 
were considered to be important and were therefore brought forth by the participants. These 
themes may potentially resurface during future cycling of this action research as a means to 
continue upon the improvements necessary in medication adherence.  
 
6.0 Conclusions, Reflections, and Implications 
 
6.1 Moments of Inquiry 
 
This thesis pursed actionable knowledge as to put forth a set of recommendations that not only 
made sense by looking at the existing knowledge, current views, and possible solutions regarding 
medication adherence but also that which had practical application within the retail pharmacy 
setting. In other words, the actionable knowledge garnered from the research inquiry and insight 
had to enable ‘achievable’ actions and move from theory to the real world. 
 
This chapter provides a view into the early thoughts of what already existed regarding the subject 
matter and how the cycles were means to put forth an attempt for improvements where little have 
improved over decades. The alignment of important themes paved the way for the participants to 
come forth with possible ideas or practical solutions and what barriers may be in the way to 
realization. Two recommendations were subtly tested with their membership associations as to 
their plausibility or realistic ability to succeed. In order to identify success, the actions will 
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require a long-term perspective in the practical setting. Furthermore, ongoing cycling will be 
needed beyond the scope of this study but more likely directly within the profession and 
organizations that they operate. Evaluation and further improvements will be ongoing.  
The details of the smart recommendations along with a subset of secondary requirements are 
presented and aligned to each of the five ‘important’ themes. 
 
6.1.1 Mapping the Terrain 
 
It is very possible that industry or government will take on either or both of these 
recommendations. It is important to note that the two recommendations are uniquely different 
and will require different implementation plans. 
 
Recommendation number one (medication reviews) will require significantly more effort, 
coordination, and acceptance than recommendation number two (centralized repositories). The 
evolvement of medication reviews beyond those that are currently available to patients and 
funded by governments will require a national plan, but would be approved and implemented at 
the provincial level. As highlighted in the limitations of this research, federal and provincial 
associations may disagree on the required content, balance relating to medication adherence, and 
compensation. Furthermore, determination of who will be the owner and acceptant of its 
continued evolvement is also required. This recommendation was put forth by retail pharmacists 
as a result of this research and is top of mind as a necessity as it relates to timing of medication 
adherence discussions.   
 
The recommendation of establishing a centralized repository of information regarding access and 
availability of Patient Assistance Programs in Canada will have a high likelihood of acceptance 
within pharmacy practice. It is a direct response to addressing the correlation between patient 
out-of-pocket expenses and prescription abandonment or non-adherence for specialty 
medications (Lee et al, 2016). At this time, the information exists, but lacks centralization and is 
ad-hoc. This research uncovers the need for such a centralized resource which is easily 
accessible by patients and clinicians while updated in a timely fashion. This recommendation 
does not require the coordination levels and approvals as the previous one.  As such, it requires 
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the assimilation of the information and the communication of the availability of the central 
resources. To enhance even these requirements, the action will commence with one disease, 
Multiple Sclerosis, and add other diseases over time. 
 
6.1.2 Testing Plausibility 
 
A national pilot in coordination with the Canadian Pharmacist’s Association is scheduled to 
launch September 1, 2020. The pilot will focus on one recommendation at this point in time. The 
pilot will focus on providing an online platform whereby patients may engage in activities to 
better understand their disease, treatments, and access to medicines. The recommendation of 
establishing a centralized repository of information regarding access and availability of Patient 
Assistance Programs in Canada, as an output of this research, will be imbedded in the content 
within the platforms so as to avail easy access for both patients and clinicians.  
 
The platform will commence within Multiple Sclerosis and the sixteen Disease Modifying 
Therapies (DMTs) that are available to Canadian patients affected with the disease. Actions in 
parallel with the pilot will align with the coordination and centralization of content repositories 
of other diseases such as cancer and autoimmune disorders and implemented when timing is 
appropriate. 
 
6.1.3 Evaluating Action 
 
The actionable knowledge garnered during this study is the critical link to the recommendations 
put forth. This knowledge was generated directly from the participants throughout the focus 
groups assessing the totality of the information put forth during the action cycles. The spirit of 
the study was that of a ‘working group’ better known within the commercial sector rather than an 
academic study. This supported the concept of finding new knowledge and aligning practical 
application in that the proposed actions are directly usable by those that put them forth. They are 
actionable intentions that with coordination and support may be implemented effectively within 




Evaluation of the two recommendations will commence once both have been fully established. 
The recommendations will also require a continuous improvement process as to enact ongoing 
practical cycling. These actions are beyond the timeline of this thesis. Furthermore, the actions 
should have a long-term view as to embed in the practical pharmacy setting. To this end, the 
process of taking action on the recommendations, continuous evaluation, and evolvement 
thereafter has commenced with a formal agreement by each of the noted associations, if needed, 
to sit on an advisory board. The advisory board will be spearheaded by Blue Charm Adherence 
Inc. Although unintended, this company has been established by myself, the researcher, in order 
to enact these and other future recommendations put forth and handling the complexities of such 
innovation including coordination, limitation, measurement, and continuous improvement. This 





Increase the emphasis and support for a national standardized approach of medication 




✓ Increase the frequency of mini medication reviews as opposed to the current comprehensive 
model normally implemented on an annual basis. The annualized medication review is 
largely driven by the funding available. Medication adherence discussions, as a subset of this, 
would naturally increase.  
Alignment with Themes: F, G 
 
✓ Given that pharmacists are in a unique position and have the ability to interact with a patient 
multiple times during a year, devote more formalized attention as a focus on medication 
adherence than that during a broader medication review, generally done annually, if at all. 
This may avail an opportunity for optimal communication that establishes a connection 
during a time when the receptivity of important medication adherence information is needed. 
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Alignment with Themes: E, F, G 
 
✓ Offer the ability to facilitate medication reviews within alternative settings such as the 
patient’s home as an option. This may create an environment for increased comfort and 
information receptivity. 




✓ Standardize a national fee for service for medication reviews. Funding of the service, which 
is consistent throughout the practice of pharmacy nationally, is currently the responsibility of 
the individual provinces.  
Alignment with Themes: B, D 
 
✓ Consider other funding alternatives such as those in the private sector.  
Alignment with Themes: B, D, E 
 
✓ Set funding models to incentivize the retail pharmacists, who are in the ‘for profit’ scenario, 
at an acceptable level which is high enough to generate adequate levels of supply relative to 
demand. 
 
✓ Compensation models may need to be developed that provide the incentive for pharmacists 
to spend a greater amount of time discussing medication adherence with the patient, with or 
without a full medication review. 
Alignment with Themes: B, D, E 
 
 Training  
 
(Although not aligned with important themes, a training component is suggested as to support 
the ongoing reinforcement of the recommendations. This is based on my own personal 
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experience and meant to support the generation of current and future actionable knowledge). 
 
✓ Expand the agenda topics during national and provincial pharmacy conferences to include 
medication adherence. Participants suggested that little presentation or formal training exists 
as part of the agendas during pharmacy conferences. Pharmacy conferences are not only a 
means whereby pharmacists are able to obtain up-to-date information regarding the current 
topics in pharmacy practice, but are also often an avenue of acquiring ‘credits’ necessary to 
maintain their professional license to practice.  
Alignment with Themes: N/A.  
 
✓ Within the current acceptable context that pharmacists are able acquire training, list 
‘behavioral training’ as a core offering. Such content may increase the communication skills 
required to approach medication adherence as a multifactorial perspective. 




✓ Utilize the pharmacy technician for the first upfront conversation on medication adherence in 
order to engage the patient’s interest and triage the patient towards the appropriate direction 
of optimum care thereafter. The profession of a pharmacy technician has developed 
significantly over recent years whereby higher levels of accreditation, education, and 
certification are required.  
 
The technician is of critical importance and assistance in the workflow within pharmacy 
today, arguably more than ever before. Essentially, the pharmacy technician works closely 
with the pharmacist to free up time for the pharmacist. Any increase in available time for the 
pharmacist may provide them with the ability to pursue medication adherence discussions 
with patients. Coordinating roles of both the pharmacy technician and the pharmacist may be 
determined based on a variety of criteria including disease, type of medication, and 
individual patient requirements. Furthermore, the operational process may be set up similarly 
to that of the entry into a hospital setting and formal triage whereas patients are directed and 
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cared for based on a formalized set of criteria such as urgency and other mitigating factors. 




✓ Federal and provincial pharmacy associations may disagree on the required content and 
balance of the medication review. 
✓ What would the national compensation model for the service be? How would this be chosen? 
Challenges may occur within the pharmacy profession in agreeing upon the current funding 
models as provided by public and private payers. Those at the higher end of the 
compensation model may feel compromised relative to a risk in a decrease in fee for other 
services. 
✓ If further training on the concept of medication reviews were to pursue a formalization 
pathway, who would fund and implement the training?  
✓ What are the legal and monitoring limitations required for the pharmacy technician’s role 
expansion within the practice of pharmacy?  
 
Establish a Centralized Repository of Information regarding access and availability of 




✓ Centralize one standardized system for healthcare providers to access information relating to 
the access for patients of Patient Support Programs (PAP) for any given disease. 
Unfortunately, manufacturers of the medications used in diseases requiring specialty 
medications often view the ability to provide a patient with financial assistance an important 
sales and marketing tactic.  
 
Given the wide-spread demand for this type of financial support to supplement one’s own 
drug benefit plan, it is perceived by the research participants that manufacturers sometimes 
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limit the amount of available information on the programs and only direct the offerings to a 
select few customers. The centralized repository of program information could be 
coordinated in partnership with the federal or provincial pharmacy associations as any 
pharmacy that would process the prescription on behalf of the patient would be affiliated 
with these formalized pharmacy bodies. This specific recommendation is an area that 
‘technology’ may optimize the availability and accessibility of the information needed to be 
centralized. 
 
✓ Mandate, with the support of the federal and provincial pharmacy associations, that all PAPs 
provide a communication during the implementation of any programs availed to the patient 
by the use of an electronic drug card, explaining to the patient that there is a possibility of 
discontinuation of the program. This should be communicated clearly within any central 
repository of program information. Suggest the explicit print of an expiration date on the 
electronic drug card. This may help mitigate any negative impact to the patient who may 
need to find alternate funding for the medication, and could increase trust due to 
transparency. 
Alignment with Themes: A, B, D, E 
 
✓ Require all PAP providing any form of financial assistance to follow a specified design 
pathway for accessing the offering. This should include not only the central repository of 
possible PAPs available but also a standardized model of the application process, including 
similar forms, the submission process, and the ability to transfer information from one 
program to the next in the event of a requirement to switch a medication. This specific 
recommendation is an area that ‘financial assistance may be optimized by the availability of 
the offerings as all pharmacies within Canada are able to process these payment cards.  




Although there is little variation regarding the context of the findings related to political, 
economic, or technological factors for the pharmacy profession across Canada and beyond the 
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geographical boundaries of the study there may be slight variations in the socio-cultural 
perspective. The actionable knowledge put forth by this study is not suggested that it may be 
required for all patients but rather a limited number that potentially will non-adhere due to the 
important themes generated. The concept of a multifactorial number of variables that impact 
patients may be slightly different depending on the socio or cultural background of the different 
regions within such a large geographical area. Implementing practical solutions as an output of 
the new knowledge garnered throughout this study for all patients in such a broad scope was not 
the intention. Rather, the recommendations put forth are meant to assist a minor segment of the 
overall population but be novel enough to have improvement potential.      
 
✓ Patient Support Programs may be limited to a maximum number of patients given the 
perceived demand as a result of return on investment (ROI) requirements of the individual 
manufacturer and brand. If manufacturers were forced to provide a centralized repository of 
information for all programs, the demand may far outweigh the supply. Unfortunately, this 
could potentially pressure the manufacturers to either provide it for all patients or discontinue 
the programs altogether. 
 
✓ With the consideration of any centralized repository of information regarding PAPs, the 
question will be posed as to who coordinates, maintains, and funds the effort. Assumingly, 
the repository would require not only human resources but also IT hardware and software 
resources. 
 
✓ Lack of desire by the manufacturers and current funders of PAPs to participate within the 
concept of a centralized repository may arise. The manufacturers of the medications available 
under such programs have a vested interest in maintaining their individual uniqueness of 
marketing and sales efforts. Any efforts to centralize information and standardize access may 
be seen as limiting or neutralizing to these efforts. 
 
Overall, although there are two recommendations put forth by the participants the potential to 
have a major impact on improving medication adherence rates are significant. However, the 
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actions will require time, effort, coordination, and financial resources. Unfortunately, up until 
this point in time in Canada, these resources have not been established.  
 
Both recommendations put forth as a result of this research constitute the collective output of 
efforts by practicing retail pharmacists in Atlantic Canada through a set of three action cycles. 
The key deliverables of this research for the major stakeholders involved are:  
 
1. Design and implementation of a Pilot whereby patients are able to engage in activities to better 
understand their disease, treatments, and access to medicines. This deliverable will be in 
coordination with the Canadian Pharmacist’s Association as the major stakeholder involved and 
which represents the frontline retail pharmacists’ membership in Canada. The fulfillment of the 
recommendation of establishing a centralized repository of information regarding access and 
availability of Patient Assistance Programs in Canada will be embedded within this action.  
 
2.  Regular communication to the Canadian Pharmacist’s Association and the MS Society of 
Canada, which represents a patient centric association, on the progress of each recommendation. 
 
6.3  Discussion 
 
Medication adherence continues to pose a problem to healthcare providers, as well as 
researchers, in the push to improve patient care. It is critical for all healthcare practitioners along 
the continuum of patient care to consider the importance of medication adherence as it directly 
relates to health outcomes. Although significant knowledge, effort, and formalized protocols 
exist to prescribe the most appropriate medication and counsel accordingly, the patient’s 
responsibility to take certain actions and adhere to a specific regimen is paramount. Even 
considering modern-day technologies and financial assistance provided by third party interest 
groups, along with advances in the categorizations put forth by the WHO, medication 
nonadherence rates across chronic diseases remain around 50%. As a result, there continues to be 
a negative impact on direct and indirect factors affecting patient care, including cost, quality of 
life, and overall clinical outcomes. Although it is already generally well-understood, this action 
research further supported the concept of medication costs and the ability to fund them as being 
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of paramount importance to improving medication adherence rates. Furthermore, the patient 
motivation, coordination, and engagement aspects must be considered. These perspectives where 
highlighted and contributed to the development of practical smart recommendations. 
 
The findings throughout this action research suggest that retail pharmacists in Atlantic Canada 
believe that medication adherence is a significant issue in the delivery of healthcare. Ideas and 
innovations seeking to improve medication adherence rates outlined in the literature have shown 
limited success. Interventional strategies and tactics have rarely shown promise. It is 
overwhelmingly agreed that taking a ‘multifactorial’ approach to the challenge of non-adherence 
is fundamental to complement any consideration of improving upon medication adherence rates. 
Furthermore, the same participants believe that there are feasible avenues for improvements in 
that they themselves could be directly involved with regarding the important themes they 
discussed. Specifically, although there is much communication and information exchange that 
currently takes place during early counselling and follow-up with a patient, there seems to be an 
agreement amongst the research participants that longer term and continuous follow-through are 
lacking, given the immediacy of the day-to-day business responsibilities of most retail 
pharmacists.  
 
Could it be possible that the paradigms of research up to this point in time have largely missed 
the logical considerations of using more appropriately what we already know in a coordinated 
fashion by simply filling in the blanks or information that is readily available? This may be a 
practical issue to consider as the profession has significant knowledge, processes, healthcare 
infrastructure, and technology. Yet, overall improvements are evasive. Yes, it is critical of the 
current status quo but upon reflection of the baseline knowledge the participants put forth and 
how the cycling using a practical scope may be a missing link. Furthermore, it could be argued 
that lack of research using an action research focus relating to cycling may be a determent to the 
overall pursuit of solutions using predominantly academic one-off studies. Arguably, it may be 
less about the breath of extant research and more about the depth of the research. Specific 
research on individual factors and the multitude of issues may need to be pursued with 




Given the feedback from this research with retail pharmacists in a practical setting, the 
possibilities of improving upon medication adherence rates seem a reality. Certainly, in the 
opinions of the participants, who often provided practical examples of medication nonadherence, 
while simultaneously suggesting possible solutions, it seems achievable. Furthermore, to 
strengthen the argument that improvement is possible, similar important themes emerged 
throughout the action cycles. Narrowed perspectives arose even in light of each independent 
focus group not being privy to the discussions of their counterparts in other provinces. This 
design approach was pursed so as not to bias the participants but to avail clear pathways for new 
ideas or themes. Assimilated information was not provided to the broader group until the 
commencement of the next action cycle in the sequence. The important themes considered of 
high importance were top of mind with retail pharmacists. This is encouraging, given the history 
of medication nonadherence and the healthcare system’s inability to make significant 
improvements to adherence rates, even with the enormous amount of research and understanding 
that currently exist.  
 
The broader findings of this research emphasizes that there is no one unified approach to 
medication adherence. The concept is complex, as are the potential solutions. Efforts to improve 
upon medication adherence rates need to involve both the patient and the healthcare providers in 
the individualized patient process. Patients need to be seen as participants in their care and accept 
or ‘adhere’ to the regimen instructions rather than a healthcare provider’s push to ‘comply’. 
Patients need not only to be properly educated about their medications and the importance of 
adhering to instructions, but a consistency across healthcare providers such as the retail 
pharmacists, doctors, and nurses is a must. Furthermore, resources are needed to assist healthcare 
workers and patients by setting up the right environment with the right tools for success. Smart 
recommendations put forth by the retail pharmacists within this research should be acted upon in 
order to create opportunities for improvement.  
 
6.4 Future Requirements in Research and Practice 
 
The findings of this research, though small relative to the massive amounts of available 
information on medication adherence, may have implications for healthcare practitioners and 
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new knowledge in the field if implemented correctly. This would not only require action on the 
set of smart recommendations which itself would require a coordinated effort, but also longevity 
in order to instill the recommendations as part of the overall process in the provision of patient 
care. “Medication nonadherence is a growing concern to clinicians, healthcare systems, and 
other stakeholders (payers of medication drug plans) because of mounting evidence that it is 
prevalent and associated with adverse outcomes and higher costs of care” (Ho et al, 2009). 
Given the demographics of an aging population and the growing strain on the healthcare system's 
ability to provide optimal care to the general population, contributions put forth by practitioners 
in the field such as the retail pharmacists are important to implement in order to assess their 
ability to enact positive changes.  
 
Future action research with a variety of participants from different practical healthcare 
backgrounds is recommended in order to not only assess these smart recommendations but to put 
forth others. Both recommendations are important but the ability to formalize a central repository 
of information that aligns the provision of healthcare services funded by the public domain to 
that of commercial industry may be useful to other healthcare professions outside of pharmacy. 
The actionable knowledge put forth through this study is critical of the knowledge transfer across 
domains that provide patient care. The good news is that solutions are within reach utilizing 
existing knowledge. Given that many of the healthcare systems within the developed world are 
similar and information readily available it is possible that these same recommendations may be 
easily transferrable across borders. Further research into the healthcare systems in other 
countries, beyond the scope of this study, is desired and assessed by professions in those areas. 
Arguably, if implemented, various countries would have different success rates leading to the 
ability to critically assess what actions are put forth in terms of the coordination of information, 
as well as, implementation within the practical setting with measurable variables such as 
program quality, funding, and longevity. Actions should be implemented with considerations of 







6.5 Limitations of this Action Research 
 
Representation of the broader perspective of Retail pharmacists: 
 
Medication nonadherence is a global problem throughout all diseases. This research was limited 
to a select group of retail pharmacists in Atlantic Canada. The online survey was meant to 
provide a convenience sample with which to lead into the focus group sessions and action cycles. 
Given the findings within this study, broader research including more action cycles with 
pharmacists throughout various regions is warranted.  
 
Research directly related to diseases requiring Specialty Medications: 
 
Most of the current empirical research surrounding medication adherence revolves around the 
broader aspect of chronic diseases. Lack of improvement in medication adherence rates is 
consistent across all chronic diseases inclusive of those requiring specialty medications. The 
literature search did review many diseases associated with specialty medications and the 
adherence rates were consistent with those of chronic diseases. Given the advancements of 
specialty medications within the past decade, it is recommended that further research be pursed 
specific to that area as a subset of chronic medications.  
 
Financial assistance from other sources beyond that facilitated by the pharmaceutical 
industry: 
 
Financial assistance may come from various pathways. In this action research, it was assessed by 
the participants in the context of funding provided by pharmaceutical manufacturers as a means 
to commercially promote their specialty medications and access new patients who need 
assistance. Other forms of financial assistance may exist. Some with commercial intent and 






A broader assessment of ~200 variables already studied regarding medication adherence: 
 
Previous empirical research is generally categorized within five WHO fields. Within these five 
areas, as many as 200 individual factors directly related to medication adherence have been 
studied. This action research was designed to pursue three action cycles given the time 
limitations. Further action research is necessary to pursue a continuous pathway of action cycles 
in order to avail deeper conversation and insight into a wider range of variables. 
 
Continuous evolution of these Smart Recommendations: 
 
The smart recommendations put forth during this action research are a genuine set of opinions 
put forth from those practitioners on the front lines with patients. These recommendations have 
yet to be implemented. Limitations exist on the desire to move beyond the current day to day 
activities of pharmacists, the business of pharmacy, and the associations that are meant to 
represent their interests. This is a known difficulty from at least three perspectives. Firstly, 
change is difficult and going against the status quo is always a risk. Secondly, who will support 
the effort? And thirdly, will there be momentum to ensure that over time it has enough 
foundation to be measured?  
 
Assuming that the smart recommendations do get past this stage and are implemented within 
some areas within Canada, they would be expected to evolve over time and act as their own 
sequence of cycling outside that of research. In other words, the recommendations would take on 
a commercial application whereby those involved and participating in the evolution are rewarded 
for their efforts in some way, either professionally or commercially. There are positive 
implications for patients, the pharmacy profession, and other healthcare professionals including, 
most importantly, an increase in medication adherence rates. Another benefit may be the notion 
of utilizing such approaches as action research to be more embedded into other practical 










As a first-time action researcher, the process provided a very insightful pathway to understanding 
the approach and linking the participant’s own norms, understandings, and opinions on how to 
improve medication nonadherence. It makes logistical sense to engage those directly practicing 
in the field of a given subject matter, most of those who would rarely participate in the formal 
research. This action research was able to involve the pharmacy associations that represent the 
membership of those in Atlantic Canada along with individual pharmacists, some of whom had 
the best interest of their pharmacy employers up front and center during the research 
commencement. It seemed as if the patient was secondary in the thought process. Interestingly, 
the formal association or commercial responsibilities that may have been promoted early in the 
action cycles were quickly dissolved once the concept and importance of medication adherence 
were posed to the group.  
 
Reflection leads me to believe that although the participants did have employer and commercial 
interests to protect, given the desire and intent to improve upon medication adherence rates for 
the betterment of patients and health outcomes, superior motives and energy to engage in order 
to put forth a viable set of smart recommendations took precedent. The participant’s professional 
attributes, rather than their commercial or political interests, took over. As an observer, this was 
very rewarding. 
 
Given this is my first time as a researcher, I would likely not change anything about this first 
study. I would however engage more cycles in further studies as I think this is where new 
knowledge lies and considering action research separates it from past approaches. 









Reflecting upon the process, and coming from the perspective of a scholarly practitioner, the 
concept of action research, especially the approach of cycling along with cause and effect, made 
logical sense to me. Similar to work environments, the participatory point of view and equal 
voice in moving towards improvements created a bidirectional relationship. Comparatively, I did 
not sense this during the review of the extant literature in that there was little examination or 
future action based on learnings. Other research, without the practical perspective, seemed too 
rigid. Especially, in this field of research in which little improvement has changed as a result.  
 
The ability to be an insider discussing in detail the finer points or human perspectives on 
medication adherence brought out the socially responsive nature of each participant. As such, I 
did not find any difficulty in implementing the action research. The process of moving through 
the cycles including the smaller details of working with the pharmacy associations, invitations, 
setting choice and setup along with meeting execution was not only informative, but exciting. 
Activities required during the meetings including audio requirements, journaling, and facilitation 
were tedious to navigate, but necessary. Ultimately, little of the audio requirements were used as 
the extensive journaling worked well. This accuracy of the notes was partly reflective of, 
although a non-participant insider, understanding what the pharmacists were communicating 
during facilitation and not having to intervene much during discussions.  
 
The recommendations were an accumulation of the knowledge put forth during the cycles, 
especially relating to the taken-for-granted and underlying tacit knowledge that already exists 
within the profession. This brought a sense of accomplishment or liberation even if the 
recommendations have yet to be implemented. It was a sense of ‘we have something here that 
may finally be actionable with results’. I would use this type of practical research again, not only 
from an academic perspective, but certainly in formalized process within organizations. For other 
future action researchers, I would suggest that this form of research will open up your mind to 
what is possible but recommend commencing with the cycles early as to avail the possibility of 
additional ones as needed given the process is continuous. The more cycles, the better as it is an 





I have acquired many skills over the years in the pursuit of scholarly practice. In doing so, I have 
realized the need for an understanding of the structure and proper context of the environment or 
subject matter in order to have an influence upon it (Aram & Salipante Jr., 2003). Arguably, 
knowledge and attention are only relevant in context. The closer I may get to the locus of action, 
or the physical, the better the practice centric learning becomes.   
 
In the broader sense, I have an enhanced understanding of the importance of scholarly practice. 
This not only includes the movement through the cycles in a formalized approach by acting, 
planning, observing and reflecting but diving deeper into a lessened ‘knowledge’ focused 
paradigm to that of an ‘attention’ based mindfulness. For most, including myself, a lifetime of 
learning with the focus on ‘knowledge’ has created and embedded a paradigm or rigidity of 
habits. My professional development within this DBA program has taught me to push forward by 
challenging “the unchallenged supremacy of knowledge as the goal of management higher 
education” (Ramsey, 2014, p.7) and utilize an attention focus within the scholarly process. I do 
admit that the consistency required to create this new habit will not be easy. New habits will 
need to be formed during the implementation of future research projects.  
 
Professionally, I am able to deploy a formalized process of engagement, inquiry, and navigation 
(Ramsey, 2014, p.7). Furthermore, I understand that a mindful, deliberate, generative, and 
conscious top of mind approach is critical to the scholarly practice while at the same time, 
realizing each practitioner will put forth a different individual profile. Easterby-Smith, Thorpe, 
Jackson (2012) highlight the importance of mindfulness of my own identity within the research 
and its significance in the structure and process.  
 
Scholarly practice skills developed from concepts in the practical setting were an output of this 
research. Along the way, I personally was able to apply different methodologies in this context. 
In terms of a mixed methods approach, there are arguments for and against using it let alone 
using it in a first research attempt. Although arguably more difficult to implement, the combined 
methodologies layered into the study enabled me not only to end up with practical applications 
 
 179 
for the healthcare profession, but commenced the training necessary to understand its value, 
especially in the organizational setting.  
 
Easterby-Smith, Thorpe, & Jackson (2012) note that a mixed methods approach may increase the 
explanation of credibility, generalization, and availing deeper insights. In this study, I would 
agree with this argument. I did not struggle with the duality of roles, likely because of my 
aligned background within the pharmacy setting for many years along with my Executive 
Masters in Business Administration which, as well as, had a practical scope to it. The concept of 
cycling was new to me although I have participated in various continuous improvement 
processes within organizations over the years. This skill will be very applicable within my 
professional life. Medication adherence was not new to me as I have had an interested in it for 
some time but lacked formal background knowledge on the subject matter. Any pre-





Considering the novel findings and contribution of this action research, it is important to reflect 
on the overall objective. It wasn’t only to assess the current opinions of retail pharmacists in 
Atlantic Canada, but also engage those participants to put forth a set of smart recommendations. 
Although four of the top five prioritized themes discussed during the research evolved around the 
cost of medications and its funding other themes critical to improving upon medication 
adherence arose including the amount of time required to implement adequate discussions and 
when to do so. Furthermore, the amount of misunderstanding regarding both the disease and 
treatment were also noted. Although the top nonadherence themes emerged, unfortunately, 
pharmacist’s time and misunderstandings seemed to get lost in the consideration of prioritizing 
those important themes which led to the set of smart recommendations. For patients with 
diseases requiring specialty medicines such as multiple sclerosis, cancer, and HIV to name a few, 




At this point in time, it is difficult to argue the extent of how novel the findings may be. I submit 
that many great findings over history may have not been impressively novel but rather slightly 
novel and highly logical, especially in hindsight. Although the potential for societal contributions 
are possible and incremental upside is great, limitations of the findings are significant. 
Considering the lack of improvement of medication adherence rates over time it is important to 
be cautious as to the potential of these smart recommendations chance for long term success. The 
broad-based complexities inherent in any of the WHO categorizations along with technological 
advancements and the availability of financial assistance programs will undoubtedly all play a 
critical role in health outcomes and individual wellness.  
 
Rates of medication nonadherence across chronic diseases which require specialty medicines 
will be challenging to improve upon given the human actor perspective. The recommendations 
put forth within this study address only a very limited number of the multifactorial variables 
known to cause nonadherence. Whether intentional or not, patients will find all kinds of creative 
ways to avoid and alter their treatment regimens. The practical reality is that, for many patients, 
this will mean direct and indirect implications associated with their adherence. The ‘working’ 
patient, for example, may experience required time off from their work. The elderly, in 
particular, may also encounter secondary negative consequences such as falling and injuring 
themselves. Ultimately, the web of connected problems is concerning if improvements to rates of 
medication adherence aren’t pursued. 
 
As demographics continue to change with the aging of populations throughout the world there 
will be increased pressure on healthcare budgets and those who fund it will be challenged to find 
new ways to ensure the best return on investment. From a business perspective, how do societies 
get the most out of the spending allocated towards healthcare? In order to best manage the 
resources available, a heightened level of attention from the human or patient perspective will be 
needed. Furthermore, the factors that are not patient-driven, including the advancements in 
medicinal and technological offerings, may then be more effectively utilized when patients 
engage in their own care. It will be important to maximize available resources. Patients will 
become empowered, and potentially pressured, to utilize these resources to their full worth in 
order to optimize health outcomes and manage their personal illnesses. As part of treatment 
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regimes, medications will be expected to be taken as prescribed. Unfortunately, that will not 
always be the case. There is no doubt that medication adherence will factor greatly into all 
aspects of society’s ability for healthcare resources to be optimized to their fullest. 
 
Academically, over the years both researchers and advocates suggest multifactorial approaches, 
which can potentially be just as complex as the reasons for medication nonadherence. Long term 
practical approaches will need to compliment academic findings and perspectives. Most patients 
attempt to follow the treatment plans put forth by their healthcare provider and generally give the 
indication or impression that at the time of the communication the plan is understood, accepted, 
and ready to implement. In other words, the patient intends to follow the healthcare practitioner’s 
advice. Unfortunately, studies have shown that what happens thereafter is far from what is 
desired. Nonetheless, as researchers, practitioners, and patients, we all need to continue to focus 
on the possibilities of improvement. This action research project has attempted to contribute to 
that though academic assessment by way of a mixed methods approach and the suggestion of 
practical applications thereafter.  
 
The ability to engage in longer term action research cycling may be critical to success. The 
research participants came from a variety of backgrounds regarding age, gender, work 
experience, and so on. Furthermore, they came from various retail pharmacy organizations, each 
with their own set of commercial priorities. It is recommended that future activities evolve 
implementation of the smart recommendations utilizing the provincial pharmacy associations in 
Canada to partner with available resources to bring them to life. Thereafter, those same 
associations should engage formally around the ongoing steps for continuous improvements. 
Incentive to do so may be both professional, in terms of the pharmacy profession, but also 
financial to avail a ‘return on investment’ and align with the commercial needs of the 
organizations. Retail pharmacists, in the day to day practice settings, need not view medication 
adherence discussions as unrewarding, or a diversion from other responsibilities, but as a 
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or if there is anything that you do not understand. Please feel free to discuss this with your friends, relatives and Greg Patey (Student Researcher) if you 
wish. We would like to stress that you do not have to accept this invitation and should only agree to take part if you want to. If you choose to participate the 
research will take approximately 90 minutes per session involving two sessions at a minimum.  
 
4. What is the purpose of the study?  
The purpose of this study to to help answer the question, “From a retail pharmacist’s perspective in the practical setting, does the intervention of financial 
assistance by the pharmaceutical industry provided to patients through the use of electronic payment cards and / or technology have an impact on 
medication adherence within specialty diseases?” Answers to this question are arguably very complex. A common theme in the literature search recognized 
that medication adherence is a multifactorial concept. In order to potentially enact new knowledge on the topic, this research will focus on 5 broad 
categories of medication nonadherence put forth by the World Health Organization along with considering the impact of layering in the use of technology 
and financial incentive provided by the pharmaceutical industry utilizing the medium of electronic card based programs. This research is separate and 
distinct from the Researcher's professional role.  
 
5. Why have I been chosen to take part?  
The research will focus on the input of retail pharmacists in Atlantic Canada and selected through a qualification criteria of either experience in processing, 
or been witness to the processing, of an electronic payment card that has provided financial assistance to a patient. These participants will be identified by 
having worked in a setting in which have dispensation of prescriptions associated with specialty diseases. The research is seeking to garner new knowledge 
from the retail pharmacist’s perspective in how to improve medication adherence rates within Specialty diseases. As a retail pharmacist, you have been 
selected to participate to share your experience, expertise, and opinion.  
 
6. Do I have to take part?  
Participation is voluntary and participants are free to withdraw at anytime without explanation and without incurring a disadvantage.  
 
7. What will happen if I take part?  
The research will utilize two forms of research methods. Firstly, an anonymous survey and secondly, Focus Groups. The research will be conducted solely 
by Greg Patey (Student Researcher). The survey will be conducted online and the Focus Groups will be done in person. All findings may be shared at 
either the discretion of the participant or through the provincial pharmacy association. With respect to the Focus Groups, all questions, interviews, and 
interaction with participants will be carried out using observational techniques in both verbal and written perspectives. Participants will be asked to interact 
on more than one occasion. The research we be conducted at varying dates and times throughout 2017. All information provided at the time of any research 
interaction will be displayed in an appropriate format for the participant involved in the research to fully understand the context of why a question is asked 
or discussion to take place. If any part of the research will involve audio or visual recording the participant will be informed. Focus Group session will take 
approximately 90 minutes all inclusive.  
 
8. Expenses and / or payments  
Participation within the online survey will be without compensation. Participants within the Focus Groups will be compensated in return for their time a 




9. Are there any risks in taking part?  
There should be no aspect of the research that will disadvantage the participant with any interaction. If at any time there is any discomfort or perceived 
disadvantage on the part of the participant it should be made known to the researcher immediately.  
 
10. Are there any benefits in taking part?  
The purpose of the study is to help garner the practical knowledge of the Retail Pharmacist with respect to improving adherence rates within Specialty 
diseases. Your participation in the study will potentially contribute new knowledge towards this objective.  
The implications of this research for practitioners, academia and professional knowledge may be significant. Medication non adherence is a growing 
concern to clinicians, healthcare systems, and other stakeholders (payers of medication drug plans) because of mounting evidence that it is prevalent and 
associated with adverse outcomes and higher costs of care. Given the potential impact on medication nonadherence, even a small positive contribution may 
warrant the effort.  
11. What if I am unhappy or if there is a problem?  
If you are unhappy, or if there is a problem, please feel free to let us know by contacting Greg Patey (Student Researcher) at (902) 489 8954. If you remain 
unhappy or have a complaint which you feel you cannot come to us with then you should contact the Research Governance Officer at ethics@liv.ac.uk. 
When contacting the Research Governance Officer, please provide details of the name or description of the study (so that it can be identified), the 
researcher(s) involved, and the details of the complaint you wish to make.  
 
12. Will my participation be kept confidential?  
There is minimal risk potential for any of the participants regarding confidentiality. The concept of privacy and confidentiality play an important role in 
consideration of a methodological choice. Very limited personal data will be required and personal data should be reasonably guarded against risks such as 
loss, unauthorized access, modification and disclosure. In this context, it is important to note what is a reasonable mode of electronic communication 
always has the possibility to be accessed by those desiring the information as often seen by security breaches within large scale commercial enterprises. 
Survey data will be collected online using either SurveyMonkey or Google Forms website and stored according to their storage and privacy policy. Focus 
Groups data will be collected either at the retail pharmacy (work setting) or a neutral site, conducted at various times of the day, audio taped, and journaled 
to provided clarity and reference to assimilate the findings. The data will be stored as to maintained privacy and downloaded to an encrypted flash drive 
having business-grade security that safeguards 100 per cent of confidential data. The drive will also enforce complex password protection. Data will be 
stored for five years and disposed of thereafter utilizing a professional services qualified to do so.  
 
13. What will happen to the results of the study?  
The results of the research will be made available to the participants upon request or through the provincial pharmacy associations. If published, the 
research results will be accessible by both the participants and the general public at large. It is important to note that if the research results are published to 
the general public the participants will not be identifiable from the results.  
 
14. What will happen if I want to stop taking part?  
As a participant, I may withdraw from the research at anytime, without explanation. Your input up to the period of withdrawal may be used unless 
otherwise requested to be destroyed at which point no further use will made of it. If your input into the research is anonymized, the results may only be 
withdrawn prior to anonymization.  
 
15. Who can I contact if I have further questions?  
Greg Patey 




























My name is Greg Patey and I am a student with the University of Liverpool, England conducting research 
on ‘Medication Adherence’.  I was hoping you could help me. I am a resident of Nova Scotia and this 
research is part of my Doctorate of Business thesis.  A short online survey (see link below) is meant to gain 
a small convenience sample from Atlantic Canadian pharmacists.  It should take approximately 10 – 15 




Student within the Doctorate of Business Administration (DBA), University of Liverpool, England 
Retired from the pharmaceutical industry. 
 
Thesis Title:   
 
Medication Adherence in Specialty Diseases:  A Pharmacist’s Perspective on the 
Interventional Impact of Technology and Pharmaceutical Industry initiated financial 
assistance through the medium of electronic Payment Cards 
 
The thesis research is intended to: 
 
Firstly, assess what opinions Atlantic Canadian pharmacists have around Medication Adherence directly 
related to the formal categorizations of the World Health Organization (WHO).  The survey is meant to 
assess the current opinions upfront before leading into small focus groups in the fall (October – 
November). 
 
Secondly, put forth a set of Smart Recommendations that would be an output of Focus Groups with 
Atlantic Canadian pharmacists thereafter.  These would be shared with the provincial associations. 
 





The second part of this research will pursue action research though small Focus Groups in an 
attempt to garner new knowledge to assist in improving medication adherence rates within 
Specialty diseases such as cancer, rheumatoid arthritis, and multiple sclerosis.  These sessions 
will be conducted throughout October and November of 2017. It is hoped that a set of ‘Smart 




Appendix E  Survey Action Research Questions Cycle 1 (Online) 
Introduction  
Medication adherence is a term used to summarize whether a medication is being used in the manner in which it was prescribed. This research being conducted by Greg 
Patey as a student through the University of Liverpool, seeks to understand the traditional and accepted beliefs surrounding medication adherence, especially as it 
relates to the work of the World Health Organization. The information from the survey will be used to further pursue action research with retail pharmacists to 
understand the potential impact of various solutions to improve medication adherence rates in specialty diseases such as cancer or multiple sclerosis.  
Please respond to these questions openly and truthfully. All results will remain confidential and will only be reported in aggregate form. No individual personal 
identifiers will be reported in order to protect your confidentiality and privacy. The data will only be available to the researcher.  
Background Information  
Please note that this background information will only be used to aggregate the data and describe the demographics of the survey sample.  
What type of retail pharmacy do you currently work in?  
• ☐  Independent Retail Pharmacy  
• ☐  Banner Retail Pharmacy  
• ☐  Chain Retail Pharmacy  
• ☐  Other - Retail Pharmacy 
 
In which province in Atlantic Canada is the Pharmacy located?  
• ☐  Newfoundland  
• ☐  New Brunswick  
• ☐  Nova Scotia  
• ☐  Prince Edward Island  
Is the Pharmacy located in an urban or rural setting?  
• ☐  Urban  
• ☐  Rural  
What is the highest level of education you have completed?  
• ☐  Technical College  
• ☐  Vocational School  
• ☐  University undergraduate Degree  
• ☐  University Masters Degree  
• ☐  University Doctoral Degree  
• ☐  Professional degree (PEng, etc)  
• ☐  Other, specify ________________________________________  
What is your age? 
☐ 20–29 ☐ 30–39 ☐ 40–49 ☐ 50–59 ☐ 60+  
Are you male or female?  
☐ Male ☐ Female 
What best describes your current job function within the Pharmacy?  
• ☐  Senior Management  
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• ☐  Middle Management  
• ☐  Front Line Staff Pharmacist  
• ☐  Administration  
• ☐  Other  
How many years have you been within the current level of job function?  
☐ < 5 ☐ 5 – 10 ☐ 11 – 15 ☐ 16 – 20 ☐ 21 - 25 ☐ 26 – 30 ☐ 31+  
How many hours to you spend with patients during an average work week?  
• ☐  <10  
• ☐  10-15  
• ☐  16-20  
• ☐  21-25  
• ☐  26-30  
• ☐  31-35  
• ☐  36–40  
• ☐  >40  
How many Patients do you interact with each day regarding their medications?  
☐ <15 ☐ 15–30 ☐ 31–45 ☐ 46–60 ☐ 61+  
WHO factors related to Medication Adherence  
The World Health Organization has identified five factors that influence medication adherence, including: social and economic factors, the health care team/health 
system, the characteristics of the disease, disease-related therapies and patient-related factors. Understanding the extent to which these factors are universal and where 
gaps exist is critical if medication adherence is to be improved.  
For each of the five WHO factors, please describe the extent to which you believe each influences medication adherence among the patients that you serve at your 
community-based pharmacy using a scale of 1 to 5, where 1 is Not Important and 5 is Extremely Important. Please note that within each subcategory, there is an option 
for you to include up to two additional responses that you feel are important contributors to medication adherence.  
Ratings scale  
The rating of each question should reflect your individual opinion and categorized as follows:  
1. Not Important 
2. Somewhat Important 
3. Important 
4. Very Important 
5. Extremely Important  
Social and Economic Factors  
1. Q1a  High cost of care  
2. Q1b  Unemployment  
3. Q1c  Poor socioeconomic status  
4. Q1d  Poverty  
5. Q1e  Illiteracy  
6. Q1f  Sex of the patient  
7. Q1g  Non-English speaking  
8. Q1h  Recent immigrants  
9. Q1i  Inadequate social support  
10. Q1j  Inadequate family support  
11. Q1k  Lack of transportation  
12. Q1l  Long distance from treatment setting  
13. Q1m  Family dysfunction  
14. Q1n  Cultural and lay beliefs about illness and treatment  
15. Q1o  Other, specify ________________________________  
16. Q1p  Other, specify ________________________________  
Health Care Team/Health System Factors  
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1. Q2a  Health care providers inadequate understanding of the disease  
2. Q2b  Inadequate reimbursement by health insurance plans  
3. Q2c  Inadequate relationship between health care provider and patient  
4. Q2d  Inadequate health care providers  
5. Q2e  Poor delivery of care education to the patient  
6. Q2f  Poor delivery of care education to family and caregivers  
7. Q2g  Short consultations  
8. Q2h  Lack of training in changing the behaviour of non-adherent patients  
9. Q2i  Other, specify ________________________________  
10. Q2j  Other, specify ________________________________  
Disease or Condition  
1. Q3a  Poor understanding of the disease and its symptoms  
2. Q3b  Co-morbidities  
3. Q3c Asymptomatic patients  
4. Q3d  Previous treatment failures  
5. Q3e  Duration of disease  
6. Q3f  Other, specify ________________________________  
7. Q3g  Other, specify ________________________________  
Disease-Related Therapy Factors  
1. Q4a  Complex treatment regimen  
2. Q4b  Long duration of treatment  
3. Q4c  Adverse effects of treatment  
4. Q4d  Misunderstanding about how to take the medication  
5. Q4e  Dietary restrictions  
6. Q4f  Fitting medication to patient’s lifestyle  
7. Q4g  Other, specify _______________________  
8. Q4h  Other, specify _______________________  
Patient-Related Factors  
1. Q5a  Forgetfulness  
2. Q5b  Lifestyle and health beliefs  
3. Q5c  Polypharmacy  
4. Q5d  Misunderstanding of instructions about medications  
5. Q5e  Lack of understanding about vulnerability to illness  
6. Q5f  Perceived ineffectiveness of the medication  
7. Q5g  Fear of addiction  
8. Q5h  Life stress  
9. Q5i  Alcohol use  
10. Q5j  Drug use  
11. Q5k  Other, specify ________________________________  
12. Q5l  Other, specify ________________________________  
Most Important Factors  
Q. Based on your own personal experience, what do you think are the five most important sub-factors (including those you may have provided) contributing to medication 
nonadherence overall, in order of importance where 1 is the most important, 2 is the second most important, etc.? Have a drop down list  
Most Responsive to Uptake  
Q. Again, based on your own personal experience, what do you think are the five sub-factors most open or responsive to change, where 1 is the most open, 2 is the second most 
open, etc.?  
Have a drop down list  
Greatest Impact on Medication Adherence  
Q. Of the five sub-factors most responsive to change, which do you believe have the greatest potential to impact medication adherence, in order of impact where 1 has the greatest 
impact, 2 has the second most impact, etc., in order of impact where 1 has the greatest impact, 2 has the second most impact, etc.  
Have a drop down list  
Technological Interventions  
Many forms of technology have been used in recent years in an attempt to help improve medication adherence. Some of these technological interventions are listed 
below. Again, there is an opportunity for you to include an additional two interventions that you feel are important to medication adherence.  
 
 205 
1. Not at All 2. Very Little 3. Somewhat 4. Quite a Bit 5. A Great Deal  
1. Q6a  SMS (Short Message Service) / Text Reminders  
2. Q6b  Email Reminders  
3. Q6c  Telephone Call Reminders  
4. Q6d  Patient awareness using SmartPhone Apps  
5. Q6e  Self-Directed Electronic Monitors of Adherence  
6. Q6f  Illness-Specific Medical Devices (such as tracking on Blood Glucose monitors  
7. Q6g  Online Links providing education  
8. Q6h  Social Media (such as Facebook)  
9. Q6i  Medication packaging Microchips (used to report when the package is open)  
10. Q6j  Prescription Refill Monitoring using Pharmacy Software systems  
11. Q6k  Other, specify ________________________________  
12. Q6l  Other, specify ________________________________  
Most Responsive to Uptake  
Q. Based on your own personal experience or perceptions, what do you think are the five technological interventions (including those you may have provided) that would be most 
open or responsive to uptake, where 1 is the most responsive, 2 is the second most responsive, etc.?  
Have a drop down list  
Greatest Impact on Medication Adherence  
Q. Of the five technological interventions, which do you believe have the greatest potential to impact medication adherence, in order of impact where 1 has the greatest impact, 2 
has the second most impact, etc.  
Have a drop down list  
Financial Assistance using Electronic Payment Cards  
Electronic cards have been used for many years to entice loyalty (i.e., AirMiles, Optimum, Aeroplan, etc.). These same type of cards have also been used by 
Pharmaceutical companies to off-set the payment of medication at the retail pharmacy level either in full or partial payment of the prescription medication.  
Below are different potential electronic card benefits that could be used to help individuals access the medications they require (note: there is an option to include up to 
two of your own ideas in Q7e and Q7f).  
Again, please rate as follows in terms of the importance:  
1. Not at All 2. Very Little 3. Somewhat 4. Quite a Bit 5. A Great Deal  
Q7a Financial assistance to help in the partial or full payment of a remaining balance of medication costs after coordination with the Patient’s own private or public plan. 
Q7b Potential for third party assistance other than through the Physician Clinic or Pharmacy in accessing medication coverage with the Patient’s private or public plan. (This is 
termed a Drug Navigation service and is generally funded by the providers of the financial assistance through the use of electronic cards. In general, this is offered by a 
Pharmaceutical company using a third party organization trained in providing this unique service).  
Q7c Potential for other services of non-financial assistance relating to a specific disease (ie, non-medication offerings such as free devices. An example would be a free blood 
pressure monitor). 
Q7d The psychological aspect of using a card to access a ‘freebie’ similar to gift card offering or points schemes (regardless if the patient ever uses the freebie or points that may 
be accumulated or not).  
5. Q7e  Other, specify ________________________________  
6. Q7f  Other, specify ________________________________  
Most Responsive to Uptake  
Q8. Based on your own personal experience or perceptions, which electronic card types (including those you may have provided) do you think would be most open or responsive 
to uptake, where 1 is the most responsive, 2 is the second most responsive, etc.?  
Have a drop down list  
Greatest Impact on Medication Adherence  
Q. Of the electronic card types you mentioned, which do you believe have the greatest potential to impact medication adherence, in order of impact where 1 has the greatest 
impact, 2 has the second most impact, etc.  
Have a drop down list  
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SPECIAL NOTE  
The second part of this research will pursue action research though small Focus Groups in an attempt to garner new knowledge to help assist in improving medication adherence 
rates within Specialty diseases such as cancer, rheumatoid arthritis, and multiple sclerosis. These sessions will be conducted throughout September, October, and November of 
2017 and a nominal participation fee will be provided. It is hoped that a set of ‘Smart Recommendations’ will be the outcome of these sessions.  
If you are interested in participating in a Focus Group please indicate by providing your contact information below:  
Name: 
Address: 
Email contact: Telephone contact:  
Thank you, 



































Appendix G Power Point Presentation Action Research Cycle 3 (Focus Group Session) 
 
 
 
 
 
